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Abstract 
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Abstract 
Worldwide, cardiovascular disease (CVD) is the leading cause of death. It is widely 
accepted that both active smoking and exposure to secondhand smoke (SHS) are 
associated with CVD. About 20% of the global population smoke tobacco or 
tobacco-related products. The global prevalence of smoking is increasing, 
although it is decreasing in some high-income and upper middle-income countries. 
Globally, about a third of adults and 40% children are regularly exposed to SHS. 
According to the World Health Organisation (WHO), only 16% of the global 
population is protected by a comprehensive smoke-free legislation. Coronary 
heart disease (CHD), stroke and peripheral arterial disease (PAD) are all types of 
atherosclerosis and often co-exist in the same patients. Therefore, they share 
many common risk factors including cigarette smoking. However, previous 
epidemiological studies on CVD including those on cigarette smoking mainly 
focused on CHD and stroke and   pay little attention to PAD. Evidence is increasing 
in support of the association between exposure to SHS and both CHD and stroke. 
In contrast, there is a paucity of studies on SHS and the risk of PAD. The 
overarching aim of this thesis was to collate the published evidence on the 
association between active cigarette smoking and PAD, and examine the 
association between exposure to SHS and PAD in the general population. 
This thesis starts with a systematic review on the association between active 
cigarette smoking, SHS and PAD undertaken using four databases: Medline, 
Embase, PubMed and Web of Science to identify existing published evidence up to 
30 April 2012 (Chapter 2). Prior to the published studies contained in this thesis, 
there had been no meta-analyses on the association between active cigarette 
smoking and PAD and only two studies published on the association between SHS 
and PAD. Therefore, this systematic review was followed by a meta-analysis on 
the association between active cigarette smoking and PAD. This meta-analysis 
identified 55 studies: 43 cross-sectional, 10 cohort and 2 case-control. Of the 68 
results for current smokers, 59 (86.8%) were statistically significant and the pooled 
odds ratio (OR) was 2.72 (95% confidence interval [CI] 2.28-3.21). Of the 40 results 
for ex-smokers, 29 (72.5%) were statistically significant and the pooled OR was 
1.67 (95% CI 1.54-1.81). Active cigarette smoking significantly increases the risk 
of PAD, compared with never smokers. The magnitude of association between 
active cigarette smoking and PAD was greater in current smokers than ex-smokers. 
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In contrast, prior to my studies in this thesis, only two studies on SHS were 
identified. Only one showed an overall association between self-report SHS and 
PAD in Chinese never smokers, with a clear dose-response relationship. The other 
study used serum cotinine as measure for SHS exposure and found neither an 
overall association nor a dose-response relationship but suggested a very high 
cotinine concentration as threshold. 
Chapter 3 examines the association between SHS exposure and PAD in adult non-
smokers in Scotland. This chapter includes two cross-sectional studies using the 
Generation Scotland: Scottish Family Health Study (GS: SFHS) and the Scottish 
Health Survey (SHeS), and one retrospective cohort study using the record linkage 
of the SHeS. In the cross-sectional study using SFHS, PAD was measured using ankle 
brachial pressure index (ABPI) but SHS exposure was self-report. Of the 5,686 
never smokers, 134 (2.4%) had PAD (defined as an ABPI <0.9). Participants who 
reported overall high level of SHS exposure (exposed to ≥40 hours per week) were 
more likely to have PAD, compared with those who reported no exposure to SHS. 
After adjustment for potential confounders, the association between SHS and PAD 
persisted (adjusted OR 4.53, 95% CI 1.51-13.56, p=0.007), with suggestion of a 
dose-response relationship. In the other cross-sectional study using SHeS, SHS 
exposure was measured objectively using cotinine concentration but PAD was 
based on self-report symptoms of intermittent claudication (IC) using the 
Edinburgh Claudication Questionnaire. Of the 4,231 non-smokers (defined as self-
reported non-smokers with a salivary cotinine concentration <15 ng/mL), 134 
(3.2%) had IC. Participants with high exposure to SHS (cotinine ≥2.7 ng/mL) were 
at significantly higher risk of IC, after adjustment for potential confounders 
(adjusted OR 1.76, 95% CI 1.04-3.00, p=0.036).  A dose-response relationship was 
suggested, whereby the risk of IC increased with increasing cotinine concentration. 
However, the association varied by age category. Participants aged <60 were more 
strongly associated with PAD. This may be explained by survival bias. For the third, 
retrospective cohort study in Chapter 3, I used record linkage of SHeS to Scottish 
Morbidity Record 01 (SMR01) records and death certificates to identify the first 
hospital admission/death following the SHeS in which PAD was recorded as the 
primary or secondary cause. Of the 4,045 confirmed non-smokers who were free 
of baseline IC were included. Over the follow-up period (mean follow-up 9 years), 
there were 568 deaths, none of which were coded as due to PAD, and 64 
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participants were hospitalised for PAD. High exposure to SHS was associated with 
increased risk of all-cause mortality (adjusted hazard ratio [HR] 1.42, 95% CI 1.09-
1.86, p=0.011) among all non-smokers and increased risk of incident PAD (adjusted 
HR 2.82, 95% CI 1.14-6.96, p=0.024) among male non-smokers. Increased cotinine 
concentrations at baseline were associated with increased risk of all-cause 
mortality, with a dose-response relationship. 
SHS contains both sidestream smoke, from burning cigarette tips, and exhaled 
mainstream smoke. Shortened telomere length is broadly viewed as a biomarker 
for biological ageing including atherosclerosis phenotypes such as PAD. Evidence 
is strong that active smoking increases telomere length attrition but whether such 
association occurs between SHS and telomere length is unknown. Therefore, 
Chapter 4 aimed to add to growing evidence that exposure to SHS is associated 
with disproportionately higher biomarkers of cardiovascular risk compared with 
active smoking and may accelerate normal biological ageing. This chapter includes 
two cross-sectional studies. The first study investigated the relationship between 
salivary cotinine and several preclinical cardiovascular biomarkers: C-reactive 
protein (CRP), high-density lipoprotein (HDL) cholesterol, TC/HDL cholesterol 
ratio and fibrinogen in 10,081 adults from the SHeS. CRP concentration and the 
TC/HDL cholesterol ratio increased, and HDL cholesterol concentration decreased 
with increasing cotinine concentration among both non-smokers and active 
smokers. There were step changes in the relationship between tobacco exposure 
and cardiovascular biomarkers at the interface of non-smokers exposed to SHS and 
active smokers. Non-smokers with high exposure to SHS had lower cotinine 
concentrations than light active smokers but comparable concentrations of CRP 
(p=0.709), HDL cholesterol (p=0.931) and the TC/HDL cholesterol ratio (p=0.405). 
Fibrinogen concentration was less clear-cut and only increased in moderate and 
heavy active smokers. The second study in this chapter explored the association 
between self-reported levels of SHS exposure and telomere shortening per annum 
using a subgroup of participants from the SFHS. Of the 1,303 non-smokers, 
telomere length decreased more rapidly with increasing age among participants 
with high level of SHS exposure, compared with both those with no exposure 
(adjusted coefficient -0.006, 95% CI -0.008- -0.004) (high vs no SHS: p=0.010) or 
low exposure (adjusted coefficient -0.005, 95% CI -0.007- -0.003) (high vs low SHS: 
p=0.005). 
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In summary, there is now substantial evidence of an association between active 
cigarette smoking and PAD. This thesis adds to the limited existing evidence on 
SHS as an independent risk factor for PAD. There was an overall association 
between exposure to SHS and PAD, with suggestion of a dose-response relationship. 
However, the association varied by age category. Individuals aged <60 were more 
strongly associated with the prevalence of IC. SHS was significantly associated 
with incident PAD only in men. This thesis further demonstrates that exposure to 
SHS carries a disproportionately higher cardiovascular risk than active smoking for 
a given level of smoke exposure. Telomere shortening per year of age may be an 
intermediate step between SHS and CVD including PAD. This also supports the 
association between SHS exposure and the atherosclerosis-related biomarkers, 
which play an important role in the pathophysiology of PAD. Further research is 
needed in the future to better understand the association between SHS and PAD, 
and the underlying mechanisms. The research in this thesis supports the need to 
protect the general public from exposure to SHS. 
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1.1 Chapter outline 
This chapter provides the context for the subsequent chapters by discussing 
exposure to secondhand smoke (SHS) as a risk factor for atherosclerotic diseases, 
measurement of SHS exposure and legislation to protect the general public from 
exposure to SHS. Furthermore, it discusses lower extremity peripheral arterial 
disease (PAD) in terms of its diagnosis, risk factors, management and public health 
burden. This chapter concludes with the aims and objectives that will be 
addressed in the subsequent chapters.  
Section 1.2:  Secondhand smoke 
1.2.1:  Prevalence of secondhand smoke exposure 
1.2.2:  Chemical composition 
1.2.3:  Measures of secondhand smoke exposure 
1.2.4:  Health effects of secondhand smoke exposure 
1.2.5:  Smoke-free legislation 
Section 1.3: Peripheral arterial disease 
1.3.1:  Prevalence and classification of peripheral arterial disease 
1.3.2:  Development of peripheral arterial disease 
1.3.3:  Management of peripheral arterial disease 
Section 1.4: Summary of the introduction 
Section 1.5:  Aims and objectives of this thesis 
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Introduction 
SHS refers to inhaling other people’s cigarette smoke. It is a mixture of air-diluted 
‘sidestream’ smoke from a burning cigarette tip, and the ‘mainstream’ smoke 
exhaled by the smoker. SHS contains over 4,000 chemicals of which more than 250 
are known to be harmful to health (1). Worldwide, approximately a third of adults 
and 40% children are regularly exposed to SHS in 2004. Exposure to SHS is 
associated with around 603,000 deaths across 192 countries; equivalent to about 
1% of global mortality. Of these, 379,000 deaths are from ischaemic heart disease 
(2). The World Health Organisation (WHO) has recognised no-safe level for SHS 
exposure. The first WHO public health treaty to be published focused on tobacco 
control and comprehensive smoke-free legislation was one of its recommendations. 
In spite of this, only around 18% of the global population is covered by 
comprehensive smoke-free legislation (3) .  
SHS has been shown to be associated with increased risk of atherosclerotic disease 
(4-6). Atherosclerotic disease may manifest as coronary heart disease (CHD), 
stroke or PAD. The presence of one is associated with a higher risk of the others 
(7) but the relative frequency of the conditions varies between subgroups of the 
population; for example by age (8) and ethnicity (9-11). Also, whilst the three 
conditions share many common risk factors (12, 13), the relative importance of 
some risk factors varies between the conditions. In comparison with CHD and 
stroke, PAD has been relatively neglected as a focus of research. Both active 
smoking and SHS exposure are now well established as risk factors for CHD and 
stroke (4, 6, 14, 15). In contrast, whilst a number of studies have now addressed 
active smoking and PAD (16), there has been a paucity of studies on SHS exposure 
and PAD. In this thesis, I aim to help address this neglected area.  
1.2 Secondhand smoke 
SHS is the inhalation of tobacco smoke by people other than the active smoker. 
SHS can also be called ‘environmental tobacco smoke (ETS)’ or ‘passive smoking’ 
or ‘involuntary smoking’ (3). SHS is the leading source of indoor air pollution in 
developed countries (17). 
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Inhaling tobacco smoke is unavoidable for active smokers. However, non-smokers 
also inhale SHS when tobacco smoke permeates any environment. SHS fills 
enclosed spaces including workplaces, restaurants, bars, hospitals, public 
transport, educational institutes and other public places, home and vehicles, 
when people burn tobacco products such as cigarettes, bidis and water pipes. In 
my thesis, I focus on exposure of non-smoking adults to the SHS generated from 
cigarette smoking.  
1.2.1 Prevalence of secondhand smoke exposure 
Implementation and enforcement of smoke-free legislation is effective at reducing 
exposure to SHS (18). The World Health Organization Framework Convention on 
Tobacco Control (WHO FCTC) has been signed by 168 countries and is legally 
binding in 180 ratifying countries as of March 2015 (19). However, currently only 
16% of the world’s population is protected by comprehensive nationwide smoke-
free legislation (3). Furthermore, whilst legislation usually covers all or most 
enclosed public places and workplaces, outdoor public places, homes and vehicles 
are generally not covered by legislation. 
 
Worldwide, according to the fact sheet from WHO, almost half of the children 
regularly breathe in SHS. Over 40% of the children have one or two parents who 
are active smokers (20). For children, private vehicles and homes are the places 
they are most likely to be exposed to SHS. Globally, about a third of adults are 
regularly exposed to SHS (Table 1.1). Within Europe, exposure is highest in WHO-
Region C (Belarus, Estonia, Hungary, Kazakhstan, Latvia, Lithuania, Republic of 
the Republic of Moldova, Russian Federation, Ukraine), where 66% of adults are 
exposed to SHS. In China, public awareness of the health risks associated with SHS 
exposure is low (21). A Chinese nationally representative household survey 
reported that, among non-smokers aged ≥15 years, 556 million (72.4%) were 
exposed to SHS, and 50% were exposed daily. Exposure in public places, 
households and indoor workplaces was 72.7%, 67.3% and 63.3% respectively (22).  
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Table 1.1 Proportion of non-smoking adults exposed regularly to second-hand 
tobacco smoke, by WHO region 
 
   
WHO sub-region Exposure in men (%) Exposure in women (%) 
   
   
Africa (D)  7  11 
Africa (E)  4  9 
The Americas (A)  16  16 
The Americas (B)  13  21 
The Americas (D)  15  18 
Eastern Mediterranean 
(B)  
24  22 
Eastern Mediterranean 
(D)  
21  34 
Europe (A)  34  32 
Europe (B)  52  53 
Europe (C)  66  66 
South-eastern Asia (B)  58  41 
South-eastern Asia (D)  23  18 
Western Pacific (A)  50  54 
Western Pacific (B)  53  51 
Global  33  31 
   
 
Source: Adapted from Öberg et al. (23) 
 
 
In Scotland, on 26 March 2006, a comprehensive smoke-free legislation was 
implemented to ban smoking in virtually all enclosed public places and workplaces 
(24).  Repeated national cross-sectional surveys were conducted to compare 
exposure to SHS among Scottish adult non-smokers aged 18 to 74 years old before 
and after implementation of this legislation. Pre-legislation data were collected 
between 1 September and 20 November 2005 and between 9 January and 25 March 
2006. Post-legislation data were collected between 1 September and 10 December 
2006 and between 8 January and 2 April 2007. The surveys demonstrated 
significant reductions in exposure to SHS in places covered by legislation: 
workplaces (from 12.4% to 4.3%); in pubs and bars (from 33% to 1.7%), on public 
transport (from 3.3% to 0.9%); and in other enclosed public places (from 9.4% to 
2.6%). In contrast there was no significant change in SHS exposure in private homes 
and cars which were not covered by the legislation. Non-smokers living in smoking 
households continued to have high levels of exposure to SHS in their own homes 
(17.4% and 17.1% pre- and post-legislation respectively) and the homes of others 
(21.3% and 20.8% pre- and post-legislation). Prior to the legislation, 8.1% of non-
Chapter 1 General introduction 
 23
smokers reported exposure to SHS. Following the legislation, this fell but 6.8% still 
reported that they were exposed (25). Semple and his colleagues compared the 
levels of SHS exposure measured by fine particulate matter in diameter < 2.5 µm 
(PM2.5) in 41 pubs in two Scottish cities (Aberdeen and Edinburgh) eight weeks 
before and then after the legislation. Levels of SHS were reduced after the 
legislation, with the average reduction in PM2.5 by 86% (averaged 246 µg/m3 and 
20 µg/m3 pre- and post-legislation) (26). Six years after the legislation, in the main 
report of Scottish Health Survey 2012, 17% non-smoking adults reported exposure 
to SHS in their own home or others’ home and 11% reported exposure outside 
buildings in public places (27). 
 
1.2.2 Chemical composition 
SHS is a mixture of air-diluted ‘sidestream’ smoke from a burning cigarette tip, 
and ‘mainstream’ smoke exhaled by the smoker. Mainstream smoke is the smoke 
inhaled and exhaled by smokers directly from tobacco products. Sidestream is the 
smoke which goes into the ambient air from a burning cigarette, cigar, or other 
smoking device. Sidestream smoke is often the major source of SHS. SHS contains 
over 4000 chemicals including at least 250 harmful chemicals, such as tar and 
carbon monoxide (CO), and more than 50 carcinogens, such as polycyclic aromatic 
hydrocarbons (PAH) and arsenic (20). Sidestream smoke contains a range of 
chemicals similar to mainstream smoke. However, sidestream smoke contains 
higher concentrations of toxic gases and small (<2.5µm), respirable particles than 
mainstream smoke (28-31). The concentrations of the constituents in SHS can vary 
with time, environmental conditions and commercial cigarette brands (32). Table 
1.2 summarises the concentrations of some representative constituents of SHS.
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Table 1.2 Concentrations (in µg/m3) of selected constituents of secondhand tobacco smoke in some experimental and real-life 
situations†  
 
      
Constituent 
 
18-m3 chamber: mean 
for 50 best-selling 
US cigarettes (µg/m3) 
 
Living quarters 
 
(µg/m3) 
Tavern 
 
(µg/m3) 
Disco 
 
(µg/m3) 
Home 
 
(µg/m3) 
      
Respirable suspended particles 1440 240–480 420 801‡ – 
Nicotine 90.8 8–87 71 120 51.8 
CO (ppm) 5.09 – 4.8 22.1 – 
Benzene 30 – 27 – 17.6 
Formaldehyde 143 – 104 – – 
1,3-Butadiene 40 – 19 – – 
Acetaldehyde 268 – 204 – – 
Isoprene 657 50–200 150 – 83.3 
Styrene 10 – – – 7.3 
Catechol 1.24 – – – – 
3-Ethenyl pyridine 37.1 – – 18.2 – 
Ethylbenzene 8.5 – – – 8.0 
Pyridine 23.8 – – 17.6 6.5 
Toluene 54.5 – – – 51.2 
Limonene 29.1 – – – 22.0 
      
 
–  not reported 
† Values represent the higher end of the exposure scale. 
‡ Fine particles (< 2 µm size) 
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Source: Adapted from WHO International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of carcinogenic risks to 
humans. Tobacco smoke and involuntary smoking. Volume 83. 2004. (32) 
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1.2.3 Measures of secondhand smoke exposure 
The level of exposure to SHS can be measured directly or indirectly. Direct 
methods measure the concentrations of one or more SHS constituent. Biomarkers 
of tobacco smoke can be measured in biological specimens, of which saliva is the 
most commonly used. Biomarkers specifically used to detect tobacco exposure, 
including SHS exposure, are nicotine and its metabolites such as cotinine, and the 
metabolites of NNK (4-[methylnitrosamino]-1-[3-pyridyl]-1-butanone), such as 
NNAL (4-[methylnitrosamino]-1-[3-pyridyl]-1-butanol). NNK is a tobacco-specific 
pulmonary carcinogen but the detection of its metabolites requires costly 
laboratory equipment (33).  
Nicotine, cotinine and trans-3-hydroxycotinine can also be measured in blood 
samples. Of these, cotinine is the most commonly used due to its longer half-life. 
Cotinine is an alkaloid found in tobacco and also a metabolite of nicotine. The 
concentration of cotinine in biological samples increases after active smoking or 
exposure to SHS (34). In vivo, cotinine has a half-life of approximately 20 hours, 
and is typically detectable for up to one week after tobacco exposure. Cotinine 
can be detected in different biological samples such as saliva, serum and urine, 
and even hair (35). The concentration of cotinine in the blood, saliva, and urine 
is proportionate to the amount of exposure to tobacco smoke (36, 37). Therefore, 
cotinine is suitable for cumulative doses over short exposure periods. 
Venipuncture is invasive and urine collection requires privacy and may cause 
logistical problems if undertaken as part of large population studies or studies of 
children. Also, urine cotinine concentrations can be influenced by creatinine 
clearance. Salivary cotinine is non-invasive and samples can be disseminated and 
returned by post. Therefore, salivary cotinine is often the preferred option. A 
liquid chromatography tandem mass spectrometry assay is usually used to detect 
cotinine. Previous studies suggested a value of 0.05 ng/ml is the lower limit of 
detection for cotinine assay (38, 39)  
Cotinine concentrations are used to measure exposure among both active smokers 
and non-smokers exposed to SHS. In addition, cut-offs are commonly applied to 
differentiate between the two groups, and identify smoking deceivers (active 
smokers who deliberately misclassify themselves as non-smokers). In reality, the 
cotinine concentrations of non-smokers with heavy exposure to SHS and 
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light/occasional active smokers can overlap. Therefore, the cut-off levels need to 
be selected so as to minimize misclassification. The Society for Research on 
Nicotine and Tobacco (SRNT) Subcommittee on Biochemical Verification has 
recommended a cut-off point of 15 ng/mL in saliva or serum and 50 ng/ml in urine 
for the identification of ‘current regular smokers’ (SNRT Subcommittee on 
Biochemical Verification 2002) (40).  
In addition to measuring biological samples, respirable suspended particles 
(aerodynamic diameter <10 µm) can be used to measure indoor SHS exposure. 
However, they are not specific to tobacco combustion and can be influenced by 
other ambient smoke sources, such as vehicle exhaust emissions and biofuel mass 
(41). Other components of tobacco smoke such as CO, nitrogen oxides, 
formaldehyde and thiocyanate can be measured (41, 42). But these biomarkers 
lack specificity. For example, CO can come from traffic emissions, gas heaters and 
cookers (43). Another approach that has been used is to measure SHS exposure in 
the home is measurement of nicotine concentrations in dust (44). 
Indirect measures of SHS exposure are generally obtained from survey 
questionnaires. Questionnaires usually include self-report of the level and/or 
duration of exposure or self-report of specific situations associated with SHS 
exposure (e.g. living with a partner who smokes or working in a smoky 
environment) (45) (46, 47) as summarised in Table 1.3. Measures of tobacco smoke 
exposure based on self-reported questionnaires are used more often in large 
population-level epidemiological studies. However, many studies have suggested 
that self-report may underestimate the true current smoking prevalence due to 
some current active smokers deliberately misclassifying themselves as non-
smokers. A systematic review identified 67 studies that assessed the relationship 
between self-reported smoking status and smoking status conferred from cotinine 
concentrations. The studies confirmed under-reporting of active smoking. The 
mean difference between smoking prevalence based on self-reported compared 
with cotinine measured -4.8%, -6.2% and -9.4% for saliva, serum and urine 
respectively (34).  
The two approaches (self-report and cotinine measurement) can be combined to 
improve accuracy. Participants who classify themselves as non-smokers and have 
a salivary cotinine concentration <15.0 ng/ml can be safely assumed to be non-
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smokers and those who classify themselves as smokers are likely to be so. The 
decision as to whether to include, and if so how to classify, people who report 
themselves as non-smokers but have a salivary cotinine concentration ≥15.0 ng/ml 
will depend on the question being asked and the relative importance of sensitivity 
and specificity. 
Table 1.3 contains a summary of methods of assessing SHS exposure.  
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Table 1.3 Types of methods for measuring exposure to secondhand smoke (33) 
    
 Suggested indicators Pros Cons 
    
    
Direct Biomarker concentrations:   
 Cotinine  Specific to tobacco exposure 
Reflect recent tobacco exposure 
Highly sensitive 
Short half-life in body fluids 
Only measures recent exposure 
       Saliva  Easy, non-invasive to collect 
Good for multiple measurement 
Potential issues with age, gender, race, oral 
pH, dehydration, or drug treatment 
       Blood No adjustment required for hydration Invasive to collect 
Difficulty for infants and young children 
Pregnant women have increased clearance 
rate 
       Urine Non-invasive to collect Need facilities with privacy during collection 
Need creatinine clearance adjustment 
Potential issues with renal disease and some 
prescription drugs 
 Nicotine Specific to tobacco exposure   
       Hair or nail Easy, non-invasive to collect 
Reflect longer exposure 
Age, gender, race and chemical hair 
treatments may affect hair nicotine 
concentrations 
Nail nicotine concentrations need further 
research 
       Body fluids  Very short half-life 
 CO and Carboxyhaemoglobin Integrated exposures from all sources Lack specificity 
Many indoor and vehicular sources are 
possible sources of CO 
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Concentrations depend on CO level in 
inhaled air, duration of exposure and lung 
ventilation 
Carboxyhaemoglobin blood samples are 
invasive 
 NNK metabolites Specific to tobacco exposure 
Can be detected in urine, non-invasive 
Reflect longer exposure than cotinine 
Costly  
Require analytical expertise 
 Concentration of SHS components in the air:   
 Nicotine in the air Specific to tobacco combustion 
Emitted in large quantities in sidestream 
SHS 
Can be used to measure and compare 
exposures from different sources 
Can be measured in indoor dust and 
household surfaces 
High absorption rate to indoor surfaces  
Tendency to be re-emitted even in the 
absence of active smoking 
 Respirable particles PM measurements allow multiple 
assessment of real-time indoor air quality 
Not specific to SHS 
 Other markers VOCs constitute a major proportion of the 
organic mass of SHS 
VOCs are of low sensitivity and require 
laboratory techniques 
Indirect Report of SHS exposure (questionnaire) at: Easy 
Low cost 
Feasible in large populations 
Can integrate into existing surveys 
Permits tracing long-term/lifelong 
exposure pattern 
Misclassification errors may occur due to 
recall bias, intentional alteration, memory 
failure and the respondents’ lack of 
knowledge 
Low sensitivity 
 Home   
     Presence of SHS   
     Number of smokers   
     Smoking of parents   
     Amount (number of cigarettes smoked)   
     cumulative time (hours exposure)   
 Workplace   
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     Presence of SHS   
     Number of smokers   
     Amount (number of cigarettes smoked)   
     Cumulative time (hours exposure)    
 Other indoor public places   
     Presence of SHS   
     Number of smokers   
     Amount (number of cigarettes smoked)   
     Cumulative time (hours exposure)   
    
 
SHS  secondhand smoke; pH  potential of hydrogen; CO  carbon monoxide; NNK  4-[methylnitrosamino]-1-[3-pyridyl]-1-butanone; PM 
particulate matter; VOCs  volatile organic compounds 
 
Source: Adapted from: 
Avila-Tang E,  Al-Delaimy WK, Ashley D et al. Assessing secondhand smoke using biological marker. Tob Control 2013; 22:164-171. 
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1.2.4 Health effects of secondhand smoke exposure 
Since the early 1980s, there has been growing evidence on the adverse health 
effects of exposure to SHS. Exposure to SHS is associated with lung cancer, CHD, 
respiratory diseases and stroke in adult non-smokers (4, 6, 48, 49). Worldwide, 
40% of children, 35% of female adult non-smokers and 33% of male adult non-
smokers were estimated to have been exposed to SHS in 2004. This exposure 
resulted in 603,000 deaths, about 1% of worldwide mortality, and 10.9 million 
disability-adjusted life-years (DALYs) attributable to SHS. Of these deaths, 
379,000 deaths were from ischaemic heart disease, 165,000 from lower respiratory 
infections in children under 5 years old, 36,900 from asthma and 21,400 from lung 
cancer. The largest number of deaths attributable to SHS occurred in women who 
had a partner who smoked or were exposed to SHS in enclosed places. More than 
80% of the deaths in children under 5 years old attributed to SHS exposure 
occurred in Southeast Asia, Africa and Eastern Mediterranean regions (2). Prior to 
the introduction of smoke-free legislation, SHS was responsible for an estimated 
11,317 deaths across the UK (50) and 865 in Scotland each year (51). 
1.2.4.1 Short-term health effects 
Exposure to SHS has immediate health effects including eye irritation, headache, 
cough, sore throat, dizziness and nausea. Even brief exposure to SHS brings about 
rapid cardiovascular changes including plate activation, endothelial dysfunction 
and arterial stiffening (52-60). As little as 30 minutes of exposure (comparable to 
exposure in a pub or bar) was associated with impaired endothelium-dependent 
vasodilation in coronary arteries in non-smokers comparable to habitual active 
smokers (Otsuka et al. 2001). One hour of SHS exposure increased the levels of 
11-dehydro-thromoboxane B2 (11-DH-TXB2) and malondialdehyde (MDA) to the 
levels observed in active smokers (59). Lung function was reported significantly 
reduced after one hour of SHS exposure (61). 
1.2.4.2 Long-term health effects 
There are long-term health effects as a result of exposure to SHS as well. The 2006 
the United States (US) Surgeon General’s report concluded that there is no risk-
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free level of exposure to SHS (62). Evidence on the harmful effect of SHS exposure 
has been building over decades.  
The association between smoking and cancer is strongest for lung cancer (63), 
from which 1.38 million people die every year (64). Smoking accounts for around 
90% of lung cancer incidence (65). However, lung cancer can also occur among 
people who have never smoked. Studies have pointed to an association between 
SHS exposure and lung cancer. In 2000, a meta-analysis was conducted of 35 case-
control studies and 5 cohort studies among lifetime non-smoking subjects. From a 
total of 5,140 lung cancer cases, lifetime non-smoking women and men 
experienced a 20% (pooled relative risk [RR] 1.20, 95% confidence interval [CI] 
1.12-1.29) and a 48% (RR 1.48, 95% CI 1.13-1.92) excess risk of lung cancer 
respectively, as a result of exposure to SHS from their spouse’s smoking habit. SHS 
exposure at work produced a 15% and 29% increased risk among lifetime non-
smoking women and man respectively (RR 1.15, 95% CI 1.04-1.28 for women; RR 
1.29, 95% CI 0.93-1.78 for men) (66). Another large scale study which combined 
European and US studies assessed 1,263 lung cancer cases among adult non-
smoking patients. They found evidence for a dose-response relationship between 
duration of SHS exposure and long-term risk of lung cancer for three sources of 
exposure: spousal smoking (adjusted odd ratio [OR] 1.30, 95% CI 1.04-1.63, p for 
trend=0.04 for ≥ 31 years of exposure); workplace exposure (adjusted OR 1.25, 
95% CI 1.03-1.51, p for trend=0.01 for ≥ 21 years of exposure); and social exposure 
(adjusted OR 1.26, 95% CI 1.01-1.58, p for trend=0.02 for ≥ 20 years of exposure) 
(48). 
The effect of SHS on the risk of CHD has been demonstrated in a meta-analysis 
published in 1999. This meta-analysis included 10 prospective cohort studies and 
8 case-control studies and reported a pooled RR of 1.25 (95% CI 1.17-1.32). 
Exposure at home showed a 17% excess risk and at work an 11% excess risk of CHD 
(RR 1.17, 95% CI 1.11-1.24 for exposure at home; RR 1.11, 95% CI 1.00-1.23 for 
exposure at work). There was suggestion of a dose relationship with increasing 
dose and duration of exposure to SHS from 1-19 cigarettes per day (RR 1.23, 95%CI 
1.13-1.34) to ≥ 20 cigarettes per day (RR 1.31, 95%CI 1.21-1.42); and from 1-9 
years of exposure (RR 1.18, 95%CI 0.98-1.42), and 10-19 years of exposure (RR 
1.31, 95%CI 1.11-1.55) to ≥20 years of exposure (RR 1.29, 95%CI 1.16-1.43) (4). In 
2004, Whincup et al. examined the risk of CHD events during 20 years of follow-
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up in the British Regional Heart Study which recruited participants from England, 
Wales and Scotland. Among 2,105 male non-smokers, 1,722 (81.8%) had a serum 
cotinine concentration >0.8 ng/mL. The risk of CHD among non-smokers exposed 
to high levels of SHS (adjusted hazard ratio [HR] 1.57, 95% CI 1.08-2.28), who had 
a mean cotinine concentration 4.9 ng/mL, was comparable to light active smokers 
(adjusted HR 1.66, 95% CI 1.04-2.68), who had a mean cotinine concentration 
138.4 ng/mL (67). The comparable risk of CHD and the high prevalence of SHS 
exposure suggested the effect of SHS in earlier studies may have been 
underestimated. Published meta-analyses have concluded a significantly higher 
risk of lung cancer among active current smokers (pooled overall RR 8.96, 95%CI 
6.73-12.11) (63) than non-smokers exposed to SHS (pooled RR all < 2.00 for either 
men or women exposed at home or at work) (66). Therefore, it has been concluded 
that for CHD, SHS exposure conveys a disproportionately high risk (in relation to 
level of nicotine exposure) that is not true for other smoking-related conditions, 
such as lung cancer.  
Another common cardiovascular risk of being exposed to SHS is stroke. A meta-
analysis of 20 studies, published in 2011, has indicated an increased risk of stroke 
among those exposed to SHS (pooled RR 1.25, 95%CI 1.12 to 1.38). The dose 
relationship was clear. The relative risk was 1.16 (95%CI 1.06-1.27) for exposure 
to 5 cigarettes per day, 1.31 (95%CI 1.12-1.54) for exposure to 10 cigarettes per 
day, 1.45 (95%CI 1.19-1.78) for exposure to 15 cigarettes per day and 1.56 (95%CI 
1.25-1.96) for exposure to 40 cigarettes per day (6). These findings are consistent 
with the pattern observed for CHD. The 2010 US Surgeon General’s report 
concluded that current evidence was insufficient to infer a causal relationship 
between exposure to SHS and stroke (68).  
Aortic arch calcification (AAC) is independently associated with CHD, stroke and 
PAD (69). A recent study in China has found the risk of AAC increased significantly 
with increasing duration of exposure to SHS at home in adulthood (adjusted OR 
1.24, 95%CI 1.07-1.43 for 40 hours per week over >5 years, p for trend=0.005) and 
indoor workplaces exposure to SHS (adjusted OR 1.22, 95%CI 1.04-1.43 for 40 hour 
per week over >5years, p for trend=0.012) among never smoking women. 
Significant trends were also found for increasing severity of AAC with increasing 
duration of SHS exposure (70).  
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Chronic obstructive pulmonary disease (COPD) is one of the leading causes of 
morbidity and mortality worldwide. Active cigarette smoking is a well-established 
risk factor for COPD (62). SHS has been linked to the development of COPD, but 
most studies included current smokers in their analysis. In the Guangzhou Biobank 
Cohort Study, researchers analysed data from 15,379 never smokers aged ≥ 50 
years on self-reported SHS exposure and risk of COPD. They found that the risk of 
COPD increased with increasing  cumulative lifetime exposure to SHS at home 
(adjusted OR 1.60, 95%CI 1.23-2.10 for 40 hours per week over >5 years), in indoor 
workplaces (adjusted OR 1.50, 95%CI 1.14-1.97 for 40 hours per week over >5 
years); and total exposure (adjusted OR 1.48, 95 %CI 1.18-1.85 for 40 hours per 
week over >5 years, p for trend=0.001) (71).  
Long-term exposure to SHS can induce asthma and exacerbate symptoms such as 
nasal symptoms, headaches, cough, wheezing, sore throat, hoarseness and eye 
irritations (32, 72). Nicotine, aldehydes and other toxic components in the tobacco 
smoke are associated with asthma and these symptoms. In a Finnish study, over a 
2.5-year period, exposure to SHS increased the risk of asthma onset among adults 
aged ≥ 21 years, with an adjusted OR of 2.16 (95%CI 1.26-3.72) for exposure at 
work and an adjusted OR of 4.77 (95%CI 1.29-17.7) for exposure at home (73). A 
meta-analysis of 79 studies attributed a 21-85% increase in incident asthma and a 
30-70% increase in incident wheezing to pre- or postnatal SHS exposure among 
children aged up to 18 years (74). In Scotland, before the introduction of smoke-
free legislation, hospital admissions for children asthma were increasing by a mean 
of 5.2% per year among children aged <15 years. Following smoke-free legislation, 
admissions decreased at a mean rate of 18.2% per annum (75).   
There are other long-term health effects of exposure to SHS such as cancers other 
than lung cancer (63) and mental health issues (76, 77). Evidence has emerged of 
a possible association between exposure to SHS and nasal sinus cancer (78). A 
cross-sectional study published in 2009 showed an association between high level 
of SHS exposure (cotinine 0.8-13.5 ng/mL) and increased risk of cognitive 
impairment (adjusted OR 1.44, 95% CI 1.07-1.94) among adult non-smokers aged 
>50 years (79). High SHS exposure (cotinine 0.7-15.0 ng/mL) among adult non-
smokers was associated with increased risk of psychological distress (adjusted OR 
1.49, 95% CI 1.13-1.97) and admission to psychiatric hospitals (adjusted HR=3.74, 
95%CI 1.55-8.98) in prospective data (77). For children, home is the major source 
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of exposure due to parents and other household members smoking cigarettes 
indoors. Prenatal exposure can have impact on both the mother and the foetus 
including female fertility, low birth weight, preterm birth, stillbirth and 
spontaneous abortion (80-83).  
Therefore, SHS is a substantial threat to public health. There is no safe level of 
exposure (62). The most effective measure to prevent any harmful effects of SHS 
is to protect the general public from SHS exposure.  
1.2.5 Smoke-free legislation 
Because of the risk to health posed by exposure to SHS, tobacco control experts 
recommend the introduction of smoke-free legislation that prohibits smoking in 
indoor public places and protects workers and the general public. According to 
the WHO FCTC guidelines article 8, the countries which have ratified the WHO 
FCTC have a legal obligation to implement effective smoke-free legislations for 
protection from exposure to tobacco smoke in indoor workplaces, public transport, 
and indoor public places and as appropriate, other public places (84). Since the 
WHO FCTC entered into force in 2005, 180 parties have ratified their legal 
obligation (19). As of 2014, 125 of these 180 parties have actually implemented 
smoking bans in indoor public places, public transport, and as appropriate, other 
public places to protect their citizens from exposure to SHS. Of these, 111 have 
introduced national legislation to protect their citizens from exposure to SHS, and 
65 have introduced administrative and executive orders or a combination of these 
orders and the national legislation. Twenty-nine parties use voluntary agreements 
(85). However, a factsheet from the  WHO  has indicated that only around 18% of 
the world’s population is covered by comprehensive smoke-free legislation (3).  
 
1.2.5.1 An overview of smoke-free legislation 
On the 29 March 2004, Ireland was the first country in the world to institute an 
outright ban on smoking in general indoor workplaces, including offices, shops, 
factories, restaurants, bars, educational facilities, hospital facilities and public 
transports, with on the spot fines of up to €3,000. However, the legislation does 
not cover smoking in designated hotel rooms, private residential places and 
prisons (86). One year after the Irish smoke-free law, a 94% compliance rate among 
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all eligible workplaces was recorded under the National Tobacco Control 
Inspection Programme and 96% of all indoor workers reported working in smoke-
free environments (87). Air quality in pubs has improved significantly since the 
smoke-free law. A study of 24 pubs throughout Dublin measured the exposure 
levels of airborne particles (Particulate matter [PM]), which were mainly from 
tobacco smoke, before and after the smoke-free law over at least a three hour 
period at each premises with repeat measurements on the same day of the week 
and the same month, one year on. The average levels of small particles (PM2.5) 
reduced by 87.6% while the average levels of large particles (PM10) reduced by 53% 
(87, 88). Following introduction of the Irish smoke-free legislation, exposure to 
SHS dramatically declined in all venues: workplaces from 62% to 14%, restaurants 
from 85% to 3%, and bars/pubs from 98% to 5%. (18). 
 
In the United Kingdom (UK), smoking prevalence peaked in 1948, at which time 
82% of adult men smoked (89). Overall the smoking prevalence among both male 
and female adults has been declining since 1974 when the first national survey on 
smoking began. In 2011, smoking prevalence among adults in the UK had reduced 
to 20% (90).  
 
Prior to the smoke-free legislation, it was estimated that exposure to SHS in public 
and private places caused 11,317 premature deaths among adult non-smokers in 
the UK each year (50). Since July 2007, smoking in virtually all enclosed public 
places and workplaces has been banned by comprehensive smoke-free legislation 
across all UK jurisdictions. Smoke-free legislation was first introduced in Scotland 
in 2006 followed by England, Wales and Northern Ireland in 2007. The Scottish 
smoke-free legislation prohibits smoking in wholly and substantially enclosed 
public places and workplaces, with few exemptions such as designated rooms, 
seating and playing areas of sports stadia and private dwellings (24). Compliance 
rates have been high. Since the implementation, exposure to SHS has declined in 
all public places covered by the legislation (91). A study of 41 Scottish pubs 
demonstrated an 86% reduction of PM2.5 levels two months after implementation 
of the legislation (26). The legislation has resulted in reduced exposure among 
both bar workers and the general population. Among adult non-smokers in the 
general population, the geometric mean salivary cotinine concentration has fallen 
by 39% since the legislation (25). Similar results have been found in England. 
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During the first 9 months following introduction of the English legislation, 98.2% 
of 390,148 premises inspected were found to be smoke-free (92). Since October 1 
2015, smoking is also no longer permitted in a private vehicle carrying children in 
England and Wales (93). 
 
Comprehensive smoke-free legislation has been introduced in other jurisdictions 
such as Norway and Italy. In Brazil, since December 2011, the Federal Law 12546 
bans smoking in enclosed spaces throughout the country. Tobacco advertising is 
restricted to posters in shops and banned on television and radio. In 2012, Brazil 
became the first country in the world to outlaw all flavours and additives in 
tobacco products because they lure people to start smoking (94-96). Brazil has 
reduced its smoking prevalence by 46% in the last 20 years. A study attributed 14% 
of the reduction to the implementation of smoke-free air laws, 14% to marketing 
restrictions, and 8% to health warnings (97).  
 
Both direct studies of hospitality venues (25, 26, 98, 99) and surveys (87, 100) of 
the general population have shown that compliance with smoke-free legislation 
remains high in countries with good enforcement and sufficiently high fines. 
However, compliance in some countries has been poorer. In Greece, the level of 
indoor exposure to SHS remains high, with 72.2% of the population exposed in 
restaurants and 52.3% in workplaces, in spite of its comprehensive smoke-free 
legislation (101). In Russia, 21.9 million adults (34.9% of the adult population) are 
still exposed to SHS in their workplace (102). 
 
Furthermore, there are some countries that still do not have comprehensive 
smoke-free law with national coverage, such as the US, China and Australia. 
Alternative methods such as regional laws have been proposed to eliminate the 
harmfulness of environmental tobacco exposure. 
 
The US Congress has not yet enacted any nationwide federal smoking ban. Since 
California became the first state to introduce a statewide smoking ban, an 
increasing number of states have enacted statewide legislation. To date, 40 states 
and the District of Columbia have local laws in effect which require non-hospitality 
workplaces, restaurants and bars to be 100% smoke-free. According to the 
American Non-smokers’ Rights Foundation, 81.9% of the US population lives under 
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the smoking bans, but only 49.3% under a ban that covers all workplaces, 
restaurants and bars (103). Although the US Surgeon General’s report has 
concluded that the only way to fully protect non-smokers from exposure to SHS 
exposure is to prohibit smoking in all indoor areas, including private-sector 
worksites, restaurants, and bars (62), regional disparities remain in policy 
adoption (104).  
 
In Australia, smoking bans have been determined on a state-by-state basis. 
Currently, all Australian states and territories have banned smoking in most 
enclosed public places and in vehicles carrying children under the age of 16 years. 
Tobacco products are not allowed to be sold to people under 18 years old (105). 
From July 2015, commercial outdoor dining areas in New South Wales, Australia 
are also smoke-free (106). 
 
The FCTC came into force in China in 2006 (107). Action has been limited to 
several cities such as Beijing, Shanghai, and Guangzhou which have enacted local 
regulations to prohibit smoking in public places (108). National legislation is 
urgently needed to effectively reduce the increasing health and economic burden 
of smoking- and SHS-related diseases.  
 
1.2.5.2 Public opinion 
Opinion polls have shown considerable support for smoke-free air legislation. 
Worldwide, over 75% of young people support smoke-free laws (109, 110). In 
Ireland, after implementation, 93% of the population supported the smoke-free 
legislation, compared with 59% before (87). Public support for total bans also 
increased. Among smokers, 46% reported that the legislation made them more 
likely to quit. Among those who had quit smoking post-legislation, 80% indicated 
that the law had helped them quit smoking and 88% reported that the law made 
them less likely to smoke again (18). In Norway, the smoke-free legislation had 
the support of over 75% of the population by the end of the first year after 
implementation (111).  
 
1.2.5.3 Health impact of smoke-free legislation 
There is growing evidence that links the implementation of smoke-free legislation 
with a reduction in hospital admissions for outcomes related to exposure to SHS. 
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A meta-analysis published in 2013 examined the effectiveness of smoke-free 
legislation on the risk of acute myocardial infraction (AMI). This review of 18 
studies (44 estimates of effect size since the first smoke-free law in 2004) 
demonstrated a significant reduction in the incidence of AMI following 
implementation of smoking bans in workplaces and public places, with a pooled 
estimate of RR of 0.87 (95% CI 0.84-0.91) (112). Another meta-analysis was 
conducted in 2012 to determine the association between smoke-free legislation 
and hospitalisations for cardiac, cerebrovascular and respiratory diseases. They 
included 45 studies of 33 smoke-free laws with a median follow-up of 2 years. The 
outcomes in this study included: AMI, acute coronary syndrome (ACS), acute 
coronary events (ACE), ischemic heart disease (IHD), angina, CHD, sudden cardiac 
death (SCD), stroke, transient ischemic attack (TIA), COPD, asthma, respiratory 
infections, and spontaneous pneumothorax. They found that comprehensive 
smoke-free legislation was significantly associated with lower hospital admission 
rates (or deaths) for 4 diagnostic groups: coronary events (RR=0.85, 95% CI 0.82–
0.88), other heart disease (RR=0.61, 95% CI 0.44–0.85), cerebrovascular accidents 
(RR=0.840, 95% CI 0.75–0.94), and respiratory disease (RR=0.76, 95% CI 0.68– 0.85) 
(113). A study in Norway evaluated the effect of an indoor smoking ban on 
respiratory symptoms including morning cough, daytime cough, phlegm cough, 
dyspnea and wheezing among workers in the hospitality industry five months after 
enactment. There was a significant decrease in these symptoms, with the largest 
decrease observed among people who had quitted smoking and among those who 
reported a positive attitude towards the smoking ban (114). In a meta-analysis, 
researchers extracted data from five North American local smoking bans and six 
European national bans. Implementation of smoking bans was associated with a 
10.4% reduction in preterm birth and a 10.1% reduction in hospital attendances 
for asthma (115). 
 
In Scotland, 10 months after the implementation of the legislation, there was an 
overall 17% reduction of the number of hospital admission for acute coronary 
syndrome, with a 14% reduction among smokers, a 19% reduction among ex-
smokers and a 21% reduction among never smokers, when compared with those 
numbers during the 10 months before implementation (116). As for admissions for 
childhood asthma in Scotland, there was a mean reduction of 18.2% per year 
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relative to the rate on the legislation implementation day, in contrast to a mean 
rate of 5.2% admission per year before the legislation (75). 
  
Therefore, there is now ample evidence that smoke-free legislation can reduce 
SHS exposure in both workers and the general population. The implementation of 
smoke-free legislation is associated with many benefits including reduced hospital 
admission for health conditions related to SHS exposure. 
 
1.3 Peripheral arterial disease 
Peripheral vascular disease (PVD) refers to diseases of blood vessels (arteries and 
veins) located outside the coronary, aortic arch vasculature or brain. PVD is 
commonly referred to as PAD, or peripheral artery occlusive disease (PAOD) 
resulting from atherosclerotic blockages in the arteries in the lower extremity. 
PAD is often defined, in studies, as an ankle brachial pressure index (ABPI or ABI) 
of less than 0.9. ABI is the ratio of the ankle to the arm blood pressure. The main 
cause of PAD is chronic atherosclerosis in the lower extremity (117). A variety of 
risk factors for PAD are almost identical to those of atherosclerotic disease 
elsewhere (12). Active cigarette smoking is the most important risk factor (13, 
118).  
1.3.1 Prevalence and classification of peripheral arterial disease 
1.3.1.1 Prevalence  
Worldwide, about 202 million people were diagnosed with PAD in 2010. Of these, 
69.7% were living in low-income or middle-income countries (LMIC). More than one 
quarter of the people who had PAD were living in Southeast Asia and more than 
one fifth living in West Pacific Region. In the last decade, the prevalence of PAD 
has increased by 28.7% and 13.1% in LMIC and high-income countries (HIC) 
respectively (119).  
Sex-specific prevalence of PAD increased with advancing age. In HIC, PAD affected 
5.28% (95% CI 3.38-8.17%) in women and 5.41% (95% CI 3.41-8.49%) in men aged 
45-49 years, and 18.38% (95% CI 11.16-28.76%) in women and 18.83% (95% CI 12.03-
28.25%) in men aged 80-89 years. In LMIC, prevalence was higher in women than 
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in men aged 45-49 years (6.31% [95% CI 4.86-8.15%] for women; 2.89% [95% CI 
2.04-4.07%] for men). The prevalence in LMIC was 15.22% (95% CI 10.80-21.02%) 
in women and 14.94% (95% CI 9.58-22.56%) in men aged 80-89 years (119). 
In the Edinburgh Artery Study, PAD affects 16.6% in people aged 55-74 years (120). 
Price and her colleagues have reported from the 5-year follow-up of the Edinburgh 
Artery Study, the incidence of symptomatic PAD is 5.1% in people aged 55-74 years 
(121). 
1.3.1.2 Classification  
PAD may be asymptomatic or symptomatic. In Europe and North America, an 
estimated 27 million people have PAD. Of these, 60% are asymptomatic (122). 
Symptomatic patients usually present initially with intermittent claudication (IC). 
This is defined as muscle discomfort (ache, cramp, numbness or sense of fatigue) 
felt by the patient, classically in the calf, which occurs during exercise, such as 
walking, and is relieved with rest. Clinically, PAD is commonly classified using 
Fontaine’s stages or Rutherford’s categories (Table 1.4) (123). Progression of the 
disease can result in rest pain: more severe pain that is not relieved by rest or can 
occur at rest. Finally, severe and prolonged ischaemia can cause ulceration or 
gangrene in the lower limb.     
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Table 1.4 Classifications of peripheral arterial disease by Fontaine’s stages 
and Rutherford’s categories 
 
  
Fontaine’s classification Rutherford’s classification 
  
Stage clinical description grade category clinical description 
     
     
Ⅰ Asymptomatic 0 0 Asymptomatic 
Ⅱa Mild claudication Ⅰ 1 Mild claudication 
Ⅱb Moderate to severe claudication Ⅰ 2 Moderate claudication 
Ⅲ Ischemic rest pain Ⅰ 3 Severe claudication 
Ⅳ Ulceration or gangrene Ⅱ 4 Ischemic rest pain 
  Ⅲ 5 Minor tissue loss 
  Ⅲ 6 Major tissue loss 
     
Source:  Adapted from:  
Fontaine’s classification: (124) 
Rutherford’s classification: (125, 126) 
 
1.3.2 Development of PAD 
PAD often co-exists with CHD and/or cerebrovascular disease (121). The presence 
of PAD increases an individual’s risk of suffering angina, myocardial infarction (MI) 
or stroke (7). PAD is also more frequent among diabetic patients than among non-
diabetic subjects (127) . 
The development of PAD is a complex, multifactorial process of atherogenesis that 
involves three stages: initiation of the lesion of the arteries, progression of the 
lesion, and plaque complications. Many risk factors are common to those of 
atherosclerotic disease elsewhere in the body, including demographic and lifestyle 
factors as described below. 
1.3.2.1 Demographic factors 
The prevalence of PAD is age-dependent. In a German study, the prevalence of 
PAD increased from 3.0% in men aged 45-49 years to 18.2% in men aged 70-75 
years. PAD affected 2.7% in women aged 45-49 years and 10.8% in women aged 
70-75 years (128). Approximately 8 million people in the US are affected by PAD 
and 20% of adults older than 55 years require treatment for PAD (129).  
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In relation to cardiovascular diseases (CVDs), there are widely accepted sex 
differences in risk. In contrast, the influence of gender on the prevalence of PAD 
is controversial. Some studies have suggested an increased risk among men (130, 
131). While some other studies have reported that, between the ages of 60 and 
85 years, the prevalence of PAD is higher among women (8). The Rotterdam study 
also showed a higher prevalence of PAD among women aged ≥ 55 years. The 
frequency of PAD varies by ethnic subgroup (9-11). Criqui et al. documented that 
non-Hispanic blacks had significantly higher PAD prevalence compared to non-
Hispanic whites (132). 
 
1.3.2.2 Lifestyle factors 
Lifestyle factors that are strongly associated with PAD include cigarette smoking, 
obesity, diabetic mellitus (diabetes), dyslipidaemia and hypertension.  
Smoking  
Smoking is one of the most important, modifiable risk factors for PAD (13). The 
association was first identified by Erb in 1911 who reported that the risk of IC was 
three times greater among smokers (133). Many studies have since been conducted 
corroborating his findings. According to WHO, almost 20% of the global population 
smoke tobacco (84) and 84% of these smokers live in developing and transitional 
economy countries (134).  
 
Active smoking and SHS exposure can have detrimental effects on cardiomyocytes 
and peripheral vessels. Though the exact mechanism of how smoking induces 
atherosclerosis is not completely understood, experimental models suggest toxins 
in cigarettes, including oxidative free radicals, impair mitochondrial function and 
energy metabolism of the endothelial cells thus altering cell function and 
damaging vessel walls (135). This increases lipid permeability, platelet 
aggregation and adhesion, and formation of coagulation factors and decreases 
fibrinolysis, resulting in arterial stiffness and narrowing. The main component of 
cigarettes, nicotine, is a euphoriant affecting mood and behaviour and has been 
clearly implicated as the source of smoking addiction (136). Nicotine and its 
metabolite cotinine increase the level of platelet-dependent thrombin (137). 
Chapter 1 General introduction 
45 
Thrombin is an important enzyme in the coagulation cascade and also a potent 
platelet agonist. Increased platelet activity is a key risk factor for atherosclerosis. 
Platelet-dependent thrombin may play a role in thrombus formation (138). Also 
nicotine stimulates sympathoadrenal activity, and therefore may lead to changes 
in blood flow (139). Another major component, CO, exacerbates vessel 
constriction by competitively attaching to haemoglobin (normally bound with 
oxygen) which reduces oxygen supply in the blood (140, 141). The lack of 
oxygenated blood and reduced blood flow through smaller vessels and capillaries 
together may lead to ischemia in the lower limbs.  
 
In a meta-analysis published in 2013, on prevalent PAD and its risk factors, current 
smoking was the strongest lifestyle risk factor for PAD, with a pooled OR of 2.72 
(95% CI 2.39-3.09) in HIC and 1.42 (95%CI 1.25-1.62) in LMIC, followed by diabetes, 
hypertension and hypercholesterolemia (119). Willigendael et al. suggested that 
in countries where approximately 30% of the population are smokers, 50% of PAD 
cases are attributable to smoking (16). The US National Health and Nutrition 
Examination Survey (NHANES) 1999-2004 which comprised 3,947 men and women 
aged over 60 years showed current smokers were 5.84 times more likely to develop 
PAD, and former smokers were 1.94 times more likely, compared to never smokers 
(142). Continuous and long-term exposure to active smoking is associated with a 
higher risk of developing PAD. People who have a long history of smoking 
constitute a high risk group for PAD. Merino and other researchers have reported 
that the incidence of new PAD at five years follow-up is around 20% overall but is 
significantly higher among those who had smoked more than 40 pack-year (143). 
There appears to be a dose relationship, whereby the risk of PAD increases with 
the number of cigarettes smoked.  
 
The Edinburgh Artery Study is a cohort study in which the study population is 
comprised of 1,592 Edinburgh inhabitants aged 55 to 74 years. In a previous study, 
heavy smokers (defined as pack years ≥ 25) were demonstrated to have 3.94 fold 
risk of developing intermittent claudication compared with never smokers, and 
moderate smokers (defined as pack year <25) to have 1.87 fold higher risk (121). 
Since PAD is considered to be associated with previous cardiovascular events (13, 
144) and smoking is one of the major factors responsible for CVDs (14, 15, 118) 
and diabetes mellitus (145, 146), being a smoker and at the same time having 
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additional comorbid factors may even enhance the probability of developing PAD 
(13) and aggravate the condition of these diseases (12, 147). Among type 2 
diabetic patients in a cohort followed up for 12-years, current smokers who 
smoked over 25 cigarettes per day were nearly 11 times more likely to develop  
PAD, and those who consumed less than 14 cigarettes a day were almost 5 times 
more likely, compared with never smokers (148). People who start smoking at an 
early age and those who continue to smoke long-term are at greatest risk of the 
disease. Some studies indicate that initiating smoking at an early age (less than 
16 years) doubles the risk in comparison with those who start smoking later than 
16 years of age (149).   
 
As with current smokers, former smokers are also at increased risk of developing 
the disease in comparison with never smokers. Being a former smoker appears to 
be associated with a risk of PAD that lies between that of current and never 
smokers (13, 118). This suggests that cessation of smoking is associated with 
reduced risk (150, 151). However, ex-smokers comprise both recent quitters and 
those who have not smoked for many years. The effect of smoking cessation has 
been studied extensively for CVDs in terms of the rate of risk reduction, whether 
the reduction is linear or non-linear, whether it eventually reverts to the level of 
risk among never smokers and whether this is dependent on the duration of 
smoking (152-154). In contrast there is a relative paucity of information on the 
impact of smoking cessation on the risk of PAD. Among people who quit smoking 
≥ 21 years previously the relative risk of PAD, in comparison with current smokers, 
was 0.41 among those who originally smoked for 11 years and 0.49 among those 
who had smoked 20 years (151). Quitting smoking is believed to reduce risk of 
PAD, even among diabetic smokers due to reduced chronic inflammation (150). 
Quitting or reducing smoking may also reduce the risk of disease progression 
among those who have already developed PAD (155). Hobbs et al. reviewed the 
published evidence relating to smoking cessation on the MEDLINE and the 
Cochrane Library including meta-analyses of randomised controlled trials. They 
suggested that permanent smoking cessation is probably the most clinically and 
cost effective intervention for PAD patients (156). It is also suggested by 
researchers that a comprehensive program including smoking cessation is 
important to prevent cardiovascular events among patients with PAD (157). 
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In conclusion, smoking impairs normal circulation by narrowing the blood vessels 
and decreasing the amount of oxygen in the blood, leading to ischemia in lower 
limbs, and thus PAD (158). Cigarette smoking is a stronger risk factor for PAD than 
for other CVDs (159) and also the most modifiable major factor. Hence, smoking 
cessation plays a vital role in reducing PAD risk, slowing down PAD progression and 
improving prognosis (158). 
 
Other modifiable risk factors 
Other modifiable risk factors for PAD include diabetes, hypertension, and 
dyslipidemia (160). A recent meta-analysis has demonstrated the association 
between these three risk factors and risk of PAD: diabetes (pooled OR 1.88, 95% 
CI 1.66-2.14 in HIC; pooled OR 1.47, 95% CI 1.29-1.68 in LMIC); hypertension 
(pooled OR 1.55, 95% CI 1.42-1.71 in HIC; pooled OR 1.36, 95%CI 1.24-1.50 in LMIC); 
and hypercholesterolemia (pooled OR 1.19, 95%CI 1.07-1.33 in HIC; pooled OR 1.14 
95%CI 1.03-1.25 in LMIC) (119). Diabetes is associated with large and small vessel 
atherosclerotic occlusive diseases. In one study using the 1999–2004 NHANES, PAD 
prevalence among adults aged ≥ 40 was significantly higher among adults with 
undiagnosed (9.2%) and diagnosed diabetes (7.5%) than those with normal glucose 
concentrations (3.9%) (161). Researchers have suggested that the risk of 
developing PAD is proportional to the severity and duration of diabetes (162). 
Other studies have linked hypertension with an increased risk of PAD. The 
Framingham study suggested that the risk of IC was increased 2.5 fold among men 
with hypertension and 3.9 fold among women with hypertension (163). 
Dyslipidemia, such as hypertriglyceridemia, lipoproteinemia and 
hyperhomocysteinemia, has also been related to an increased risk of PAD (164-
166). A study, among 14,916 healthy men aged >40 years, examined the predictive 
values of lipid and non-lipid biomarkers as risk factors for incident PAD. Among 
lipid biomarkers, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-
C), High-density lipoprotein cholesterol (HDL-C), TC/HDL-C ratio, Apolipoprotein 
B-100 and fibrinogen were predictors of the development of PAD.  The TC/HDL-C 
ratio was the strongest lipid predictor of risk (adjusted RR for the highest vs lowest 
quartile 3.9, 95% CI 1.7-8.6). C-reactive protein (CRP) was the strongest nonlipid 
predictor (RR for the highest vs lowest quartile 2.8, 95% CI 1.3-5.9) (167). In the 
Cardiovascular Health Study, higher body mass index (BMI) was found to be 
associated with PAD prevalence in older persons in good health who had never 
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smoked (prevalence ratio 1.30, 95% CI 1.11-1.51) (168).The concurrence of 
multiple risk factors increases the risk for PAD. The RR for PAD increased from 2.3, 
3.3 to 6.3 when smoking, diabetes and systolic hypertension concurred 
respectively (169).  
1.3.2.3 Pathophysiology  
PAD is similar to atherosclerosis elsewhere in the body. Atherosclerosis can be 
briefly described as being divided into several stages: lesion initiation, progression 
of the lesion, and plague complications (170). Smoking, diabetes, dyslipidemia, 
high blood pressure and other risk factors can cause endothelial injury or 
endothelial dysfunction (171-174). 
The lesion initiation stage is endothelial injury. This stage involves recruitment of 
monocytes to the intimal layer of the vessel wall, dependent on a number of 
adhesion molecules including selectins and vascular cell molecule-1 (VCAM-1) 
(170). Selectins are responsible for transient deposition of leukocytes on the 
epithelium. VCAM-1 is involved in binding monocytes and lymphocytes on the 
epithelial cells (175). After the leucocytes have immigrated into the intima, they 
collect lipids and become foam cells. The release of some growth factors, 
including platelet-derived growth factor (PDGF), leads to smooth muscle cell 
migration and proliferation. Foam cells of atheromatous plaques are originated 
from macrophages or smooth muscle cells via the very-low-density lipoprotein 
(VLDL) receptor and LDL modifications recognized by scavenger receptors. The 
foam cells form so-called “fatty streaks”, inflammatory lesions that affect the 
intima of the artery. The fatty streaks are largely constituted of smooth muscle 
cells, macrophages, monocytes, and T and B cells. The final stage of atherogenesis 
is that the fatty streaks then develop into fibroproliferative atheroma (plaque) 
that contains a number of smooth muscle cells filled with lipids. The advanced 
lesion contains intrinsic vascular wall cells (endothelial and smooth muscle cells) 
and inflammatory cells (monocytes, macrophages and T lymphocytes). This 
cellular component is then combined with a lipid core covered by a fibrous cap 
(170). Two factors play an important role in determining whether the plaque is 
stable or not: the thickness of the fibrous plaque and the amount of extracellular 
matrix including collagen synthesised by proliferated smooth muscle cells (176). 
T cells may inhibit collagen synthesis (177). Macrophages can digest the collagen 
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of the fibrous cap and make the plaque unstable (178). The progressively built-up 
plague in the lining of artery leads to the narrowing of the vessels (174). 
When the fibrous cap is disrupted, a coagulation cascade initiates. The platelets, 
fibrinogen and other coagulation factors form a platelet clump (170). If the 
platelet clump is attached to the vessel wall firmly, it can continue to build in 
size until it completely blocks the vessel lumen. However, if the platelet clump is 
not firmly attached to the vessel wall, it may separate into smaller clumps due to 
the blood flow (174). The detached clumps flow to downstream vessels and 
occlude peripheral vessels, and cause relevant clinical events of ischemic injury 
such as thrombotic stroke, MI and peripheral arterial disease (179). Figure 1.1 
shows the stages of atherosclerosis briefly.  
The compensatory mechanisms involve remodeling such as vasodilation, anaerobic 
metabolism and development of collateral vessels (174, 180). As PAD progresses, 
these compensatory mechanisms cannot offset the oxygen demands for the 
ischemic region. Tissues in the relevant region tend to experience necrosis (ulcer, 
gangrene, amputation) (13, 181, 182).  
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Figure 1.1 Atherosclerosis stages of development 
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1.3.3 Management  
1.3.3.1 Public health burden  
Since PAD often co-exists with CHD and other cerebrovascular disease and shares 
many risk factors, the prevalence of PAD is high and increasing. In the US, PAD 
affects 8 to 12 million individuals (12). It is estimated that the initial treatment 
episode of a patient requiring major lower limb amputation costs about $65,000 
(£40,000), representing a huge cost to the health service (183). In the UK, there 
are approximately 3,500 lower limb amputations carried out every year as a result 
of PAD (184). Critical limb ischaemia has been estimated to cost the health service 
over £200 million per year (185).  
Of the estimated 27 million people who have PAD in Europe and North America, 
60% are asymptomatic (122). In the late stages of the disease, PAD progresses to 
ischemic ulcer and gangrene. Major amputation may be required eventually in at 
least a third of these patients (186). However, public awareness of PAD - diagnosis, 
risk factor knowledge, symptoms and amputation risk – is low (187). In the USA, 
only 25% of people with PAD are under treatment. In a 10-year follow-up, patients 
with PAD were found to have a higher risk of all-cause death (adjusted RR 3.1, 
95%CI 1.9-4.9) death from CVDs (adjusted RR 5.9, 95%CI 3.0-11.4) and death from 
CHD (adjusted RR 6.6 95%CI 2.9-14.9), compared with patients without PAD (188).  
1.3.3.2 Treatment 
The treatment of PAD mainly aims to improve lifestyle risk factors, alleviate 
symptoms, halt or slow the progression of PAD, and reduce the risk of 
cardiovascular events (MI, stroke and death)(12). In some cases, surgery may be 
required. What type of treatment is suitable depends on the extent and severity 
of the disease condition (12, 189). 
Smoking cessation has received a class I recommendation in the American College 
of Cardiology/American Heart Association (ACC/AHA) guidelines. Smoking 
cessation has been shown to not only reduce claudication symptoms but also 
reduced overall mortality and cardiovascular events (190). A Finnish study 
reported adjusted OR 0.86 (95% CI 0.75-0.99) of IC in ex-smokers, compared with 
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current smokers (191). Cui et al. reported no significant difference within 19 years 
of smoking cessation but the risk of PAD was significantly reduced among those 
who had stopped smoking at least 20 years previously (OR 0.30, 95% CI 0.10-0.90) 
(155).  
Modifying diet and/or taking up exercise may help slow down the progression of 
PAD when IC is the only symptom. Törnwall et al. reported an inverse association 
between incidence of IC and dietary intake of anti-oxidants such as vitamin C, α-
Tocopherol and β-carotene (191). A meta-analysis of three different randomised 
trials has found that surgical reconstruction combined with subsequent physical 
training increased the symptom-free walking distance in patients of IC (192). In 
the management of PAD, supervised exercise has been recommended by the 
National Institute for Health and Care Excellence (NICE) as one of the first steps.  
Diabetes, hypertension and hyperlipidemia are the other three major risk factors 
for PAD (160). The American Diabetes Association suggested tight control of 
diabetes (hemoglobin A1c of <7%) among PAD patients to reduce 
complications(193). In the Diabetes Control and Complication Trial, type I 
diabetes patients experienced a 22% risk reduction of PAD events following 
intensive insulin therapy (194).  Whether anti-hypertensive treatment reduces the 
progression of PAD is not fully known. But the Heart Outcomes Prevention 
Evaluation Study found that the anti-hypertensive therapies, angiotensin 
converting enzyme inhibitors and angiotensin receptor blockers, diminished the 
progression symptoms of PAD (195). Researchers have suggested a target LDL-C 
concentration of <100 mg/dL for PAD patients and a target LDL-C concentration 
of < 70 mg/dL if PAD coexists with other CVDs (196). Statins are commonly 
recommended for hyperlipidemia and antiplatelet medications may be 
recommended to reduce the risk of blood clot (197). 
Endovascular therapy for PAD includes angioplasty and stenting. Owing to the 
advances of catheter and balloon design, the number of percutaneous procedures 
has increased (198). If endovascular therapy is not appropriate, arterial bypass 
surgery can be performed to divert blood which is not able to flow down a blocked 
artery through an artificial vessel to reach the tissues which need it.  
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1.4 Summary of the introduction 
SHS is inhaled smoke from other people’s cigarettes and contains over 250 harmful 
chemicals. Exposure to SHS has both immediate and long-term adverse effects on 
health, and the WHO has recognised no-safe level for SHS exposure. In spite of 
this, only 16% of the global population is currently protected from SHS exposure 
by comprehensive smoke-free legislation (3).  
Among non-smoking adults, SHS has been linked with increased risk of many 
diseases, including coronary heart disease and stroke (4, 6). In a meta-analysis, 
exposure to SHS was associated with a 25% increased risk of CHD (4). In the British 
Regional Heart Study, the risk of CHD among non-smokers exposed to high levels 
of SHS was comparable to that among light active smokers, in spite of a 30-fold 
difference in cotinine concentration (67). This contrasts with the relationship 
between tobacco smoke exposure and lung cancer where there is a linear 
relationship between cotinine concentration and lung cancer risk across the 
continuum from SHS exposure to active smoking (63, 66). The disproportionately 
high risk of CHD associated with SHS exposure is thought to be due to constituents 
other than nicotine (199). SHS is a mixture of air-diluted ‘sidestream’ smoke from 
a burning cigarette tip, and the ‘mainstream’ smoke exhaled by the smoker but 
sidestream smoke contains more toxic gases and small (< 2.5 µm), respirable 
particles than mainstream smoke. These appear to be particularly injurious to the 
vascular system (199).  
PAD refers to atherosclerosis in the limbs. It shares many risk factors with other 
atherosclerotic conditions and, therefore, often co-exists with CHD and 
cerebrovascular disease (200). Many studies have reported a significant 
association between active smoking and PAD (118, 200). In contrast, research 
studies are generally lacking on the association between SHS exposure and risk of 
PAD. PAD is a relatively common condition and its prevalence is increasing due to 
the ageing population (13, 200). It is associated with increased risk of major 
morbidity and mortality (200). Therefore, it is important to identify and address 
modifiable risk factors and, specifically, to determine whether exposure to SHS 
may play a role.   
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1.5 Aims and objectives of this thesis 
The aim of this thesis is to establish whether tobacco exposure is associated with 
PAD.  
Firstly, in order to inform my own studies, I undertook a systematic review of the 
published literature pertaining to the association between exposure to tobacco 
smoke (both active cigarette smoking and exposure to SHS) and PAD. I confirmed 
that there is already sufficient evidence of the association between active 
smoking and PAD and I performed a meta-analysis to summarise this evidence. I 
also confirmed the current lack of published evidence on the association between 
SHS exposure and PAD.  
Therefore, I focused on the association between SHS exposure and PAD. I used 
existing sources of data collected from the Scottish general population to examine 
the association between exposure to SHS and PAD. I identified two potential data 
sources: the Generation Scotland: Scottish Family Health Study (GS:SFHS) and the 
Scottish Health Survey (SHeS). These studies used different approaches to both 
measuring SHS exposure and the definition of PAD. Therefore, I was able to 
determine whether the results were consistent using these complementary studies 
that, effectively, addressed some of the weaknesses of each other. I used both 
resources to undertake cross-sectional studies. I then addressed the limitations of 
using a cross-sectional design by using record linkage of the SHeS data to 
undertake a third, cohort study.  
Having demonstrated an association between SHS exposure and PAD, I then aimed 
to explore whether the disproportionately high risk of CHD associated with SHS 
exposure also holds true for PAD. In the Physician’s Heart Study, researchers have 
suggested that TC/HDL-C ratio and CRP are strong predictors of incident PVD, 
independent of heart disease (167). A review of 13 prospective studies on CRP as 
a predictor for PVD has shown a strong association between CRP and PVD (201). I 
then used the SHeS to examine whether exposure to SHS is associated with 
disproportionately higher biomarkers of cardiovascular risk compared with active 
smoking. 
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Finally, since PAD is an age-related condition (13, 200), I took advantage of the 
existence of leukocyte telomere length data in a subgroup of the SFHS, to explore 
whether SHS exposure was associated with evidence of biological ageing. 
Therefore, this thesis comprises six complementary studies that address the 
following specific objectives: 
1. To undertake a systematic review on the association between exposure to 
tobacco smoke (both active cigarette smoking and exposure to SHS) and 
PAD (Chapter 2, 1 study: systematic review). 
2. To determine whether exposure to SHS (measured as self-reported in 
GS:SFHS and as salivary cotinine concentrations in SHeS) was independently 
associated with PAD (defined by ABPI in GS:SFHS and by the Edinburgh 
Claudication Questionnaire in SHeS), whether exposure to SHS was an 
independent predictor of incident hospitalisations of PAD and all-cause 
mortality, and whether the associations varied by sex (Chapter 3, 2 cross-
sectional studies and 1 retrospective study). 
3. To determine whether SHS carries a disproportionately higher 
cardiovascular risk than active smoking for a given level of smoke exposure 
(Chapter 4, 1 cross-sectional study) 
4. To determine whether there is any association between SHS and leukocyte 
telomere shortening per year of age (Chapter 4, 1 cross-sectional study) 
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2.1 Chapter summary 
 
Cigarette smoking is an important risk factor for CHD, stroke and PAD. Many 
studies have also demonstrated an association between exposure to SHS and CHD 
and stroke. In contrast, there have been fewer studies on the association between 
active cigarette and PAD, and very few studies on SHS and PAD. In this chapter, a 
systematic review on the association between exposure to tobacco smoke (both 
active cigarette smoking and exposure to SHS) and PAD was conducted.  
 
Medline, Embase, PubMed and Web of Science databases were used to identify 
relevant articles published up to 30 April 2012. Prior to the published studies in 
this thesis, there had been no published meta-analyses on the association between 
active cigarette smoking and PAD. Only two published studies on the association 
between exposure to SHS and PAD were identified. Therefore, this systematic 
review was followed by a meta-analysis of the published studies on the association 
between active cigarette smoking and PAD. Overall and stratified random effects 
meta-analyses, cumulative meta-analyses and meta-regression analyses were 
conducted. Heterogeneity was tested using the I2 test, and publication and small 
study bias were tested using funnel plots and Egger’s test. Fifty-five eligible 
studies were identified: 43 cross-sectional, 10 cohort and 2 case-control. Of the 
68 results for current smokers, 59 (86.8%) were statistically significant and the 
pooled OR was 2.71 (95% CI 2.28-3.21). There was a high level of heterogeneity (I2 
94.9%, p<0.001) and the Egger’s test was significant (p=0.023). The association 
with active smoking was significant among both general (OR 3.08, 95% CI 2.56-
3.69) and disease populations (OR 1.54, 95% CI 1.31-1.83). Of the 40 results for 
ex-smokers, 29 (72.5%) were statistically significant and the pooled OR was 1.67 
(95% CI 1.54-1.81). There was moderate heterogeneity (I2 54.7%, p<0.001) and the 
Egger’s test was significant (p<0.001). 
 
There is now substantial evidence of an association between active smoking and 
PAD. The magnitude of the association is greater than that reported for CHD. The 
risk is lower among ex-smokers but, nonetheless, significantly increased compared 
with never smokers. The results highlight the need for interventions both to 
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encourage quitting among existing smokers and discourage commencement among 
never smokers. However, the paucity of evidence on the association between SHS 
and PAD suggests that research is needed to examine whether there is an 
association. 
 
2.2 Introduction 
 
Almost one-fifth of the global population smoke tobacco or tobacco-related 
products, and the prevalence is increasing (202). Tobacco-related diseases 
account for approximately one death every six seconds, and up to half of the 
world’s one billion smokers will die of a tobacco-related disease (203).  
 
As described in the introduction chapter, CHD, stroke and PAD are all types of 
atherosclerosis. They often co-exist in the same patients and share many common 
risk factors including cigarette smoking (121, 204). It is generally assumed that 
CHD, stroke and PAD are manifestations of the same atherosclerotic disease 
process (204). However, there are some important differences. It has been more 
than a decade since it was shown that the magnitude of the association between 
active smoking and PAD may be even greater than that observed for CHD (121, 
205). In spite of this, previous epidemiological studies, including those on active 
smoking have focused on CHD and stroke and pay relatively little attention to PAD.  
 
There have been numerous studies on the association between active smoking and 
CHD and stroke. In 2011, a meta-analysis of 75 cohort studies reported that active 
smoking increased the risk of CHD in both men (RR 1.72, 95% CI 1.57-1.88) and 
women (RR 1.92, 95% CI 1.66-2.23) (15). Overall, the risk among ex-smokers lies 
between that of current and never smokers (206), but falls with increasing time 
from cessation. It also varies according to the duration of smoking prior to 
cessation; such that the risk will never fall to that of never smokers if cessation 
follows a prolonged period of smoking (207, 208). In 2013, a meta-analysis of 81 
prospective cohort studies estimated the effect of active smoking in women 
compared with men. The pooled RR of stroke associated with current smoking 
compared with non-smoking was 1.83 (95% CI 1.58-2.12) in women and 1.67 (95% 
CI 1.49-1.88) in men. The risk of stroke was lower in ex-smokers than in current 
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smokers but still significantly increased compared with never smokers in both 
sexes (209).  
 
Studies collated into published meta-analyses have also shown significant 
association between SHS and CHD and stroke. In 1999, a meta-analysis of 18 
studies reported a RR of 1.25 (95% CI 1.17-1.32) for CHD. There was evidence of a 
clear dose response relationship, with the RR increasing from 1.23 (95% CI 1.13-
1.34) among those exposed to 1-19 cigarettes per day to 1.31 (95% CI 1.21-1.42) 
among those exposed to ≥20 cigarettes per day (4). In 2011, a meta-analysis of 20 
studies on SHS demonstrated an increased risk of stroke (RR 1.25, 95% CI 1.12-
1.38). A dose response relationship was also shown with the RR increasing from 
1.16 (95% CI 1.06-1.27) among those exposed to around 5 cigarettes per day to 
1.56 (95% CI 1.25-1.96) among those exposed to around 40 cigarettes per day (6).  
 
In contrast, there have been fewer individual studies on active smoking and PAD 
and very few individual studies on SHS exposure and PAD. An association between 
active smoking and PAD was first reported in 1911 (133). Smokers develop PAD ten 
years earlier than non-smokers (210), and their disease is more likely to progress 
to amputation (211). The only systematic review to examine the association 
between active smoking and PAD was published in 2004 and identified 4 relevant 
cohort studies and 13 cross-sectional studies. The authors estimated that in 
countries where 30% of the population are smokers, around 50% of the PAD cases 
can be attributable to smoking (16). However, there had been no meta-analysis. 
Therefore, in this chapter, I conducted an updated systematic review on the 
association between exposure to tobacco smoke (both active cigarette smoking 
and exposure to SHS) and PAD, and a meta-analysis of the association between 
active cigarette smoking and PAD. 
 
2.3 Materials and methods 
2.3.1 Systematic review  
A systematic review of the published literature pertaining to the association 
between smoking and PAD was undertaken. The reporting of this systematic 
review and meta-analysis was in accordance with the Preferred Reporting Items 
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for Systematic Review and Meta-Analysis (PRISMA) guidelines (212, 213). Studies 
were identified using the Medline, Embase, PubMed and ISI Web of Science 
databases. The electronic search strategy was developed on the basis of the 
Population Intervention Comparison Outcome (PICO) framework (214): i.) 
Population: participants who had either ABI measurements recorded or completed 
a claudication questionnaire such as the Edinburgh Claudication Questionnaire or 
had peripheral angiography performed; ii.) Intervention: exposure to active 
cigarette smoking or exposure to SHS; iii.) Comparison: exposure to active 
cigarette smoking or exposure to SHS versus (vs.) no exposure; iv.) Outcome: PAD. 
The following search terms were applied: (peripheral arter* OR peripheral athero* 
OR peripheral vascular OR claudication OR ABPI OR ABI OR ankle brachial) AND 
(smoking OR cigarette* OR tobacco OR nicotine OR smoke*). The final search was 
conducted on 30 April 2012. The electronic search was restricted to observational 
studies published as journal articles published in, or translated into, English and 
published between 1 January 1980 and 30 April 2012 inclusive and studies 
undertaken on humans (Appendix 1). The type of study design was restricted to 
observational study (cross-sectional study, case-control study, and cohort study).  
 
The articles identified by the electronic search were reviewed manually by 2 
researchers (my supervisor Professor Jill Pell and me). Inclusion was limited to 
original studies that: examined the risk of developing PAD rather than its 
outcomes; defined PAD based on ABI less than or equal to 0.90 (215), a 
claudication questionnaire or peripheral angiography; and quantified the 
association between active smoking, exposure to SHS and PAD and reported the 
result as an OR, RR or HR with CIs. Where the latter information was missing a 
single attempt was made to contact the corresponding author to obtain the 
relevant information. Interventional studies were excluded. The reference lists of 
the articles identified by the electronic search were checked for additional 
relevant studies. Observational studies that examined the association between 
active cigarette smoking and PAD and met the above inclusion and exclusion 
criteria were assessed to decide that whether or not they could be included in the 
meta-analysis. For the meta-analysis, studies were also excluded if some, or all, 
ex-smokers were included in the same category as current smokers or if some 
current smokers were excluded because they fell below a cut-off for the amount 
smoked. Studies were also excluded if the results were only expressed in terms of 
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the dose relationship with the amount smoked and not with smoking per se. Where 
more than one article related to the same study, only the most recent relevant 
article was used. The reference lists of eligible articles were reviewed to identify 
additional studies that might be relevant. 
 
The quality assessment for all studies included in the systematic review was 
conducted using the QualSyst tools for the quantitative studies. The QualSyst tool 
for assessment of the quality of quantitative studies is a generic validated 
checklist which is made up of 14 questions (Appendix 2) (216). The QualSyst tools 
have been used by many published systematic reviews and meta-analyses (217, 
218). The checklist for reporting meta-analyses of observational studies in 
epidemiology has been proposed and supported by the recommendations of a 
consensus statement and the National Health Service (NHS) Centres for Reviews 
and Dissemination (219, 220). This checklist for assessing the quality of 
quantitative studies includes: objective sufficiently described research question, 
appropriate study design, sufficiently described subject characteristics, well 
defined outcome and exposure, appropriate sample size, appropriate analytic 
methods, estimate of variance, control for confounding, detailed reporting of 
results, conclusions supported by the results (Appendix 2). 
 
The following information was extracted from each of the eligible studies: study 
size, design and continent, the sex of participants, decade of publication, 
definition of PAD, recruitment from the general population or a disease population, 
referent group and level of statistical adjustment. Where results were presented 
for relevant subgroups, these were used in preference to the overall results. 
Similarly, where results were presented both unadjusted and adjusted for 
potential confounders, the latter were used. Appendix 3 is the data extraction 
template (221).  
 
2.3.2 Meta-analysis 
OR can be approximated to RR if an outcome is rare (222). In those studies that 
reported only RRs, these were treated as equivalent to ORs. The results were 
categorised according to whether they compared current smokers with never/non-
smokers, ex-smokers with never smokers or ex-smokers with current smokers. 
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Random effects meta-analyses were undertaken to produce pooled estimates of 
effect size, both overall and stratified by study characteristics: study size, design 
and continent, the sex of participants, decade of publication, definition of PAD, 
recruitment from the general population or a disease population, referent group 
and level of statistical adjustment. Forest plots were used to display the results 
of the meta-analyses. I2 tests were used to estimate the magnitude and statistical 
significance of between-study heterogeneity. A value of 50% or more indicated a 
substantial level of heterogeneity (223). Funnel plots of the log ORs against 
standard errors were employed to assess visually whether publication or small 
study bias was likely. This was tested more formally using the Egger’s test of the 
intercept (224). A p value <0.05 was considered indicative of publication bias. 
Meta-influence plots were used to determine whether individual studies heavily 
influenced the pooled estimate and cumulative meta-analyses were used to 
determine the extent to which the pooled effect sizes had changed over time as 
evidence accumulated (225). In cumulative meta-analyses, the pooled estimate 
of effect size is updated each time the results of a new study are published. This 
allows detection of both temporal trends and publication bias (226). 
 
Univariable and multivariable meta-regression analyses were used to determine 
whether recorded study characteristics had contributed to between-study 
heterogeneity (227): study size, design and continent, the sex of participants, 
decade of publication, definition of PAD, recruitment from the general population 
or a disease population, referent group and level of statistical adjustment. When 
there are many covariates in meta-regressions, chances of false-positive findings 
increase. Higgins and Thompson proposed a permutation test approach to 
assessing the true statistical significance of meta-regression findings. At least 
1,000 permutations were suggested for sufficient precision (228). In this study, 
20,000 random permutations were used to produce multiplicity adjustment p 
values for each meta-regression analysis. P values <0.05 were considered 
statistically significant. All analyses were undertaken using Stata 12.0 (Stata 
Corporation, College Station, Texas, USA). 
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2.4 Results  
2.4.1 Systematic Review 
The electronic search identified 8,132 published articles. Of these, 3,631 were 
removed as duplicates and the titles of the remaining 4,501 articles were screened 
(Figure 2.1). Abstracts were reviewed for 341, and 100 justified review of the full 
text. Among these, only two studies were on SHS (38, 45). One study reported 
results for both active smoking and SHS (38), one for SHS only (45). For the meta-
analysis on the association between active smoking and PAD, the study which 
reported only on SHS was excluded. Therefore, among the 100 full texts reviewed, 
fifty-one satisfied the exclusion criteria, resulting in 49 studies eligible for 
inclusion. A further 8 eligible studies were identified following manual review of 
reference lists in the 49 selected studies. Only two studies reported results as HR 
which was insufficient to comprise a useful subgroup. Therefore, they were 
excluded. The remaining 55 studies were included in the meta-analysis. In this 
Section 2.4.1, narrative synthesis focused on the eligible studies which reported 
results for active smoking. The studies on SHS are summarised in Section 2.5.    
 
The 55 studies were published between 1989 and 2011 (Table 2.1). They included 
a total of 69,521 current smokers and 54,821 ex-smokers who were compared with 
relevant referent groups (Table 2.1). Twenty (36.4%) studies were conducted in 
Europe(130, 159, 191, 229-245), 15 (27.3%) in North or South America (38, 246-
259), 15 (27.3%) in Asia (151, 155, 260-272), 3 (5.5%) in Australia (273-275), and 1 
(1.8%) in Africa (276). One (1.8%) was multi-national (277). Eight studies (14.5%) 
recruited only male subjects (151, 155, 191, 239, 255, 260, 273, 274), 2 (3.6%) 
only female (257, 258), and 45 (81.8%) both (38, 130, 159, 229-238, 240-254, 256, 
259, 261-272, 275-277). Forty-three (78.2%) were cross-sectional studies (38, 130, 
151, 155, 159, 230-233, 235-238, 240, 241, 243, 246-249, 251-254, 256-259, 261-
273, 276, 277), 10 (18.2%) were cohort studies (191, 229, 234, 239, 245, 250, 255, 
260, 274, 275) and 2 (3.6%) were case-control studies (242, 244). Forty-seven 
(84.5%) studies defined PAD using the ABI (38, 130, 151, 155, 159, 229-233, 236-
241, 243-253, 256-259, 261-273, 275-277), and 7 (12.7%) based on symptoms of 
intermittent claudication, using either the Edinburgh, WHO/Rose or San Diego 
claudication questionnaires (191, 235, 242, 254, 255, 260, 274). One study (1.8%) 
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used both the ABI and a claudication questionnaire, and examined symptomatic 
and asymptomatic PAD separately (234).  
 
Of the 55 eligible studies, 24 (43.6%) reported results for both current and ex-
smokers (38, 130, 151, 155, 159, 229-231, 234-236, 238, 239, 244, 250, 254, 255, 
259, 260, 270, 273-275, 277), 24 (43.6%) for current smokers only (232, 233, 237, 
240-243, 245, 247-249, 251, 252, 256-258, 261, 265-267, 269, 271, 272, 276), and 
7 (12.7%) for ex-smokers only (191, 246, 253, 262-264, 268). The 48 studies on 
current smokers provided 68 estimates of effect size. Of these, 59 (86.8%) 
suggested a statistically significant association between current smoking and PAD 
(Figure 2.2). Current smokers were compared with never smokers in 29 (52.7%) 
studies (38, 130, 151, 155, 159, 229-231, 234-236, 238, 239, 244, 247, 248, 250, 
254-257, 260, 266, 270, 271, 273-275, 277), and with non (never plus ex) smokers 
in 19 (34.5%) studies (232, 233, 237, 240-243, 245, 249, 251, 252, 259, 261, 265, 
267, 269, 271, 272, 276). Seven studies (three cross-sectional (155, 243, 273), 
three cohort(255, 260, 274), and one case-control (244)) reported evidence of a 
dose-relationship with the amount smoked or duration of smoking.  
 
Of the 31 studies of ex-smokers, 29 (52.7%) studies compared ex-smokers to never 
smokers(38, 130, 159, 229-231, 234-236, 238, 239, 244, 246, 250, 253-255, 259, 
260, 263, 264, 268, 270, 273-275, 277), and provided 40 estimates of effect size. 
Of these, 29 (72.5%) suggested a significantly increased risk of PAD among ex-
smokers (Figure 2.3). Only two studies compared ex-smokers with current smokers 
(155, 191). Both reported a significantly reduced risk of PAD. Törnwall et al. 
reported the odds ratio for ex-smokers as 0.86 (95% CI 0.75-0.99) (191). Cui et al. 
reported no significant difference within ten years of cessation (OR 0.80, 95% CI 
0.62-1.07), and 10-19 years post cessation (OR 1.00, 95% CI 0.40-2.20) but the risk 
of PAD was significantly reduced among those who had stopped smoking at least 
20 years previously (OR 0.30, 95% CI 0.10-0.90) (155).  
 
2.4.2 Meta-analyses 
In comparison with non-smokers, the pooled ORs for PAD in current smokers were 
3.08 (95% CI 2.56-3.69, p<0.001) in general population studies, 1.54 (95% CI 1.31-
1.63, p<0.001) in disease population studies and 2.71 (95% CI 2.28-3.21, p<0.001) 
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overall (Figure 2.2). Overall, there was significant heterogeneity between the 
studies (I2 94.9%, p<0.001). Visual inspection of the funnel plot suggested some 
asymmetry (Figure 2.4) and the Egger’s test was statistically significant (p=0.023). 
In both the univariable and multivariable meta-regression analyses, sample size, 
definition of PAD, recruitment from the general population or a disease population, 
the sex of participants, decade of publication, and the use of never versus non-
smokers as the reference group were not significant predictors of estimated effect 
size (Table 2.2). Study design, level of statistical adjustment and the continent in 
which the study was conducted were all significantly associated with the 
magnitude of the effect size in multivariable analysis, but were no longer 
statistically significant after adjustment for multiple testing (Table 2.2). 
Furthermore, the association between current smoking and PAD was statistically 
significant in all but one of the thirty subgroup meta-analyses (Table 2.3). The 
cumulative meta-analysis suggested that the pooled estimate of effect size had 
remained relatively constant over time.  
 
In comparison with never smokers, the pooled ORs for PAD in ex-smokers were 
1.76 (95% CI 1.58-1.97, p<0.001) in general population studies, 1.52 (95% CI 1.36-
1.69, p<0.001) in disease population studies and 1.67 (95% CI 1.54-1.81) overall 
(Figure 2.3). Between-study heterogeneity was moderate (I2 54.7%, p<0.001). The 
funnel plot was slightly asymmetrical (Figure 2.5) and the Egger’s test reached 
statistical significance (p=0.003). In the meta-regression analyses, study design 
was significantly associated with the magnitude of estimated effect size (Table 
2.2). There was a significantly higher risk of PAD among ex-smokers than never 
smokers in 24 (92.3%) of the 26 subgroups (Table 2.3). The cumulative meta-
analysis suggested that the pooled estimate had remained fairly constant over 
time.  In the meta-influence graphs, no individual study had a disproportionately 
large effect on the pooled estimates of current smokers or ex-smokers. 
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Table 2.1 Characteristics of studies reporting the association between smoking and peripheral arterial disease 
 
          
First author Year Country Study design Number of smokers Sex Age (years) Study population PAD definition Referent group 
    Current Non Ex Never      
             
             
Skalkidis (244) 1989 Greece Case-control 102 - 40 58 MF ≥49 General ABI/Questionnaire Never 
Mangion (237) 1991 UK Cross-sectional 95 200 - - MF 68-92 General ABI/Questionnaire Non 
Vogt (257) 1993 USA Cross-sectional 147 - - 956 F ≥65 General ABI Never 
Bowlin (260) 1994 Israel Cohort 2,958 - 1,313 2,707 M 40-65 General Questionnaire Never 
Leng (159) 1995 UK Cross-sectional 404 - 582 593 MF 55-74 General ABI/Questionnaire Never 
Ögren (239) 1996 Sweden Cohort 129 - 104 155 M 55 General ABI Never 
Hooi (234) 1998 Netherlands Cohort 39 - 35 384 MF 40-78 General ABI/Questionnaire Never 
Meijer (238) 2000 Netherlands Cross-sectional 1,294 - 2,609 2,547 MF ≥55 General ABI Never 
Törnwall (191) 2000 Finland Cohort 22,334* - 4,538* - M 50-69 General Questionnaire Current 
Yeh (258) 2000 USA Cross-sectional 63 - - 414 F ≥50 General ABI/Questionnaire Never 
McDermott (251) 2001 USA Cross-sectional 44 246 - - MF ≥55 General ABI/Questionnaire Non 
Passos (254) 2001 Brazil Cross-sectional 337 - 268 880 MF ≥60 General Questionnaire Never 
Adler (229) 2002 UK Cohort 710 - 857 831 MF 25-65 Diabetic AAI/Questionnaire Never 
Fowler (273) 2002 Australia Cross-sectional 463 - 2,695 1,312 M 65-83 General ABI/Questionnaire Never 
Murabito (252) 2002 USA Cross-sectional 522 1032 - - MF ≥40 General ABI/Questionnaire Non 
O'Hare (253) 2002 USA Cross-sectional - - 6643 6,886 MF 60±16 Haemodialysis ABI/Questionnaire Never 
Tseng (269) 2004 Taiwan Cross-sectional 135 373 - - MF 64± 11 Diabetic ABI Non 
Faglia (233) 2005 Italy Cross-sectional 760 - - 1,799 MF 59± 11 Diabetic ABI Never 
Jensen (235) 2005 Norway Cross-sectional 6,070 - 6,117 7,342 M&F 40-69 General ABI/Questionnaire Never 
Kennedy (250) 2005 USA Cohort 184 - 944 1,161 MF ≥65 General ABI Never 
Zheng (259) 2005 USA Cross-sectional 3,945 - 4,904 6,324 M&F 45-64 General ABI Never & Non 
Allison (247) 2006 USA Cross-sectional 870 - - 3,344 MF 45-84 General ABI Never 
Collins (248) 2006 USA Cross-sectional 76 327 - - MF ≥50 General ABI/Questionnaire Never 
Cui (155) 2006 Japan Cross-sectional 492 - 519* 204 M 60-79 General ABI Never & Current 
He (262) 2006 China Cross-sectional - - 376 1,605 M&F ≥60 General ABI/Questionnaire Never 
Norman (275) 2006 Australia Cohort 68 - 191 214 MF 62±9 Diabetic ABI Never 
Rajagopalan (277) 2006 Multinational Cross-sectional 4,834 - 6,309 18,112 MF ≥18 Haemodialysis ABI/Questionnaire Never 
Woo (270) 2006 China Cross-sectional 273 - 1,190 2,529 MF ≥65 General ABI Never 
Bendermacher(230) 2007 Netherlands Cross-sectional 1,847 - 2,520 2,911 MF ≥55 General ABI Never 
Gabriel (249) 2007 Brazil Cross-sectional 54 59 - - MF 66± 13 CAD ABI Non 
Li (263) 2007 China Cross-sectional - - 592 1,055 MF 68± 11 Diabetic ABI Never 
Luo (264) 2007 China Cross-sectional - - 1,169 1,878 MF 68±11 Hypertensive ABI Never 
Paul (276) 2007 South Africa Cross-sectional 168 374 - - MF >50 General ABI Non 
Rhee (266) 2007 Asia Cross-sectional 860 5,765 - - MF ≥50 Diabetic ABI Never 
Sritara (267) 2007 Thailand Cross-sectional 357 1,948 - - MF 52-73 General ABI/Questionnaire Non 
Tapp (245) 2007 France Cohort 723 3,082 - - MF 30-65 General ABI/Questionnaire Non 
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N number; PAD peripheral arterial disease; M male; F female; MF male and female together; M&F male and female separately; ABI ankle 
brachial index; UK United Kingdom; USA United State of America; CAD coronary artery disease; CVD cardiovascular disease;  * this number 
was not included in the meta-analyses 
Reprinted with friendly permission from Heart (118) 
 
 
 
 
 
 
 
 
 
 
Yang (271) 2007 China Cross-sectional 790 3,926 - - MF 40-75 Hypertensive ABI Non 
Maeda (265) 2008 Japan Cross-sectional 898 3,008 - - MF 61±12 Diabetic ABI Non 
Schgoer (242) 2008 Austria Case-control 244 622 - - MF 67± 11 General ABI/Questionnaire Non 
Zheng (272) 2008 China Cross-sectional 2,142 3,044 - - M&F ≥40 Hypertensive/CVD ABI Non 
Agarwal (38) 2009 USA Cross-sectional 1,570 - 2,530 3,451 MF >40 General ABI Never 
Cacoub (231) 2009 France Cross-sectional 1,292 4,387 - - MF ≥55 General ABI/Questionnaire Never 
Kröger (236) 2009 Germany Cross-sectional 1,116 - 1,638 1,979 MF 45-75 General ABI Never 
Sigvant (243) 2009 Sweden Cross-sectional 2,585 2,341 - - MF 60-90 General ABI/Questionnaire Non 
Tavintharan (268) 2009 Singapore Cross-sectional - - 217 417 MF 40-80 Diabetic ABI Never 
Ramos (240) 2009 Spain Cross-sectional 1,379 4,793 - - M&F 35-79 General ABI/Questionnaire Non 
Alzamora (130) 2010 Spain Cross-sectional 624 - 992 1,975 MF >49 General ABI Never 
Chuengsamarn (261) 2010 Thailand Cross-sectional 24 195 - - MF ≥15 Diabetic ABI/Questionnaire Non 
Lakshmanan (274) 2010 Australia Cohort 292 - 2,260 1,442 M 65-83 General Questionnaire Never 
St-Pierre (255) 2010 Canada Cohort 2,834 - 757 553 M 35-64 General Questionnaire Never 
Aboyans (246) 2011 USA Cross-sectional - - 614 1,169 MF 45-84 General ABI Never 
Escobar (232) 2011 Spain Cross-sectional 210 1,252 - - MF >70 General ABI/Questionnaire Non 
Lee (151) 2011 Korea Cross-sectional 603 - 1,298 616 M ≥50 General ABI Never 
Sanna (241) 2011 Italy Cross-sectional 1,485 3,627 - - MF M≥45; F≥55 General ABI Non 
Tailor-Piliae (256) 2011 USA Cross-sectional 76 941 - - MF 60-69 General ABI Never 
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Table 2.2 Multivariable meta-regression analyses of the study characteristics associated with estimated effect size  
 
   
Current smokers 
 
Ex-smokers 
 
  Coefficient 95% CI P value Multiplicity 
adjusted p value 
Coefficient 95% CI P value 
 
Multiplicity adjusted      
  p value 
          
 
Sample size 
 
1-250* 
 
 
    
 
   
 250-500 1.37 0.62-3.03 0.437 1.000 0.93 0.34-2.56 0.884 1.000 
 500-1,500 1.33 0.60-2.98 0.484 1.000 0.79 0.21-2.97 0.726 1.000 
 >1,500 1.13 0.52-2.43 0.764 1.000 0.47 0.17-1.33 0.156 0.845 
Study design Cross-sectional*         
 Cohort  0.73 0.48-1.09 0.126 0.862 0.52 0.31-0.89 0.017 0.242 
 Case-control 4.14 1.72-9.93 0.001 0.054 0.52 0.05-5.09 0.577 1.000 
PAD definition ABI*         
 Questionnaire 1.10 0.69-1.76 0.697 1.000 1.07 0.60-1.91 0.820 1.000 
Study population General*         
 Diabetic 1.23 0.73-2.06 0.431 0.999 0.96 0.56-1.65 0.890 1.000 
 Others 0.92 0.55-1.54 0.752 1.000 0.78 0.48-1.29 0.337 0.987 
Continent America*         
 Asia 0.58 0.39-0.87 0.009 0.199 0.77 0.53-1.13 0.188 0.936 
 Europe 0.84 0.59-1.20 0.337 0.997 0.84 0.56-1.28 0.426 0.999 
 Africa 1.44 0.57-3.69 0.442 1.000 - - - - 
 Oceania 1.35 0.83-2.20 0.227 0.967 0.67 0.34-1.29 0.231 0.961 
 Multi-continent 0.49 0.20-1.21 0.122 0.871 1.02 0.64-1.65 0.919 1.000 
Sex Male only*         
 Female only 0.85 0.56-1.28 0.433 1.000 0.70 0.43-1.15 0.164 0.898 
 Male and female 0.73 0.51-1.04 0.085 0.737 0.71 0.47-1.09 0.121 0.773 
Year 1989-1998*         
 1999-2008 0.88 0.54-1.43 0.606 1.000 0.80 0.47-1.36 0.420 0.997 
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 2009-2012 0.95 0.60-1.50 0.813 1.000 0.75 0.41-1.36 0.343 0.990 
Statistical  Fully adjusted*         
adjustment Age/ sex adjusted 0.66 0.29-1.52 0.333 0.995 0.84 0.35-2.01 0.693 1.000 
 Unadjusted 0.36 0.16-0.79 0.011 0.205 - - - - 
 Unknown  0.73 0.51-1.04 0.085 0.737 1.17 0.79-1.75 0.432 0.998 
Referent group Never smokers*         
 Non-smokers 0.78 0.58-1.05 
 
0.101 0.813 - - - - 
 
CI confidence interval; PAD peripheral arterial disease; ABI ankle brachial index; * referent category 
Reprinted with friendly permission from Heart (118)
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Table 2.3 Subgroup analyses of pooled odds ratios  
 
    
Current vs never/non-smokers 
 
 
Ex vs never smokers Numbers of participants* 
   OR (95% CI) 
 
P value OR (95% CI) P value 
       
Sample size 1-250 532 3.93(2.59-5.98) <0.001 1.68(1.37-2.06) <0.001 
 250-500 2,784 2.30 (1.57-3.36) <0.001 2.41 (1.63-3.56) <0.001 
 500-1,500 6,851 2.20 (1.80-2.68) <0.001 1.66 (1.46-1.89) <0.001 
 >1,500 206,129 2.32 (1.79-3.00) <0.001 1.64 (1.46-1.84) <0.001 
       
Study design Cross-sectional 190,303 2.51 (2.06-3.06) <0.001 1.70 (1.55-1.86) <0.001 
 Cohort 24,927 2.84 (2.20-3.67) <0.001 1.55 (1.25-1.90) <0.001 
 Case-control 1,066 8.80 (5.99-12.91) <0.001 2.30 (0.37-14.18) 0.369 
       
PAD definition ABI 199,695 2.56 (2.12-3.09) <0.001 1.66 (1.52-1.81) <0.001 
 Questionnaire 16,601 3.59 (2.47-5.21) <0.001 1.72 (1.41-2.10) <0.001 
       
Study population  General 141,481 3.08 (2.56-3.69) <0.001 1.76 (1.58-1.97) <0.001 
 Diabetic 18,969 1.75 (1.13-2.69) 0.012 1.46 (0.96-2.21) 0.074 
 Other 55,846 1.46 (1.25-1.71) <0.001 1.51 (1.36-1.69) <0.001 
       
Continent America 55,125 3.20 (1.97-5.19) <0.001 1.71 (1.40-2.09) <0.001 
 Asia 44,957 1.79 (1.49-2.16) <0.001 1.67 (1.45-1.91) <0.001 
 Europe 77,480 2.51 (2.02-3.10) <0.001 1.71 (1.46-2.00) <0.001 
 Africa 542 4.29 (2.66-6.91) <0.001 - - 
 Oceania 8,937 5.35 (3.69-7.74) <0.001 1.89 (1.45-2.48) <0.001 
 Multi-continent 29,255 1.46 (1.31-1.63) <0.001 1.55 (1.42-1.69) <0.001 
       
Sex Male only 23,187 3.47 (2.60-4.63) <0.001 2.01 (1.55-2.60) <0.001 
 Female only 1,580 2.59 (1.52-4.42) <0.001 1.81 (1.46-2.25) <0.001 
 Male and female 191,529 2.33 (1.97-2.76) <0.001 1.58 (1.45, 1.71) <0.001 
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Year 1989-1998 11,001 3.50 (2.19-5.59) <0.001 1.85 (1.29-2.65) 0.001 
 1999-2008 151,761 2.46 (2.05-2.95) <0.001 1.62 (1.47-1.79) <0.001 
 2009-2012 53,534 2.73 (2.11-3.52) <0.001 1.77 (1.50-2.09) <0.001 
       
Statistical  Fully adjusted 166,413 2.98 (2.47-3.60) <0.001 1.68 (1.54-1.84) <0.001 
adjustment Age/sex adjusted 20,006 2.58 (1.78-3.73) <0.001 1.70 (1.18-2.45) 0.005 
 Unadjusted 3,067 0.86 (0.61-1.21) 0.373 - - 
 Unknown 26,810 2.10 (1.52-2.91) <0.001 1.56 (1.17-2.09) 0.003 
       
Referent group Never smokers 151,698 3.22 (2.58-4.02) <0.001 - - 
 Non-smokers 
 
41,977 2.10 (1.71-2.58) <0.001 - - 
 
vs versus; OR odds ratio; CI confidence interval; ABI ankle brachial index;  * number of participants in the meta-analyses  
Reprinted with friendly permission from Heart (118) 
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Figure 2.1 Study selection (PRISMA chart)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted with friendly permission from Heart (118)
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100 full texts reviewed 
8,132 publications identified by 
electronic search  
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8 additional studies identified from reference lists 
4,501 titles screened  
49 studies included after meeting 
the inclusion criteria 
55 studies included in meta-
analysis 
 341 abstracts screened  
241 ineligible studies excluded  
 
51 studies excluded: 
5 repeat analyses of same study 
1 environmental tobacco smoke 
2 interventional studies 
25 some/all ex-smokers included with 
current smokers; some current smokers 
included with non-smokers  
18 essential information missing   
2 studies reporting hazard ratios  
3,631 duplicates removed  
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Figure 2.2 Forest plot of current smokers compared with never/non-smokers 
ES effect size; CI confidence interval; MF Male and female;  M Male; F Female;  DM diabetic;  HT 
Hypertensive;  PAD peripheral arterial disease; CVD cardiovascular disease; CAD coronary artery 
disease; cigs/d cigarettes/day;  y year  
Reprinted with friendly permission from Heart (118) 
  
NOTE: Weights are from random effects analysis 
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Figure 2.3 Forest plot of ex-smokers compared with never smokers 
 
 
  
 
 
ES effect size; CI confidence interval; MF Male and female;  M Male; F Female;  DM diabetic;  HT 
Hypertensive;  PAD peripheral arterial disease; CVD cardiovascular disease; CAD coronary artery disease; 
cigs/d cigarettes/day;  y year  
Reprinted with friendly permission from Heart (118) 
NOTE: Weights are from random effects analysis 
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Figure 2.4 Funnel plot of studies examining the association between current 
smoking and risk of peripheral arterial disease 
 
 
 
 
Figure 2.5 Funnel plot of studies examining the association between past 
smoking and risk of peripheral arterial disease 
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2.5 Secondhand smoke and peripheral arterial disease 
 
Only two studies have been published on the association between exposure to SHS 
and PAD (38, 45). One study reported results for both active smoking and SHS (38) 
and therefore was included in the meta-analysis. The other study reported results 
for only SHS (45). Both studies were cross-sectional. One study was conducted 
among 1,209 Chinese women aged ≥60 years who had never smoked. SHS exposure 
was defined by self-report in the home and workplace. The study reported 
significant association, with adjusted ORs of PAD defined by WHO Rose 
Questionnaire, by ABI<0.9, and by either were 1.87 (95%CI 1.30-2.68), 1.47 (95%CI 
1.07-2.03) and 1.67(95%CI 1.23-2.16) respectively. There was evidence of a dose-
response relationship whereby the risk of overall prevalence of PAD increased with 
increasing amount of SHS exposure amount from 1-9 cigarettes per day (OR 1.40, 
95% CI 0.87-2.28), 10-19 cigarettes per day (OR 1.76, 95% CI 1.20-2.61) to ≥20 
cigarettes per day (OR 1.90, 95% CI 1.27-2.86) (p for trend=0.002). Dose-response 
relationship was also shown between risk of PAD and duration of SHS exposure 
from ≤20 minutes per day (OR 1.62, 95% CI 1.04-2.58), ≤40 minutes per day (OR 
1.59, 95% CI 1.11-2.30) to >40 minutes per day(OR 2.68, 95% CI 1.49-4.88) (p for 
trend=0.001) (45). The other study examined 5,653 non-smokers aged >40 years 
in the USA using the pooled data from the NHANES. SHS exposure was measured 
using serum cotinine. They did not show an overall association between cotinine 
concentration and PAD defined by ABPI but suggested a possible threshold effect 
with significant association evident for cotinine concentrations >155 ng/mL (38).  
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2.6 Discussion 
2.6.1 Main findings of this research 
There are now a large number of published studies on the association between 
smoking status and PAD, and they provide consistent evidence of an increased risk 
among current smokers. The risk is lower among ex-smokers but, nonetheless, 
significantly increased compared with never smokers.    
  
2.6.2 What is already known on this topic 
The association between smoking and PAD was first recognised in 1911 (133). In 
2004, Willigendael et al. published a systematic review on smoking and PAD and 
identified 4 relevant cohort studies and 13 cross-sectional studies. One of the 
cohort studies was conducted on the same study participants included in one of 
the cross-sectional studies (16). Using data from the cross-sectional studies, they 
derived weighted ORs of 2.3 for current smokers and 2.6 for ex-smokers. However, 
to my knowledge, the study in this chapter is the first meta-analysis of the 
association between active cigarette smoking and PAD. This meta-analysis 
included 38 studies published after Willigendael et al.’s review, and produced ORs 
of 2.7 and 1.7 respectively. Individual studies have suggested that the magnitude 
of the association with active smoking is even greater for PAD than CHD (121, 
205). My results corroborate this. In this study, the pooled OR of 2.71 for current 
smokers compares with RRs of 1.72 and 1.92 for men and women respectively in 
a meta-analysis of smoking and CHD (15). In contrast to CHD, my meta-regression 
analyses did not provide any evidence that the magnitude of the association 
between smoking and PAD differs between men and women.   
 
2.6.3 Strengths and limitations  
The study in this chapter was reported in accordance with the PRISMA Statement, 
which consists of a four-phase flow diagram (Figure 2.1) and a 27-item checklist 
(Appendix 4). The PRISMA guideline is an evolution of the original QUOROM 
(Quality of Reporting of Meta-analyses) guideline. PRISMA focuses on ways to 
ensure the transparent and complete reporting of systematic reviews and meta-
analyses (212). My systematic review was undertaken using four databases 
(Medline, Embase, PubMed and ISI Web of Science) to ensure that the largest 
possible number of eligible studies were identified. Despite this effort, 8 studies 
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were added from the reference lists of the 49 identified studies. This suggests that 
the search strategy did not give an exhaustive list of relevant publications. 
However, the number of the identified studies is large enough to provide a 
meaningful result. The pooled estimates for current smokers were derived from a 
total of 47,187 current smokers who participated in 48 studies. The I2 test was 
used to measure heterogeneity. Higgins et al. argue that since clinical diversity 
and methodological diversity always occur when different studies are brought 
together in a systematic review, statistical heterogeneity is inevitable (223). 
Random effects meta-analyses allow for heterogeneity by assuming that the 
underlying effects follow a normal distribution. Also, heterogeneity may be 
explored by conducting subgroup analyses and meta-regressions. In my study, 
random effects meta-analyses were used, in preference to fixed effect models, so 
that the weighting process took account of possible between-study heterogeneity 
due to differences in study population and methodology (223, 278). Because of the 
large number of studies on the association between active cigarette smoking and 
PAD now published, I was able to supplement the overall meta-analyses with 
stratified meta-analyses that generated pooled estimates for subgroups defined 
by study size, design, continent, sex, decade of publication, definition of PAD, use 
of a general population or disease study population, reference group and level of 
adjustment.  
 
A systematic review involves defining review questions, developing inclusion and 
exclusion criteria, developing a comprehensive search strategy, assessing quality 
for all relevant studies to reduce bias, synthesising and presenting findings (279, 
280). It synthesises the evidence based on the largest possible number of studies 
on a particular topic identified under a search strategy related to PICO (281). A 
systematic review often includes a meta-analysis (quantitative synthesis) using 
statistical techniques from data extracted from the eligible studies into a pooled 
estimated effect size to examine the strength of the association or the 
effectiveness of the intervention (282). Since heterogeneity inherently occurs 
among individual studies, in a meta-analysis, meta-regressions and subgroup 
analyses are often used to examine what factors may account for the 
heterogeneity (223, 278). Narrative synthesis is the descriptive aspect of the 
studies in a systematic review and primarily uses a textual approach to summarise 
the findings from the included studies. It is often used when a statistical meta-
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analysis or another specialist form of synthesis is not feasible. Therefore, meta-
analysis is sometimes viewed as ‘superior’ technique to narrative synthesis for 
integrating data (283). However, to inform the development of policy and 
practice, systematic reviews can be used to answer a wide range of questions 
including the effectiveness of a particular intervention and why a particular 
intervention works or not (284). It is useful to include the synthesis of different 
types of evidence including qualitative evidence (285). Narrative synthesis can be 
applied to both quantitative and qualitative studies and can be used in different 
ways subject to the review question (280, 286). In my systematic review and meta-
analysis, I mainly focused on examining the strength of the association between 
cigarette smoking and PAD and so included only quantitative studies. I used 
narrative approach to describe the data extracted from the eligible studies as 
study characteristics (Section 2.4.1 and Table 2.1).  
 
A properly conducted systematic review is often viewed as the best research 
evidence for a focused clinical, social science-related or health science-related 
question (287). However, the summary provided in a systematic review or meta-
analysis relies on the methods used in the individual studies to estimate the effect 
size (288). However, there are inevitable methodological shortcomings in the 
design and execution of the individual primary studies, as a result, risk of bias can 
be introduced by the evidence itself (288). In my systematic review, a 
comprehensive search strategy was used to identify the largest number of 
potentially relevant studies. The QualSyst tools (216) which have been adopted by 
many published systematic reviews and meta-analyses (217, 218) were used to 
assess the quality of the potentially relevant primary studies. However, primary 
studies with positive results in support of the authors’ research hypothesis are 
more likely to be reported. Thus, these studies are more likely to be identified, 
summarised and pooled in a systematic review or meta-analysis than studies that 
reported smaller or non-significant effect sizes, which may lead to publication 
bias (278). In my meta-analysis, the visual inspections of the funnel plots and 
Egger’s test suggested possible publication bias. However, the limitations of 
Egger’s test are discussed in the paragraph below. During the full-text screening 
period for the eligible studies for inclusion, 18 studies were excluded due to 
missing essential information e.g. smoking status even after the attempts had 
been made to contact the corresponding authors. Excluding these studies may 
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introduce potential bias such as selection bias. Furthermore, deciding which study 
to be included to some extent can be subjective. This may lead to potential 
selection bias. In this systematic review, interventional studies were excluded 
with the hope of reducing between-study heterogeneity due to different types of 
study design. Since primary studies can vary in their design, methodological 
quality, measures of the outcome and exposure, and study populations, combining 
these studies together may lead to potential bias. However, I applied subgroup 
meta-analyses to examine how applicable the association between active smoking 
and PAD were across different subgroups by study characteristics. Meta-regression 
analyses were used to explore the factors that may contribute to the between-
study heterogeneity. There is also a growing concern about if and how risk of bias 
appraisals inform the synthesis process (279). Researchers have suggested that 
sensitivity analysis, narrative assessment and restricting the synthesis to studies 
at lower risk of bias are the most common methods to incorporate risk of bias 
assessments into the synthesis process (279). One limitation about this systematic 
review and meta-analysis was that it did not include a sensitivity analysis. Section 
2.4.1 and Table 2.1 describe the study characteristics of the studies included in 
the meta-analysis. Quality assessments of individual primary studies for inclusion 
were performed. 
 
My meta-analyses were based on the aggregated results of individual studies. I did 
not have access to individual participant data. I did not include studies published 
in languages other than English or studies on sources of tobacco other than 
cigarettes. The systematic review identified results expressed as both ORs (from 
case-control and cross-sectional studies) and RRs (from cohort studies). OR 
represents the odds that an outcome will occur given a particular exposure, 
compared to the odds of the outcome that will occur in the absence of that 
exposure. RR is the ratio of incidence rates in the exposed and unexposed groups. 
RR represents the cumulative risk over a time span (289). RR asymptotically 
approaches the OR if an outcome is rare, e.g. if a disease is rare (222). Since the 
population prevalence of PAD is relatively low (38, 121), RRs approximate to ORs 
(289). Therefore, I treated them as equivalent in my meta-analysis. The Egger’s 
test is widely used to test for the funnel plot asymmetry. However, Irwig et al. 
have pointed out the limitation of the Egger’s test. They have demonstrated that 
the standard error of the log OR is correlated with the size of the OR because of 
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sampling variability alone even in the absence of small-study effects. Funnel plots 
which were plotted using log ORs may appear asymmetric, leading to false-positive 
test results of the Egger’s test (290). Different from RR, HR is commonly calculated 
from Cox proportional regression models in survival analyses when summarising 
time-to-event data and represents instantaneous risk over the study time period. 
However, researchers have suggested that using HR for causal inference is risky 
due to the change of HR over time and the built-in selection bias in HR (291). 
There are methods to make an approximate conversion between HR and OR (292). 
HR can be approximated to RR if the outcome is rare, the follow-up period of time 
is short and the ratio of event rates of the outcome in two groups is small (292). 
Of the two studies reporting HR that met the inclusion criteria, one followed up 
at 5 yearly intervals and up to 30 years (293). The other had a median 
(interquartile range) follow-up of 12.7 (12.4-13.8) years (294). Approximating HR 
to OR to be pooled in a meta-analysis is imprecise with associated uncertainty. 
Excluding these studies would mitigate this problem. However, it is important to 
consider the totality of available evidence. As a balanced approach, I planned to 
split those studies reporting HRs as a subgroup in the meta-analyses. However, 
only two studies expressed the results as HRs and were insufficient to comprise a 
subgroup. Both reported a significant association between active cigarette 
smoking and PAD, which yielded the same conclusion as the overall pooled 
estimates in the meta-analysis. Kollerits et al. examined 1,160 men aged 40-59 
years and followed up at 5 yearly intervals and reported that current smoking was 
significantly associated with incident intermittent claudication (adjusted HR 2.20, 
95% CI 1.24-3.92, p=0.01) (293). Conen et al. reported a significant dose-
relationship, with HR increasing from 11.94 (95% CI 6.90-20.65) among current 
smokers smoking <15 cigarettes per day to 21.08 (95% CI 13.10-33.91) among 
current smokers smoking ≥15 cigarettes per day. A strong risk gradient for PAD 
was demonstrated across 10, 10 to 29, and ≥30 pack-years, with adjusted HRs 2.52 
(95% CI 1.49-4.25), 6.75 (95 CI 4.33-10.52) and 11.09 (95% CI 6.94-17.72) 
respectively. Ex-smokers also revealed attenuated risk (adjusted HR 3.16, 95% CI 
2.04-4.89) (294). Since these two studies reported consistent findings. Therefore, 
the limitation of not including them in the meta-analysis is unlikely to have 
introduced significant bias to the overall results. Most of the published studies 
were cross-sectional studies. Therefore, temporal relationships cannot be 
ascertained and caution should be heeded in inferring causation from association 
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(Appendix 5). However, the stratified analyses demonstrated significant 
associations even in the subgroup of cohort studies. One study only reported their 
results separately for unilateral and bilateral PAD (266). Since they used a common 
referent group in both analyses, their weighting was slightly inflated, but the 
overall impact on the pooled estimate from 55 studies will be small. In this meta-
analysis, in general populations, the pooled OR was much higher for current 
smokers versus non-smokers than ex-smokers versus never smokers. However, in 
disease populations, the difference in the pooled ORs for these two was less 
pronounced. One possible explanation is that people with other smoking related 
diseases may have already quit because of these diseases. Therefore, the 
proportion of ex-smokers within the non-smoker group may be higher in disease 
populations than in the general population. Thus the association for current versus 
non-smokers will be reduced among disease populations compared to the general 
population.  
 
In the meta-analysis, I combined the unadjusted and adjusted estimates from the 
individual studies to obtain the overall pooled estimates. There is a growing 
concern among researchers that the adjustment for confounders in the individual 
studies can be a considerable source of heterogeneity (295). In the individual 
studies, confounding can be reduced via study design or addressed statistically 
using multiple regressions, propensity score matching and stratified analyses 
(295). As mentioned above, I did not have access to individual participant data. 
Although there is currently no consensus about how to synthesise adjusted and 
unadjusted estimates, Quigley et al. suggested synthesising the adjusted and 
unadjusted findings separately as a common option to avoid this potential 
heterogeneity due to adjustment for confounders (296). In this meta-analysis, I 
synthesised the unadjusted estimates and adjusted estimates separately by 
subgroup analyses. The pooled estimates for PAD in current smokers based on the 
adjusted estimates and the overall pooled estimate for PAD in current smokers 
yielded the same conclusion. However, the pooled estimate for PAD in current 
smokers based on the unadjusted estimates was not statistically significant. The 
relatively low quality of some included studies due to the lack of control for 
confounding may be one possible explanation. However, all observational studies, 
irrespective of the level of adjustment, are to some extent vulnerable to built-in 
bias including selection bias, measurement bias and confounding such as residual 
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confounding (297). On the other hand, it is often pointed out by researchers that 
attention should be paid to overadjustment bias. Overadjustment bias occurs as a 
consequence of the control (including statistical adjustment, stratification and 
restriction) for an intermediate variable or a descending proxy for an intermediate 
variable on the causal pathway between the exposure and the outcome (298) 
(Appendix 5). Overadjustment would either increase net bias or decrease 
precision, and usually bias results towards the null (298). In this systematic 
review, the individual studies used empirical methods including multivariable 
statistical adjustment and stratification to reduce confounding. The choice of 
confounders in the regression models was often based on prior knowledge and/or 
stepwise regression analyses or other commonly suggested statistical methods. If 
overadjustment occurs, the adjusted estimate would be much smaller than the 
unadjusted estimate. The estimate of risk of PAD among smokers is likely to be 
attenuated due to overadjustment. Synthesising adjusted estimates alone in a 
systematic review is likely to underestimate the true effect or association due to 
overadjustment bias. Further research on the mechanisms relating smoking to PAD 
is needed to clearly define the intermediate variables on the causal pathway. 
 
Meta-regression analyses enabled me to explore possible sources of between-study 
heterogeneity. Unsurprisingly, the two case-control studies produced higher 
estimates of effect size, and contributed to the heterogeneity, but they did not 
impact greatly on the overall result. Similarly, estimates differed accordingly to 
the degree of statistical adjustment, but the association with smoking was 
statistically significant in the subgroup of studies that adjusted for all potential 
confounders available to them. Meta-regression may result in false-positive (type 
I error) findings with a small number of primary studies, with multiple covariates, 
or when there is a large magnitude of statistical heterogeneity (228, 299, 300). It 
is suggested by the Stata Journal that permutation test is useful to assess the true 
statistical significance of meta-regression. It is suggested that 5,000 or 20,000 
permutations may be necessary for sufficient precision (278). Permutation tests 
suppress P values when they are used to explore heterogeneity and will result in 
more conservative probability estimates. In other words, it is possible that the P 
values may cross over to the level of non-significance (228, 301). 
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2.6.4 Implications of this research  
Smoking is the most important modifiable risk factor for PAD and is, therefore, 
key to prevention. The lower risk among ex-smokers suggests that smoking 
cessation should be encouraged, but more research is required to determine 
whether, and when, the risk reverts to that of never smokers and whether, as with 
CHD (207, 208), this is dependent on the duration of smoking. There have been 
numerous studies on the association between SHS and CHD and stroke. In contrast, 
up to 2012 only two studies had been published on the association between SHS 
and PAD. In the light of the relative paucity of original studies in this area, the 
goal of my next chapter is to examine the association between SHS exposure and 
PAD.  
 
It is more than 100 years since the first study was published reporting an 
association between active smoking and PAD (133). In spite of this, the global 
prevalence of smoking is increasing, especially in large, developing countries such 
as China (203). My results reinforce the need to pursue tobacco control.
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3.1 Chapter summary 
 
The global prevalence of smoking is increasing. It is widely accepted that both 
active smoking and exposure to SHS are associated with CHD and stroke. As 
described in my previous chapter, there is now also a substantial body of evidence 
that active smoking is a risk factor for PAD. In contrast, there is a paucity of 
studies on the association between SHS exposure and PAD. Prior to my publication 
of the studies contained in this chapter, there had been only two studies published 
on this subject. The aim of this chapter was, therefore, to add to the existing 
evidence on the association between SHS exposure and PAD among adult non-
smokers. 
 
On viewing existing cohorts and surveys, it was clear that, in contrast with CHD, 
most studies have not collected data on PAD. Similarly, in contrast with smoking 
status, most studies have not collected data on SHS exposure. Hence, very few 
studies conducted on the general population have collected information on both 
SHS exposure and PAD. 
 
I identified two potential sources of data on the Scottish general population: the 
Generation Scotland: Scottish Family Health Study (GS: SFHS) and the Scottish 
Health Survey (SHeS). Ideally, I would have included studies with objective 
measurement of both PAD (for example ABPI <0.9) and SHS exposure (for example 
cotinine concentration).  In reality, data from SFHS measured PAD objectively 
using ABPI but used self-reported exposure to SHS. In contrast, the SHeS measured 
SHS exposure objectively, using salivary cotinine concentration, but ascertained 
PAD based on self-report of symptoms of IC using the Edinburgh Claudication 
Questionnaire. Therefore, the studies had different limitations and, effectively, 
complemented each other. By analysing data extracted from both studies, I was 
able to determine whether the findings were consistent using their different 
approaches.  A limitation of both the SFHS and SHeS was their cross-sectional 
design. Therefore, I also used record linkage of the SHeS data to identify incident 
cases of PAD in a third, retrospective, cohort study. The methodology and results 
for all three studies are contained in this chapter.  Logistic regression analyses 
were used for the two cross-sectional studies and Cox proportional hazard analyses 
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were used for the cohort study. Potential confounders (age, sex, deprivation 
quintile, BMI, physical active, alcohol consumption, and survey year) were 
adjusted for in different multivariate analyses.  
 
In my study using the SFHS, of the 5,686 never smokers, 134 (2.4%) had PAD based 
on ABPI. Three percent of participants with PAD reported being exposed to SHS 
for ≥40 hours per week, compared with only 0.6% of those without PAD (χ2 test, 
p=0.010). Following adjustment for potential confounders, participants exposed 
to ≥40 hours per week of SHS were still more likely to have PAD (adjusted OR 4.53, 
95% CI 1.51-13.56, p=0.007), with suggestion of a log-linear dose relationship 
among those exposed. 
 
In my study using the SHeS, of the 4,231 confirmed non-smokers (defined as self-
reported non-smokers with a salivary cotinine concentration <15 ng/mL), 134 
(3.2%) had IC based on the Edinburgh Claudication Questionnaire. There was 
suggestion of a dose relationship, whereby the risk of IC increased with increasing 
cotinine concentration. After adjusting for potential confounders, participants 
with a cotinine concentration ≥2.7 ng/mL were still at significantly increased risk 
of IC (adjusted OR 1.76, 95% CI 1.04-3.00, p=0.036), compared with those with a 
cotinine concentration <0.7 ng/mL. Among all non-smokers, 5.6% (95% CI -0.8%-
11.7%) of IC cases were attributable to cotinine concentrations ≥2.7 ng/mL and a 
further 3.6% (95% CI -6.6%-12.8%) to cotinine concentrations of 0.7-2.6 ng/mL.  
 
Of the 4,045 confirmed non-smokers, in the SHeS, who had consented to passive 
follow-up by record linkage to routine hospital admission and death certificate 
records, 1,163 (28.8%) had either moderate or high exposure to SHS (cotinine 
concentrations ≥ 0.7 ng/mL) at baseline. High exposure to SHS was associated with 
increased risk of all-cause death (adjusted HR 1.42, 95% CI 1.09-1.86, p=0.011) 
among all non-smokers and increased risk of PAD events (adjusted HR 2.82, 95% CI 
1.14-6.96, p=0.024) among male non-smokers. There was suggestion of a dose 
relationship as the risk of all-cause death increased with increasing cotinine 
concentration at baseline (adjusted p for trend=0.001).  
 
As with coronary heart disease and stroke, SHS exposure is independently 
associated with both prevalent and incident cases of PAD among non-smokers. Our 
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findings add to the published evidence in support of protecting the general public 
from SHS exposure. 
 
3.2 Introduction 
 
The first WHO public health treaty (The WHO Framework on Tobacco Convention) 
focused on tobacco control, and included recommendations to protect the public 
from SHS exposure. Only 16% of the global population are protected by 
comprehensive smoke-free legislation (3). Most smoke-free legislation only 
prohibits smoking in public and work places. Even in many signatory countries, 
exposure to SHS remains unacceptably high, due to either breaches of the 
legislation or exposure in places not covered by legislation, such as homes and 
vehicles. In Scotland, six years after implementation of smoke-free legislation 
(24), and in spite of observed increases in home voluntary restrictions (302), 25% 
of male non-smokers and 12% of female non-smokers reported exposure to SHS in 
one or more location (303). In large, developing countries, such as China, the 
prevalence of smoking is increasing rapidly (22, 304) and awareness of the harmful 
effects of SHS exposure is low (21, 305).  
 
Active smoking is widely recognised as a risk factor for all atherosclerotic diseases, 
including PAD (14, 15, 118). Evidence is increasing that exposure to SHS may also 
increase the risk of atherosclerosis. The sidestream smoke present in SHS contains 
high levels of fine particles (<2.5µm diameters) and toxic gases (28-31). Exposure 
produces rapid changes in platelet activation and endothelium-dependent 
vasodilation (31). The level of 11-Dehydrothromboxane B2 (11-DH-TXB2) and the 
level of malondialdehyde (MDA) increase in both non-smokers and active smokers, 
after repeated daily exposure to SHS of 30 cigarettes for 60 minutes per day over 
12 days, but the levels of these biomarkers increased more in non-smokers than 
in active smokers. After exposure, the levels remained significantly high in non-
smokers (59). The effect of exposure to SHS was cumulative in non-smokers (306). 
Many studies have demonstrated an association between SHS exposure and both 
CHD and stroke. A meta-analysis, published in 1999 of 18 studies, reported a RR 
of 1.25 (95% CI 1.17-1.32) for CHD and a clear dose relationship whereby the risk 
increased with increasing exposure from 1-19 cigarettes per day (RR 1.23, 95% CI 
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1.13-1.34) to more than 20 (RR 1.31, 95% CI 1.21-1.42) (4). In 2011, a meta-
analysis of 20 studies demonstrated an increased risk of stroke among those 
exposed to SHS (RR 1.25 95% CI 1.12-1.38). A dose relationship was shown across 
the spectrum of exposure from 5 (RR 1.16, 95% CI 1.06-1.27) to 40 (RR 1.56, 95% 
CI 1.25-1.96) cigarettes per day (6).  
 
Prior to the work described in this chapter, only two published studies had 
examined the association between SHS exposure and PAD. One cross-sectional 
study was conducted among 1,209 Chinese participants aged ≥ 60 years who had 
never smoked. This study relied on self-reported exposure to SHS and reported an 
overall association and a dose relationship (45). The other study was also cross-
sectional and undertaken among 5,653 non-smokers aged >40 years in the USA. 
This study had access to serum cotinine concentrations and reported an 
association with PAD at very high exposure levels (38). 
 
To examine the association between  level of exposure to SHS and  risk of PAD, I 
identified two potential data sources: GS: SFHS and SHeS. The baseline data from 
GS:SFHS collected objective measurement of PAD using the ABPI and an ABPI <0.9 
as the definition of PAD. Exposure to SHS was based on self-report. The baseline 
data from the SHeS contained salivary cotinine concentration measurement and 
identified prevalent PAD cases on the basis of IC identified using the Edinburgh 
Claudication Questionnaire.  I also used record linkage of SHeS to identify incident 
PAD events (defined as hospitalisation for PAD or death due to PAD) and all-cause 
deaths.  
 
3.3  Materials and methods 
3.3.1 Data source 
Generation Scotland: Scottish Family Health Study (GS: SFHS) 
The GS: SFHS is a cross-sectional study of the general population. Proband is a 
term used to describe an individual who is the initial member of a family to come 
under study in the medical genetics or other medical fields (307). In GS: SFHS, 
probands aged between 35 and 55 years of age were recruited between 2006 and 
2011 from two cities in Scotland (Glasgow and Dundee) where they were randomly 
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selected from general practitioner records. The probands were invited to identify 
and recruit their adult (≥18 years of age) first degree relatives (308). All 
participants completed a questionnaire on demographic information (including 
age, sex, and postcode of residence) and lifestyle (including smoking status, 
exposure to SHS alcohol consumption and physical activity). Trained research staff 
measured height, weight, brachial blood pressure, as well as ankle systolic blood 
pressure in the dorsalis pedis and posterior tibial arteries in both legs using 
standard procedures, and obtained blood samples for assays (including lipid 
concentrations).  
 
Scottish Health Survey (SHeS) 
The SHeS uses multi-stage, stratified probability sampling of residents of private 
households across Scotland (309). The Survey was undertaken in 1995, 1998, 2003 
and then annually from 2008. Different households were recruited in each Survey.  
Household response rates were 81% in 1995, 76% in 1998, 68% in 2003, and 61%-
64% between 2008 and 2010. The Surveys used a two-stage interview process: a 
face to face interview undertaken by the trained staff in which they administered 
questionnaires on demographics (including age, sex, social status and postcode of 
residence) and lifestyle (including smoking status, alcohol consumption and 
physical activity) followed by a nurse visit in which they collected anthropometric 
measurements (including height, weight, and blood pressure) and biomedical 
measurements (including blood, urine and saliva samples). In each survey, all 
individuals aged ≥16 years were asked by the nurse to provide a saliva sample to 
measure cotinine concentrations. In my study, I collated data from the 1998, 2003, 
2008 and 2010 Surveys as they provided consistent information on both IC and 
salivary cotinine. 
 
Over 90% of the SHeS participants consented to passive follow-up via record 
linkage to routine administrative data. In Scotland, the Information Services 
Division (ISD) of the NHS collates and links Scotland-wide administrative data 
including data on hospitalisations and deaths. Data on SHeS participants were 
linked, at an individual-level, to several Scotland-wide datasets including: death 
certificates (collected by the General Registrar Office) and admissions to acute 
hospitals (Scottish Morbidity Record [SMR] 01). I used the disease and procedures 
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codes to identify those hospital admissions and deaths due to PAD which I defined 
as any of the following codes recorded in any position:  
• International Classification of Disease, Tenth Version (ICD-10) A48.0, 
I10.5, I73.9, I70.2, I70.9, I74.3, I74.5, I79.2, R02,  
• International Classification of Disease, Ninth Version (ICD-9) 250.7, 
440.20, 440.21, 440.22, 440.23, 440.24, 440.29, 443.9, 443.81, 707.10, 
785.4, or 
• Office of Population Censuses and Surveys Classification of Surgical 
Operations and Procedures (OPCS) X09.3, X09.4, X09.5, X09.8, X09, X10.1, 
X10.4, X10.8, X10.9, X11.1, X11.2, X11.8, X11.9, X12.1, L54.1, L63.1. 
 
SMR data undergo regular quality assurance checks. These demonstrate that the 
data are over 90% accurate and around 99% complete (310).  The linked data 
provided follow-up to the censor date of 31 December 2011.  
 
The study designs, definitions of PAD and measurement of SHS are summarised in 
Table 3.1. 
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Table 3.1 Study Characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GS: SFHS  Generation Scotland: Scottish Family Health Study; SHeS   Scottish Health Study; Scottish Morbidity Records   SMR; PAD    
peripheral arterial disease; ABPI   ankle brachial pressure index 
*1 missing age data 
    
 GS: SFHS SHeS 1998, 2003, 2008, 
2010 
SHeS record linkage study 
    
 
Data Source Summary 
   
Coverage  Glasgow, Dundee Scotland Scotland 
Participants (n) 21,558 41,664 37,967 
Age >45 years (n, (%)) 12,135 (56.3) 17,179 (41.2) 17,128 (45.1) 
Age range (years) 18-92 0-97 0-97 
PAD definition ABPI<0.9 Edinburgh Claudication  
Questionnaire 
Hospitalisation or death 
SHS exposure Self-reported 
 
Salivary cotinine Salivary cotinine 
Study Summary    
Study design Cross-sectional Cross-sectional Cohort 
Age (years) ≥18 >45 >45 
Participants (n) 5,686 never smokers 
(3,056 aged >45) 
4,231 non smokers 
(2,293 never smokers) 
4,045 non smokers 
(2,216 never smokers) 
PAD cases (n) 134* 134 64 
 (47 among aged 18-
45) 
(55 never smokers) (37 never smokers) 
 (86 among aged >45) (79 ex-smokers) (27 ex-smokers) 
SHS exposure (n) 1,769 1,366** 1,163** 
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**either moderate or high exposure to secondhand smoke (cotinine 0.7-14.9 ng/mL)
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3.3.2 Ethical approval 
Both GS: SFHS and SHeS have an ethics approval which permits the provision of 
anonymised data extracts to other researchers for uses that are consistent with 
the original aims of the studies. Therefore, I did not require an additional NHS 
ethics approval to obtain anonymised data extracts for any of the studies.   
 
The GS Access Committee approved provision of an extract of data from GS: SFHS. 
Access to SHeS was obtained via the UK Data Service. Students or members of staff 
at a UK institution of higher or further education can register using the user 
account issued by their institution. I registered as a student from University of 
Glasgow and was able to download an extract of SHeS data. The Privacy Advisory 
Committee of the ISD, NHS National Services Scotland approved provision of 
follow-up data via individual-level linkage to death certificates and hospital 
admission records (SMR01, SMR04 and SMR06).  
 
3.3.3 Inclusion criteria and definitions 
Generation Scotland: Scottish Family Health Study (GS: SFHS) 
For the study using GS: SFHS, participants who classified themselves as never 
smokers were included. The ABPI was calculated for each leg as the ratio of the 
highest measurement of ankle systolic blood pressure (either dorsalis pedis or 
posterior tibial artery) to the brachial systolic blood pressure. The presence of 
PAD was defined as an ABPI <0.9 in one or both legs (311). The level of SHS 
exposure was self-reported. Participants classified their exposure in their 
workplace, home and other locations as: none, a little, some or a lot, and 
classified their overall duration of exposure (total hours per week) as: none, 1-19, 
20-39 or ≥40 hours per week. Alcohol consumption was self-reported and classified 
as never, stopped >1 year previously, stopped ≤1 year previously or drink 
currently. Physical activity was defined as self-report of moderate or vigorous 
activity of at least ten minutes duration on at least four days each week. Body 
mass index (BMI) was categorized into normal weight (<25 kg/m2), overweight (25-
30 kg/m2) and obese (≥30 kg/m2) (312). In Scotland, there are 6,505 datazones, 
based on postcode of residence, with a mean population of 800. The Scottish Index 
of Multiple Deprivation (SIMD) for each datazone is derived from information on 
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income, employment, health, education (including skills and training), housing, 
crime, and access to services (313). The SIMD has been used to derive quintiles of 
socioeconomic status for the Scottish population; ranging from 1 (most deprived) 
to 5 (least deprived). The postcode of residence was used to categorise study 
participants according to these general population quintiles.  
 
Scottish Health Survey (SHeS) 
I combined the 1998, 2003, 2008 and 2010 Surveys for use in both the cross-
sectional study and the retrospective cohort study as they provided consistent 
information on salivary cotinine and diagnosis of PAD at baseline. The 1995 Survey 
used serum to measure cotinine and, therefore, the concentrations, at any given 
level of SHS exposure, would differ from measurement using saliva samples. For 
both the cross-sectional and retrospective cohort studies, inclusion was restricted 
to participants who, at the time of participation in the Survey, were aged >45 
years old, classified themselves as non (never or ex) smokers and whose salivary 
cotinine concentration was <15.0 ng/ml, as higher concentrations usually indicate 
smoking deception (40). Participants who reported taking nicotine replacement 
products were excluded. SHS exposure was categorised into low (cotinine <0.7 
ng/mL), moderate (cotinine 0.7-2.6 ng/mL) and high (cotinine 2.7-14.9 ng/mL).  
 
For the cross-sectional study, the presence of prevalent IC at the time of the study 
was determined using the results of the Edinburgh Claudication Questionnaire 
(314) (Table 3.2). The information on deprivation quintile (SIMD) was incomplete 
in the 1998 survey among participants who did not consent to the passive follow-
up. Therefore, I used social class, as an alternative to SIMD, to adjust for 
confounding due to socioeconomic status in the logistic regression analyses. Social 
class was categorised into: professional, managerial technical, skilled non-
manual, skilled manual, semi-skilled manual and unskilled manual. 
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Table 3.2 The Edinburgh Claudication Questionnaire 
 
 
 
Source:  Adapted from Leng GC, Fowkes FG. J Clin Epidemiol. 1992; 45:1101-1109.
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Participants with IC at baseline were excluded from the retrospective cohort 
study. The SHeS records had already been linked to several Scotland-wide 
databases including death certificates and SMR01. As described in section 3.3.1 
data source, incident cases of PAD were defined as a hospital admission or death 
with relevant codes recorded in any position. For participants who had consented 
to passive follow-up via record, ISD was able to provide SIMD data.  These were 
used to derive quintiles of deprivation, ranging from 1 (most deprived) to 5 (least 
deprived) (313).  Participants were categorised into these quintiles based on the 
postcode of residence. BMI was classified as underweight or normal weight (<25 
kg/m2), overweight (25-30 kg/m2) and obese (≥30 kg/m2) (312). Physical activity 
was defined as self-report of any kind of physical activity for at least 3 hours per 
week (315). Alcohol consumption status was self-reported as: never drinker, ex 
drinker, low-risk drinker (< 28 units/week, women < 21 units/week), increasing-
risk drinker (men < 50 units/week, women < 35 units/week) and high-risk drinker 
(men ≥ 50 units/week, women ≥ 35 units/week) (316).  
 
For the study using GS: SFHS datasets, an ABPI <0.9 was used to define the 
presence of PAD. This included both asymptomatic and symptomatic PAD. For the 
study using SHeS datasets, the Edinburgh Claudication Questionnaire was used to 
identify intermittent claudication, the typical form of symptomatic PAD. PAD can 
progress from asymptomatic to symptomatic. Therefore, the latter is suggestive 
of a more severe form of the disease, and generally occurs at an older age (13). 
Therefore, I included those participants aged younger than 45 years in my study 
using GS: SFHS datasets to identify more PAD cases including asymptomatic cases 
in order to increase statistical power. In contrast, I included only participants aged 
>45 in my study using SHeS to keep the age inclusion criterion consistent to the 
previous published study on SHS and PAD (38). Furthermore, many studies on 
smoking and cardiovascular diseases have used an age of >45 years as the inclusion 
criteria. 
 
As mentioned in the above section, according to the WHO, BMI was categorised 
into normal weight, overweight and obese (312). The categorisations of SIMD 
quantiles and socioeconomic status variable were predefined in SHeS. In SFHS, the 
categorisation of the variable on alcohol consumption was already predefined in 
the datasets provided. In SHeS, categorisation of variable on alcohol consumption 
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was also predefined. In order to maximise available power to ensure sufficient 
cases, I combined some groups based on units/week in accordance with NHS 
alcohol risk assessment health check into low-risk, increasing-risk and high-risk 
(316). In SFHS, physical activity was predefined as “ how many days per week did 
you do physical activity?” Due to statistical power, I defined at least 4 days per 
week as physically active. In SHeS,  physical activity was predefined as  “average 
hours doing all physical activities per week: no time, less than 1, less than 3, less 
than 5, less than 7, 7 hours or more”. According to the WHO, for adults aged 18-
64, or 65+, physical activity comprises at least 150 minutes of moderate activity 
or at least 75 minutes vigorous activity (315). Based on the predefined categories 
in the SHeS, I defined at least 3 hours per week as physically active. 
 
The interaction between SHS and other risk factors (including age, sex and 
socioeconomic status) related to CVD have been tested by previous studies (317-
319). Researchers suggested that SHS exposure is inversely associated with 
socioeconomic status (320, 321) and socioeconomic status is known risk factors for 
CVD (322, 323). In my studies, interactions tests with age, sex, variables on 
socioeconomic status were performed. 
 
3.3.4 Statistical analyses 
Generation Scotland : Scottish Family Health Study (GS: SFHS) 
Categorical data were summarized using frequencies and percentages. Chi-square 
tests were used for categorical variables and Chi-square tests for trend for ordinal 
variables. Univariate and multivariate logistic regression models were used to 
examine the association between SHS exposure and PAD using no exposure as the 
referent category. I developed several models with increasing level of statistical 
adjustment: unadjusted, partially adjusted (age, sex and deprivation quintile) and 
fully adjusted (partially adjusted model plus alcohol consumption, physical 
activity and BMI category). The confounders were chosen based on the available 
prior knowledge and in keeping with the published literature. The covariates were 
selected via a combination of a forward-stepwise selection approach (significance 
level <0.20 for inclusion) (326) on one hand and published evidence on the other 
hand. Missing data on categorical or ordinal variables were coded as dummy values 
and included in the adjusted models. I tested whether there were statistically 
significant interactions with age, sex and socioeconomic status using the likelihood 
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ratio test (39, 324). Statistical significance was defined as a two-sided p-value 
<0.05 for both main effects and interactions.  All statistical analyses were 
undertaken using Stata 12.0 (Stata Corporation, College Station, Texas, USA). 
 
Scottish Health Survey (SHeS) 
Categorical data were summarised using frequencies and percentages. Chi-square 
tests for trend were used for ordinal variables and chi-square tests for categorical 
variables. Univariate and multivariate logistic regression models were applied to 
examine the association between SHS and prevalent IC using cotinine <0.7 ng/mL 
as the referent category (67, 325). I adjusted for the potential confounding effects 
of age, sex and social class. The confounders were chosen based on the available 
prior knowledge and in keeping with the published literature. The covariates were 
selected via a combination of a forward-stepwise selection approach (324) on one 
hand and published evidence on the other hand. A margin plot was used to predict 
the probability of IC over salivary cotinine concentration. ‘Marginsplot’ is a 
command in Stata that graphs the results from ‘margins’ command. The ‘Margins’ 
command can calculate functions of fitted values after estimation commands 
including logistic regression. The ‘Marginsplot’ command in stata automatically 
adds CIs (326). For the study using logistic regression analyses based on SHeS data 
in this chapter, the Y-axis of the margin plot was the predicted probability of 
having IC. The X-axis was the value of cotinine concentration. The margin plot 
graphed the predicted probability of IC as a function of the cotinine 
concentration. Cotinine concentrations of 0, 5, 10 and 14.8 ng/mL were used as 
fitted values. In this study, cotinine  The adjusted odds ratios and prevalences of 
raised cotinine concentrations were used to derive the attributable percentages 
(326). All statistical analyses were conducted using Stata 12.0 (Stata Corporation, 
College Station, Texas, USA). 
 
For the retrospective cohort study using record linkage, differences in baseline 
characteristics across the SHS exposure groups of the study participants were 
summarised and assessed as above. Tests of Cox proportional-hazards assumptions 
were performed using Stata estat phtest (327). Separate Cox proportional hazard 
models were developed to examine the association between levels of SHS 
exposure and two separate outcomes: incident PAD (hospital admission or death) 
and all-cause mortality. I ran a series of models with increasing levels of statistical 
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adjustments for potential confounders: unadjusted, partially adjusted (age and 
sex) and fully adjusted (partially adjusted plus deprivation quintile, BMI category, 
physical active, alcohol consumption and survey year) using cotinine <0.7ng/mL 
as the referent category (328). For both the cross-sectional study and the cohort 
study, missing data were coded as dummy values and included in the adjusted 
models. Statistical interactions with covariates (age, sex, and socioeconomic 
status) were tested using the likelihood ratio test (39, 324). Statistical significance 
was defined as a two-sided p-value <0.05 for both main effects and interactions. 
All statistical analyses were performed using Stata 12.0 (Stata Corporation, 
College Station, Texas, USA). 
 
 
3.4  Results 
Generation Scotland : Scottish Family Health Study (GS: SFHS) 
Of the 21,558 participants in the Scottish Family Health Study, 6,168 were 
classified as never smokers. Among these, 5,686 (92.2%) had both brachial and 
ankle blood pressure measurements recorded and comprised the study population. 
One hundred and thirty-four (2.4%) had PAD (ABPI <0.9). Participants with PAD 
were significantly older and more likely to be female (Table 3.3). There were no 
significant differences in the prevalence of diabetes and dyslipidaemia between 
participants with and without PAD (Table 3.3). Three percent of the participants 
with PAD reported being exposed to at least 40 hours of SHS per week, compared 
with 0.6% of those without PAD (χ2 test, p=0.010) (Table 3.4).    
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Table 3.3 Characteristics of never smokers by presence or absence of 
peripheral arterial disease, Scottish Family Health Study 
 
  
PAD 
(ABPI <0.9) 
N=134 
N (%) 
 
 
No PAD 
(ABPI ≥0.9) 
N=5,552 
N (%) 
 
P value* 
 
Age group (years) 
   
0.002 
    18-45 47 (35.1) 2,556 (46.0)  
    46-59 45 (33.6) 1,852 (33.4)  
    ≥60 41 (30.6) 1,118 (20.1)  
    Missing  1 26  
Sex    <0.001 
    Male  30 (22.4) 2,161 (38.9)  
    Female  103 (76.9) 3,365 (60.6)  
    Missing  1 26  
Deprivation quintile   0.092 
    1 (most deprived) 16 (11.9) 495 (8.9)  
    2 19 (14.1) 658 (11.9)  
    3 21 (15.7) 810 (14.6)  
    4 27 (20.2) 1,352 (24.4)  
    5 (least deprived) 40 (29.9) 1,854 (33.4)  
    Missing  11 383  
Alcohol consumption    0.466 
    Never 4 (3.0) 209 (3.8)  
    Stopped >1 year 8 (6.0) 202 (3.6)  
    Stop ≤1 year 4 (3.0) 67 (1.2)  
    Current 114 (85.1) 4,959 (89.3)  
    Missing  4 115  
Physically active   0.425 
    No 55 (41.0) 2,593 (46.7)  
    Yes 70 (52.2) 2,639 (47.5)  
    Missing  9 320  
Body mass index (kg/m2)   0.873 
    <25.0  65 (48.5) 2,377 (42.8)  
    25.0-29.9 34 (25.4) 2,045 (36.8)  
    ≥30.0 33 (24.6) 1,098 (19.8)  
    Missing  2 32  
Hypertension 57 (42.5) 1,942 (35.0) 0.070 
Diabetes 4 (3.0) 128 (2.3) 0.554 
Total cholesterol (mmol/L)    0.740 
    ≤6.2 102 (76.1) 4,361 (78.5)  
    >6.2 20 (14.9) 781 (14.1)  
    Missing  12 410  
HDL cholesterol (mmol/L)    0.766 
    ≥1.0  112 (83.6) 4,760 (85.7)  
    <1.0  10 (7.5) 376 (6.8)  
    Missing 12 416  
    
 
PAD peripheral arterial disease; ABPI ankle brachial pressure index; N number; HDL high-density 
lipoprotein. 
*χ2 test for trend 
Reprinted with friendly permission from Atherosclerosis (46) 
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Table 3.4 Self-reported exposure to secondhand smoke among never smokers 
by presence or absence of peripheral arterial disease, Scottish Family Health 
Study 
 
  
PAD 
(ABPI <0.9) 
N=134 
N (%) 
 
 
No PAD 
(ABPI ≥0.9) 
N=5,552 
N (%) 
 
P value* 
 
Work 
 
None  
 
102 (76.1) 
 
4,338 (78.1) 
 
0.394 
 A little 4 (3.0) 444 (8.0)  
 Some 5 (3.7) 126 (2.3)  
 A lot 3 (2.2) 36 (0.7)  
 missing 
 
20 608  
Home None  104 (77.6) 4,646 (83.7) 0.314 
 A little 5 (3.7) 232 (4.2)  
 Some 5 (3.7) 126 (2.3)  
 A lot 3 (2.2) 100 (1.8)  
 missing 
 
17 448  
Other locations None  84 (6.3) 3,419 (61.6) 0.635 
 A little 28 (2.1) 1,536 (27.7)  
 Some 7 (5.2) 238 (4.3)  
 A lot 4 (3.0) 49 (0.9)  
 missing 
 
11 310  
Total hours per week 0 83 (61.9) 3,534 (63.7) 0.214 
 1-19  33 (24.6) 1,634 (29.4)  
 20-39  3 (2.2) 61 (1.1)  
 ≥40  4 (3.0) 34 (0.6)  
 missing 
 
11 289  
 
PAD peripheral arterial disease; ABPI ankle brachial pressure index; N number  
*χ2 test for trend  
Reprinted with friendly permission from Atherosclerosis (46)
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On univariate logistic regression analysis, participants with PAD were found to be 
significantly more likely to report high levels of SHS exposure at work, and at other 
locations, and an overall duration of exposure of at least 40 hours (Table 3.5). 
When adjusted for age, sex and deprivation quintile as potential confounders, the 
significant associations with work, other locations and overall exposure persisted 
(Table 3.5). When further adjusted for age, sex, deprivation quintile, alcohol 
consumption, physical activity and BMI category, the association between PAD and 
SHS exposure at work, at other locations and overall exposure remained significant 
(adjusted OR=3.80, CI 1.12-12.89, p=0.032 for SHS exposure a lot at work; 
adjusted OR=3.56, CI 1.20-10.56, p=0.022 for SHS exposure a lot in other places; 
adjusted OR=4.53, CI 1.51-13.56, p=0.007 for overall SHS exposure at least 40 
hours per week) (Appendix 6). When the adjusted odds ratios were plotted on a 
logarithmic scale, there was suggestion of a log-linear dose relationship among 
those exposed to SHS (Figure 3.1). There were no statistically significant 
interactions with any of the covariates.  
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Table 3.5 Logistic regression analyses of the association between secondhand smoke exposure and peripheral arterial disease, 
Scottish Family Health Study                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OR odds ratio; CI confidence interval  
*adjusted for age, sex and deprivation quintile  
Reprinted with friendly permission from Atherosclerosis (46) 
   
Unadjusted 
  
 Adjusted* 
 
   
OR 
 
95% CI 
 
P value 
 
 
P value for trend 
 
OR 
 
95% CI 
 
P value 
 
P value for trend 
 
Work  
 
None 
 
1.00 
 
- 
 
- 
 
0.395 
 
1.00 
 
- 
 
- 
 
0.278 
 A little 0.38 0.14-1.05 0.061  0.43 0.16-1.19 0.105  
 Some 1.69 0.68-4.21 0.262  1.88 0.75-4.74 0.179  
 A lot 
 
3.54 1.07-11.70 0.038  3.56 1.06-11.90 0.040  
Home  None 1.00 - - 0.316 1.00 - - 0.334 
 A little 0.96 0.39-2.38 0.935  0.92 0.37-2.31 0.866  
 Some 1.77 0.71-4.42 0.220  1.78 0.70-4.48 0.224  
 A lot 
 
1.34 0.42-4.30 0.622  1.18 0.36-3.83 0.786  
Other locations None 1.00 - - 0.635 1.00 - - 0.609 
 A little 0.74 0.48-1.14 0.176  0.79 0.51-1.24 0.313  
 some 1.20 0.55-2.62 0.652  1.34 0.60-2.99 0.474  
 A lot 
 
3.32 1.17-9.42 0.024  3.30 1.13-9.67 0.029  
Total hours per week 0 1.00 - - 0.214 1.00 - - 0.078 
 1-19  0.86 0.57-1.29 0.468  0.93 0.61-1.43 0.748  
 20-39  2.09 0.64-6.81 0.219  1.96 0.59-6.51 0.272  
 ≥40  
 
5.01 1.74-14.44 0.003  4.61 1.56-13.61 0.006  
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Figure 3.1 Adjusted odds ratios for the association between total number of 
hours exposed to second hand smoke per week and peripheral arterial 
disease, Scottish Family Health Study 
 
 
PAD  peripheral arterial disease  
Reprinted with friendly permission from Atherosclerosis (46) 
 
When I re-ran the models using dummy values for missing data for the most 
incomplete variables (deprivation quintile, alcohol consumption and physical 
activity) the associations were still apparent (≥ 40 hours per week exposure: 
adjusted OR 4.29, 95% CI 1.43-12.83, p=0.009). After further adjustment for 
hypertension, diabetes and dyslipidaemia, they remained statistically significant 
(≥ 40 hours per week exposure: adjusted OR 5.36, 95% CI 1.74-16.54, p=0.003). 
 
Scottish Health Survey (SHeS) 
Of the 41,664 participants in the SHeSs, 8,519 were aged >45 years, classified 
themselves as non-smokers and completed the Edinburgh Claudication 
Questionnaire. Of these, 4,434 had provided a saliva sample. When these were 
compared with the 4,085 participants who did not, there was no significant 
difference in the prevalence of IC (χ2 test p=0.318). Of the 4,434 participants, 203 
(4.5%) were excluded because they had a cotinine concentration ≥15.0 ng/mL 
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which suggested that, contrary to their self-report smoking status, they were 
likely active smokers. Therefore, 4,231 participants comprised the study 
population.   
 
Of the 4,231 participants, 2,293 (54.2%) classified themselves as never smokers 
and 1,938 (45.8%) as ex-smokers. Among the ex-smokers, 1,882 (97.1%) had quit 
smoking at least one year prior to each survey. Overall, 134 (3.2%) eligible 
participants had IC. Individuals with IC were older and had significantly higher 
salivary cotinine concentrations than those without IC (Table 3.6). In the 
univariate logistic regression model, there was a dose relationship such that IC 
increased with increasing cotinine concentration. Adjustment for age, sex and 
social class only attenuated the association slightly and it remained statistically 
significant (Table 3.7). Further adjustment for body mass index did not alter the 
relationship (cotinine 2.7-14.9 ng/mL: adjusted OR 1.74, 95% 1.02-2.96, p=0.042). 
When age was taken as a continuous variable in the fully adjusted logistic 
regression models, the association persisted (cotinine 2.7-14.9 ng/mL: adjusted 
OR 1.92, 95% 1.13-3.27, p=0.016, p for trend=0.016). The predicted margins of 
the cotinine level were based on four point estimates: 0, 5, 10 and 14.8 ng/mL, 
the latter being the maximum permissible value in the study population. The 
margin plot suggested a linear, positive dose relationship between cotinine 
concentration and IC (Figure 3.2).  
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Table 3.6 Characteristics of non-smokers by presence or absence of 
peripheral arterial disease, Scottish Health Survey  
 
    
 PAD 
(N=134) 
N (%) 
 
No PAD 
(N=4097) 
N (%) 
 
P value* 
 
Age group (years)  
   
<0.001 
 45-60 33 (24.6) 1,886 (46.0)  
 ≥60 101 (75.4) 2,211 (54.0)  
 Missing 0 0  
Sex   0.230 
 Male 68 (50.7) 1,864 (45.5)  
 Female 66 (49.3) 2,233 (54.5)  
 Missing  0 0  
Social class    0.078 
 Professional  6 (4.5) 233 (5.7)  
 Managerial technical  34 (25.4) 1,118 (27.3)  
 Skilled non-manual  17 (12.7) 524 (12.8)  
 Skilled manual  37 (27.6) 1,284 (31.3)  
 Semi-skilled manual  25 (18.7) 600 (14.6)  
 Unskilled manual  14 (10.4) 253 (6.2)  
 Missing   1 85  
Salivary cotinine (ng/mL)   0.017 
 <0.7 81 (60.5) 2,784 (68.0)  
 0.7-2.6 35 (26.1) 997 (24.3)  
 2.7-14.9 18 (13.4) 316 (7.7)  
 Missing  
 
0 0  
 
IC Intermittent claudication 
*χ2 test for age and sex; χ2 test for trend for social class and cotinine concentration 
Reprinted with friendly permission from Heart (328) 
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Table 3.7 Logistic regression analyses of the association between secondhand smoke exposure and peripheral arterial disease, 
Scottish Health Survey 
 
 
OR odds ratio; CI confidence interval 
*adjusted for age, sex and social class for all ages; adjusted for sex and social class for ≥60 years of age or <60 years of age  
Reprinted with friendly permission from Heart (328) 
 
 
  
Unadjusted 
 
Adjusted* 
 
  OR (95% CI) P value P value for trend OR (95% CI) P value P value for trend 
        
Salivary cotinine (ng/mL)        
        
All ages <0.7 1.00 - 0.017 1.00 - 0.040 
 0.7-2.6 1.21 (0.81-1.81) 0.361  1.21 (0.80-1.82) 0.368  
 2.7-14.8 
 
1.96 (1.16-3.31) 0.012  1.76 (1.04-3.00) 0.036  
≥60 years of age <0.7 1.00 - 0.502 1.00 - 0.659 
 0.7-2.6 0.84 (0.50-1.39) 0.493  0.81 (0.48-1.35) 0.417  
 2.7-14.8 
 
1.49 (0.81-2.74) 0.203  1.39 (0.75-2.57) 0.300  
<60 years of age <0.7 1.00 - 0.001 1.00 - <0.001 
 0.7-2.6 3.15 (1.49-6.68) 0.003  3.41 (1.58-7.36) 0.002  
 2.7-14.8 
 
4.00 (1.40-11.41) 0.009  4.46 (1.53-12.98) 0.006  
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Figure 3.2 Associations between salivary cotinine concentration in non-
smokers and probability of intermittent claudication (unadjusted), Scottish 
Health Survey. 
 
 
 
 
 
Reprinted with friendly permission from Heart (328) 
 
There was a statistically significant interaction with age (p=0.013). Among 
participants over 60 years of age, the association did not reach statistical 
significance. However, among those under 60 years of age, there was a 
statistically significant, dose relationship that persisted following adjustment for 
potential confounders (Table 3.7). Among all non-smokers over 45 years of age, 
the adjusted attributable percentages were 3.6% (95% CI -6.6%-12.8%) for cotinine 
concentrations of 0.7-2.6 ng/mL, and 5.6% (95% CI -0.8%-11.7%) for cotinine 
concentrations 2.7-14.9 ng/mL.   
 
Of the 41,664 participants in the Scottish Health Surveys 1998, 2003, 2008 and 
2010, 37,967 (91.9%) participants had consented to passive follow-up via record 
linkage to routine administrative data. Among these, 17,128 (45.1%) were aged > 
45 years. Of these, 83 participants were excluded because of being on nicotine 
replacement therapy (NRT). Of the remainder, 10,817 participants completed the 
Edinburgh Claudication Questionnaire at baseline and were free of baseline IC. Of 
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these participants, 6,772 were excluded because: 1,246 reported being current 
smokers, 188 reported being non-smokers but had a cotinine concentration ≥ 15.0 
ng/mL, and 5,338 did not provide a saliva sample. Therefore, 4,045 participants 
classified themselves as non-smokers and had a cotinine concentration < 15 ng/mL 
and were, therefore, eligible for the record linkage, cohort study (Figure 3.3).  
 
Figure 3.3 Flow diagram of participant inclusion and exclusion, Scottish 
Health Survey, routine administrative data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
37,967 participants from collated 
Scottish Health Surveys 1998, 
2003, 2008 and 2010 had 
consented to passive follow-up 
 
17,128 participants aged > 45 years  
83 participants on nicotine replacement therapy 
(NRT) 
4,045 participants classified 
themselves as non-smokers and 
had saliva cotinine <15 ng/mL 
 17,045 participants aged > 45 
years and were not on NRT 
10,817 participants did not have 
PAD at baseline 
6,772 participants excluded: 
1,246 self-reported current smokers;  
188 self-reported non-smokers had; 
cotinine ≥ 15.0 ng/mL 
5,338 missing data on saliva cotinine 
 
20,811 participants aged ≤ 45 years 
23 missing data 
 
559 participants had baseline PAD;  
5,666 missing data on presence of baseline 
PAD; 
3 missing data on incident PAD date 
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Of these, 2,216 (54.8%) classified themselves as never smokers and 1,829 (45.2%) 
as ex-smokers. Among the ex-smokers, 1,774 (97.0%) had quit smoking for at least 
1 year prior to each survey and 1,620 (88.6%) had quit for at least 5 years prior to 
each survey. Overall, 1,163 (28.8%) had either moderate or high exposure to SHS 
at baseline. The mean age at recruitment was 61 (standard deviation (329) 10) 
years and there was a total of 29,040 person years of follow-up (mean follow-up 
9 years). Over the follow up period there were 568 all-cause deaths, none of which 
were coded as due to PAD, and 64 people were hospitalised for PAD. 
 
Compared with the no or low SHS exposure group, participants with high exposure 
were older, and more likely to be male, obese and social economically deprived; 
they drank more drank alcohol and were less physically active (Table 3.8). There 
was a statistical significant association between baseline exposure to SHS and all-
cause mortality among all participants (Table 3.9, Figure 3.4) and among male 
subgroup of participants (Table 3.9). In univariate and multivariate Cox 
proportional hazard models, participants with high exposure to SHS (cotinine 2.7-
14.9 ng/mL) were significantly more likely to die, with a clear dose-response 
relationship across the cotinine categories (Table 3.9). In relation to incident PAD, 
in terms of all participants, the association with baseline exposure to SHS did not 
reach statistical significance (Table 3.9, Figure 3.5). However, there was a 
significant interaction with sex (p=0.025). Male participants with high exposure to 
SHS were significantly more likely to experience PAD events when unadjusted or 
adjusted for age only, compared with the low exposure group (Table 3.9, Figure 
3.6). After further adjustment for other potential confounders, the HR attenuated 
but was not statistically significant. Among female non-smokers, there were no 
significant associations between baseline exposure to SHS and either all-cause 
mortality or PAD hospitalisations. There were no significant interactions with 
other covariates. The proportional hazards assumptions were met in all of the 
models (Global test: all p>0.050) except for the adjusted models for all-cause 
mortality in the female only subgroup (Global test: p=0.018 for partially adjusted 
model and p<0.001 for fully adjusted model). The numbers of participants were 
too small to run subgroup piecewise analyses stratified by the other covariates.  
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Table 3.8 Baseline characteristics of non-smokers by cotinine concentrations, 
Scottish Health Survey, routine administrative data 
 
   
 Cotinine (ng/mL)  
 0-0.6 0.7-2.6 2.7-14.9  
 N=2,882 N=850 N=313 P values* 
 N (%) N (%) N (%)  
     
 
Age (years) 
    
  45-59 1,338 (46.4) 406 (47.8) 124 (39.6) 0.042 
  ≥ 60 1,544 (53.6) 444 (52.2) 189 (60.4)  
  Missing  0 0 0  
Sex     
  Male 1,250 (43.4) 423 (49.8) 167 (53.4) <0.001 
  Female 1,632 (56.6) 427 (50.2) 146 (46.6)  
  Missing 0 0 0  
Deprivation quintile     
  1(most deprived) 315 (10.9) 137 (16.1) 75 (24.0) <0.001 
  2 479 (16.7) 190 (22.4) 82 (26.2)  
  3 622 (21.6) 202 (23.8) 55 (17.6)  
  4 697 (24.2) 153 (18.0) 50 (16.0)    
  5(least deprived) 644 (22.3) 141 (16.6) 40 (12.8)  
  Missing  125  27  11   
Body mass index (kg/m2)     
  <25.0 670 (23.2) 151 (17.8) 46 (14.7) <0.001 
  25.0-29.9 1,181 (41.0) 347 (40.8) 122 (39.1)  
   ≥ 30 757 (26.3) 272 (32.0) 122 (39.0)  
  Missing 274 80 23  
Physically active     
  No 1,442 (50.0) 450 (52.9) 177 (56.5) <0.001 
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  Yes 1,251 (43.4) 332 (39.1) 101 (32.3)  
  Missing 190 68 35  
Alcohol consumption     
  Never drinker 237 (8.2) 51 (6.0) 25 (8.0) <0.001 
  Ex drinker 129 (4.5) 43 (5.1) 23 (7.3)  
  Low-risk drinker 2,300 (79.8) 655 (77.1) 211 (67.4)  
  Increasing-risk drinker 163 (5.7) 66 (7.8) 33 (10.5)  
  High-risk drinker 51 (1.8) 34 (4.0) 19 (6.1)  
  Missing 2 1 2  
     
 
* χ2 test 
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Table 3.9 Cox proportional hazard models of the association between secondhand smoke exposure, peripheral arterial disease and 
all-cause mortality, Scottish Health Survey, routine administrative data 
 
 Cotinine 
(ng/mL) 
Unadjusted  Partially adjusted†  Fully adjusted‡  
  HR (95%CI) P value P value 
for 
trend 
HR (95%CI) P value P value 
for 
trend 
HR (95%CI) P value P value 
for 
trend 
           
           
Incident PAD           
All non-smokers1 0-0.6* 1.00 - 0.172 1.00 - 0.140 1.00 - 0.382 
(64 events) 0.7-2.6 1.26 (0.71-2.25) 0.437  1.30 (0.73-2.33) 0.372  1.15 (0.64-2.06) 0.648  
 2.7-14.9 1.64 (0.77-3.49) 0.203  1.66 (0.77-3.51) 0.184  1.38 (0.65-2.95) 0.400  
           
Male non-smokers1 0-0.6* 1.00 - 0.100 1.00 - 0.084 1.00 - 0.280 
(28 events) 0.7-2.6 0.82 (0.30-2.24) 0.702  0.91 (0.33-2.49) 0.848  0.76 (0.28-2.07) 0.595  
 2.7-14.9 2.89 (1.18-7.10) 0.021  2.82 (1.14-6.96) 0.024  2.10 (0.78-5.65) 0.141  
           
Female non-smokers1 0-0.6* 1.00 - - 1.00 - - 1.00 - - 
(36 events) 0.7-2.6 1.66 (0.81-3.38) 0.165  1.65 (0.81-3.37) 0.168  1.51 (0.73-3.15) 0.266  
 2.7-14.9 ** **  ** **  ** **  
 
All-cause mortality 
         
All non-smokers1 0-0.6* 1.00 - 0.004 1.00 - 0.001 1.00 - 0.043 
(568 events) 0.7-2.6 1.25 (1.03-1.52) 0.022  1.34 (1.10-1.63) 0.003  1.24 (1.02-1.51) 0.034  
 2.7-14.9 1.30 (1.04-1.79) 0.024  1.42 (1.09-1.86) 0.011  1.21 (0.91-1.61) 0.194  
           
Male non-smokers1 0-0.6* 1.00 - 0.006 1.00 - <0.001 1.00 - 0.004 
(304 events) 0.7-2.6 1.26 (0.98-1.63) 0.077  1.47 (1.13-1.92) 0.004  1.40 (1.07-1.83) 0.014  
 2.7-14.9 1.52 (1.09-2.13) 0.014  1.54 (1.08-2.18) 0.016  1.54 (1.07-2.22) 0.020  
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HR hazard ratio; CI confidence interval; HDL high-density lipoprotein; PAD peripheral arterial disease 
*reference; ** only one participant; † adjusted for age and sex for all non-smokers, adjusted for age for male or female non-smokers; ‡ partially adjusted plus 
deprivation quintile, body mass index, physical activity, alcohol consumption and survey yeara 
 
1Test of proportional-hazards assumption all p≥0.050 
 
2Test of proportional-hazards assumption all p<0.050
Female non-smokers2 0-0.6* 1.00 - 0.475 1.00 - 0.504 1.00 - 0.523 
(264 events) 0.7-2.6 1.14 (0.85-1.53) 0.380  1.14 (0.85-1.53) 0.368  1.03 (0.76-1.40) 0.836  
 2.7-14.9 1.07 (0.68-1.70) 0.764  1.05 (0.67-1.65) 0.828  0.80 (0.51-1.27) 0.344  
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Figure 3.4 Survival proportion of all-cause mortality among all participants by 
cotinine concentrations using Kaplan-Meier method. Scottish Health Survey, 
routine administrative data 
 
 
  
Log-rank test: P=0.013
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Figure 3.5 Cumulative hazard of peripheral arterial disease among all 
participants by cotinine concentrations using the Nelson-Aalen method. 
Scottish Health Survey, routine administrative data 
 
PAD: peripheral arterial disease 
N: Number of events 
 
Figure 3.6 Cumulative hazard of peripheral arterial disease among male 
participants by cotinine concentrations using the Nelson-Aalen method. 
Scottish Health Survey, routine administrative data  
 
PAD: peripheral arterial disease 
N: Number of events 
a. PAD among all participants (N=63)
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3.5 Discussion 
 
Overall, my two cross-sectional studies demonstrated a statistically significant, 
independent association between the level of SHS exposure and PAD. Individuals 
who had objective evidence of PAD (ABPI <0.9) were significantly more likely to 
report high, overall levels of SHS exposure, even after adjusting for potential 
confounding factors (adjusted OR 4.53, 95% CI 1.15-13.56, p=0.007 for participants 
exposed to ≥ 40 hours per week of SHS) (Appendix 6). Increased cotinine 
concentration was significantly associated with IC based on the Edinburgh 
Claudication Questionnaire, with evidence of a dose-response relationship. After 
adjustment for potential confounders, participants with a cotinine ≥ 2.7 ng/mL 
were at a significantly increased risk of IC (adjusted OR 1.76, 95% CI 1.04-3.00, 
p=0.036), compared with those with a cotinine concentration < 0.7 ng/mL (Table 
3.7). Overall, 9.2% of the cases of IC among non-smokers were attributable to 
raised cotinine concentrations. There was evidence of a statistical interaction 
whereby the association was stronger and statistically significant among 
individuals under 60 years of age and did not reach statistical significance in older 
individuals. In my cohort study, compared with no and low SHS exposure, 
increased cotinine concentration at baseline were associated with increased risk 
of all-cause mortality (adjusted HR 1.42, 95% CI 1.09-1.86, p=0.011), with a clear 
dose relationship. The association between high cotinine concentration at 
baseline and risk of incident PAD reached statistical significance in male 
participants only (adjusted HR 2.82, 95% CI 1.14-6.96, p=0.024). The cohort study 
might possibly be underpowered to assess the association between high cotinine 
concentration at baseline and risk of incident PAD among female non-smokers. 
 
Attributable risk is generally used to assess the burden of disease at the level of 
populations and involves causal inference. Attributable risk % or attributable 
fraction is calculated from the attributable risk and provides information on the 
proportion of disease attributable to this particular exposure in the exposed group 
or the proportion of disease avoidable in the exposed group if this particular 
exposure is eliminated (222). In relation to the association between SHS and PAD, 
as mentioned in Chapter 2, very few studies have collected data on both SHS 
exposure and PAD. In SHeS, the presence of IC at the time of study was defined 
by the Edinburgh Claudication Questionnaire. In my cross-sectional study, the 
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adjusted ORs and prevalences of raised cotinine concentrations were used to 
derive the attributable risk %. However, the association estimate does not reflect 
the causal estimate. This is a limitation of my study. In reality, usually there are 
many causes of a disease. It is unknown whether or not there is a temporal 
relationship between SHS and PAD. The results in my study are estimates of the 
burden of disease among Scottish adults who are exposed to SHS and may 
overestimate or underestimate the true value.  
 
Due to the limited number of incident PAD cases among female non-smokers who 
were exposed to high level of SHS (Table 3.9), the cohort study in this chapter is 
possibly underpowered to assess in particular the overall association between SHS 
exposure and PAD among female non-smokers. As mentioned in Chapter 1, the 
influence of gender on the prevalence of PAD in controversial in previous studies 
(8, 130, 131). In the main report of SHeS 2012, around 25% male non-smokers and 
12% female non-smokers reported the exposure to SHS (303). In my cohort study, 
of the 64 incident PAD cases, 28 were male non-smokers and 36 were female non-
smokers. Among the 1,840 male non-smokers (Table 3.8), the incidence rate was 
1.5%. Among 2,205 female non-smokers (Table 3.8), the incidence rate was 1.6%. 
However, as mentioned above (Table 3.8), participants with high SHS exposure 
were more likely to be male (7 male vs. 1 female). This may be a possible 
explanation for the observed association between high cotinine concentration and 
incident PAD among male non-smokers. Furthermore, the incident PAD cases were 
ascertained as severe cases that warranted hospitalisation or surgery or 
contributed to death. It is possible that a proportion of PAD cases were missed. It 
is still uncertain whether or not the magnitude of association between SHS and 
PAD is stronger in male non-smokers than female non-smokers. Future research is 
needed to explore the association and the possible explanations. 
 
PAD shares many common risk factors with CHD and the two diseases commonly 
co-exist in the same individuals (13). As described in Chapter 2, there have been 
many studies demonstrating an association between active smoking and PAD (118). 
Exposure to SHS causes similar haemodynamic and inflammatory changes in 
vessels, (58, 330-335) and predisposes to the formation, progression and instability 
of atherosclerotic plaques (59, 335-340). There is now strong evidence for an 
association between SHS exposure and both CHD and stroke (4, 6). In contrast, 
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before the publication of my studies, only two studies, both cross-sectional, had 
been published on the association between SHS exposure and PAD. A cross-
sectional study examined 1,209 Chinese women aged ≥60 years who had never 
smoked. The investigators did not have access to cotinine concentrations but 40% 
of women reported exposure to SHS. Those women who had an ABPI <0.9 were 
significantly more likely to report SHS exposure (adjusted OR 1.47, 95% CI 1.07-
2.03, p=0.018). They demonstrated a dose relationship with the number of 
cigarettes to which they were exposed each day for IC, ABPI <0.9 and either of 
the two (p values for linear trend = 0.009, 0.002 and 0.002 respectively). The 
findings were similar for the daily duration of exposure (p values for linear trend 
= 0.003, 0.048 and 0.001 respectively) (4). The second cross-sectional study, 
undertaken in the USA, examined 5,653 non-smokers. They dichotomised non-
smokers into those exposed to SHS (serum cotinine 0.05-10 ng/mL) and those not 
(serum cotinine <0.05 ng/mL) and found no significant association with PAD 
defined as ABPI<0.9. However, on further analysis, they found a significantly 
higher risk of PAD in the top decile of exposure to SHS (equivalent to cotinine 
concentration >155 ng/mL), which they interpreted as evidence of a threshold 
effect (38).   
 
My study using the SFHS is the largest published study to date on the association 
between SHS exposure and PAD. Because of its size I was able to restrict inclusion 
to never, rather than non (never or ex), smokers. The study included five times 
the number of never smokers included in the Chinese study and doubled the 
number in the USA study. As mentioned in my previous chapter, the risk of 
developing PAD is lower among ex-smokers when compared with current smokers, 
but still significantly increased when compared with never smokers. Studies have 
suggested that the prevalence of PAD among people who had stopped smoking 
declines overtime since smoking cessation (155, 191). Therefore, in the study 
using SFHS, I included only never smokers because there were sufficient 
participants who classified themselves as never smokers. A further strength was 
the ability to ascertain PAD objectively using ABPI measurements rather than self-
reported symptoms. This approach also leads to more complete case 
ascertainment as it includes participants with early stage, asymptomatic disease. 
In contrast, a weakness of this study was the reliance on self-reported level of 
exposure to SHS.  
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The GS: SFHS did not obtain cotinine, or equivalent, measurements. The GS: SFHS 
study recruited probands and their adult first degree relatives from two big cities 
in Scotland (Glasgow and Dundee). These two cities have high levels of 
socioeconomic deprivation and therefore have higher incidence of atherosclerotic 
diseases and premature atherosclerotic disease (307, 341). When I tried to re-run 
the models by splitting into age groups, the numbers of participants with different 
SHS exposure levels were too small to show the effect size precisely. Forty eight 
cases of PAD would have been excluded if I had only included participants aged>45 
years and only 3 self-reported never smokers had PAD. Symptomatic PAD increases 
with advancing age (238, 342) and most PAD cases are asymptomatic (13). 
Therefore, in this GS:SFHS study, I used a lower age cut-off (participants aged 
≥ 18) to identify more asymptomatic PAD cases.  
 
I was able to adjust for potential confounders such as age, sex socioeconomic 
status, physical activity, BMI and alcohol consumption (45, 325). It is 
acknowledged that active cigarette smoking reduces body weight loss by the 
nicotine receptor-mediated effects that lead to suppression of appetite (343). 
Reduced BMI among active smokers, which is related to cigarette smoking, may 
confound the association between cigarette smoking and CVD events (344, 345). 
Nicotine is the chemical compound that causes addiction to cigarette smoke. The 
harm of cigarette smoke on cardiovascular system is primarily from CO, tar and 
other carcinogens including PAH and arsenic (68). Studies have suggested that 
childhood exposure to SHS is positively associated with childhood BMI and obesity 
(346, 347). Exposure to SHS during pregnancy is also associated with low birth 
weight (348). However, it is not clear about the relationship between exposure to 
SHS and BMI among adults. There is published evidence supporting increased BMI 
as a risk factor for PAD (168). Researchers have suggested that BMI is not on the 
causal pathway of health related outcomes including mortality (349). In keeping 
with the previous published studies on the association between SHS and CHD, 
stroke and PAD (45, 67), I further adjusted BMI in the fully adjusted regression 
models in my studies. Previous studies have adjusted for diabetes and serum lipid 
concentrations but these are potential mediators rather than confounders. 
Exposure to SHS is associated with diabetes and lipid changes. Diabetic patients 
and dyslipidaemia patients can consequently have peripheral vasculopathy 
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including PAD (diabetic foot ulceration) (13, 28, 145, 147, 334, 335, 350-354). As 
mentioned in the pathophysiology section in Chapter 1, it is possible that the 
causal pathway through which SHS acts could be through diabetes and lipids. 
Therefore, in the studies in this chapter, I did not include them as covariates. And 
in the next chapter, the associations between SHS exposure and some 
cardiovascular biomarkers are explored. 
 
The SHeSs are pan-Scotland surveys and are intended to be representative of the 
general population living in households across Scotland. Each survey in the series 
has included an administered questionnaire on demographics (including age, sex 
and social status) and lifestyle (smoking status, alcohol consumption and physical 
activity) and measurements (height, weight, blood pressure, and if applicable, 
blood and saliva samples), with modules of questions on specific health conditions. 
A strength of the SHeS, in comparison with GS: SFHS, was the access to salivary 
cotinine measurements rather than reliance on self-reported exposure to SHS. 
However, smoking status was still self-reported and, because of the social 
undesirability of smoking, a proportion of current smokers are known to 
deliberately misclassify themselves as ex-smokers (termed “smoking deceivers”), 
especially if they already have a smoking-related condition (355). Thereby, in 
compliance with usual practice, I applied a maximum cotinine concentration of 15 
ng/mL to people who classified themselves as non-smokers in order to exclude 
smoking deceivers (40). I also excluded participants taking nicotine replacement 
therapy. My previous cross-sectional study using GS:SFHS on SHS and PAD was 
restricted to participants aged ≥ 18 in order to identify asymptomatic PAD based 
on ABPI measurements.  In a study using 38-year follow up data from the 
Framingham study aiming at developing an IC risk profile, the rate of IC increased 
with advancing age in both sexes, ranging from 0.9% and 0.4% for men and women 
aged 45-54 years, to 2.1% and 1.2% for men and women aged 55-64 years, to 2.5% 
and 1.5% for men and women aged 65-74 years, respectively (356). Thus, in my 
cross-sectional study on SHS and PAD, I applied an age cut-off of >45 years to 
identify more intermittent claudication cases based on the Edinburgh Claudication 
Questionnaire. A limitation of the studies using SHeS is that both ex-smokers and 
never smokers were included as non-smokers. Previous studies suggested that 
there can be a lag between past smoking behaviour among ex-smokers and the 
disease onset (357). Ex-smokers still carry the risk of developing cardiovascular 
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events including PAD (118, 358). Ideally, I would have included only never smokers 
in the research. In reality, the analyses were possibly underpowered to show the 
association between SHS and PAD. Therefore, caution should be taken when 
interpreting the results.  
 
In order to maximise statistical power, I included ex- as well as never smokers but 
the vast majority of ex-smokers (88.1%) had not smoked for at least five years. 
Furthermore, 79 (59.0%) PAD cases would have been excluded if I only included 
never smokers in my study using SHeS. When including both never and ex-smokers, 
the number of cases of PAD was 134, the same as in my study using GS:SFHS. In 
these analyses, I adjusted for potential confounders: demographic and 
socioeconomic risk factors and BMI. After further adjustment for other 
confounders such as physical activity, the association between cotinine and PAD 
attenuated and became statistically insignificant. A weakness of the SHeS was the 
lack of an objective measure of PAD, such as ABPI.  Therefore, case ascertainment 
had to be based on self-report of disease symptoms.  Nonetheless, cases were 
ascertained via a widely used and well validated questionnaire; the Edinburgh 
Claudication Questionnaire. In my cross-sectional study using the SHeS, I observed 
a dose relationship across the cotinine concentrations rather than a threshold 
effect as the suggested by the previous USA study, with a statistically significant 
association above a concentration as low as 2.7 ng/mL. The presented studies are 
exploratory and warrant further research. The association between SHS exposure 
and PAD would be more plausible if future longitudinal studies include only never 
smokers with repeat measures of SHS exposure and longer follow-up time.  
 
Similar to the two existing studies on SHS exposure and PAD, a limitation of both 
of my first two studies was their cross-sectional design. Cross-sectional studies are 
relatively quick and easy to conduct. However, they suffer from three weaknesses. 
Firstly, the primary limitation is that risk factor/exposure and disease/outcome 
are ascertained simultaneously. That is, it is difficult to establish a temporal 
relationship and thereby confirm that the exposure predated the onset of the 
disease. Thereby, associations may occur as a result of reverse causation (359) 
(Appendix 5). If the exposure is an inherent risk factor such as gender or race and 
the outcome developed over time, the association between the exposure and the 
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outcome is more plausible. Vice versa, if the exposure developed over time, 
causality is unknown (360).  
 
Secondly, the main outcome measure obtained from a cross-sectional study is 
prevalence rather than incidence. Another weakness of cross-sectional studies is 
that their reliance on prevalent cases of disease makes them susceptible to 
survival bias (359). Survival bias is a type of selection bias and can occur in both 
cross-sectional studies and case-control studies. It occurs when individuals with 
favourable survivorship are included in the analysis because of exposure related 
to mortality from the disease being studies (361, 362).  
 
Thirdly, alternative explanations (chance, bias and confounding) for the study 
results may need to be appropriately assessed (360). In the two cross-sectional 
studies in this chapter, SHS exposure and prevalent PAD were measured at one 
point in time. The observed associations between SHS exposure and prevalent PAD 
may result from those exposed to SHS being more likely to develop PAD, or less 
likely to die after developing PAD, or a combination of both. However, given that 
there is substantial evidence from the meta-analyses showing the association 
between SHS and cardiovascular risk including CHD (67) and stroke (45), in the 
specific case of SHS exposure and PAD, reverse causation is highly unlikely, and 
SHS exposure is unlikely to be protective against PAD case-fatality. Nonetheless, 
using record linkage of SHeS to undertake a cohort study enabled me to address 
these methodological limitations in the third study. If SHS exposure is associated 
with survival as well as incidence, survival bias may explain why the association 
appeared to be weaker in those over 60 years of age. If this is the case, then the 
magnitude of association among younger participants is likely to be a better 
measure of the true association.  
 
The cohort study using record linkage of SHeS suggested a similar relationship 
between SHS exposure and PAD but the associations did not reach statistical 
significance among non-smoker participants overall. Only the subgroup of male 
non-smokers with high exposure levels of cotinine >2.7 ng/mL reached statistical 
significance. Due to the limited number of female non-smokers in the high SHS 
exposure group, this cohort study is possibly underpowered to assess the 
association between high cotinine concentration at baseline and risk of incident 
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PAD among female non-smokers.  A major limitation of the cohort study was that 
case ascertainment was restricted to those participants with PAD that was 
sufficiently severe to warrant hospitalisation or surgery or contribute to death. 
Therefore, these incident PAD events were a highly selected subgroup of all 
participants with incident PAD.  Any association between SHS and incident PAD, 
defined in this way, could be due to an association with all incident PAD, an 
association with disease progression or a combination of both. In order to 
maximise statistical power, I analysed never and ex-smokers together as non-
smokers. The majority of ex-smokers (88.7%) had quit smoking for at least five 
years. Having access to cotinine concentrations was a strength in terms of it being 
an objective measure of baseline SHS exposure. However, a limitation of this study 
was the lack of repeat measures of SHS exposure. Therefore, it has to be assumed 
that baseline concentrations persist long-term, or at least that any changes over 
time are not systematically different between those exposed and not exposed at 
baseline.   
 
However, my findings suggested a dose-response relationship whereby the risk of 
PAD increases with increasing cotinine concentration. The number of incident PAD 
events is small but this reflects the general lack of focus on SHS and PAD in existing 
studies and surveys. In my cohort study, the number of female participants who 
had incident PAD events was too small to be split into exposure groups. 
 
All these three studies were observational studies which to some extent are 
vulnerable to built-in bias such as selection bias, information bias and confounding 
(363) (Appendix 5). Selection bias occurs when the method of selecting 
participants distorts the association between exposure and outcome in the target 
population (Appendix 5). That is, the study population does not represent the 
target population. Selection bias can be introduced at any stage of a study: design 
and implementation (361). In SFHS, participants were randomly selected from the 
general population from general practitioner records in Glasgow and Dundee. The 
SHeS used multi-stage, stratified probability sampling frame and represents the 
general population living in private households nationwide in Scotland. As 
mentioned in the results (Section 3.4), when the participants who had provided a 
saliva sample for cotinine assay were compared with those who did not, there was 
no significant difference in the prevalence of IC. In this respect, selection bias is 
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unlikely to explain the observed associations. However, in the study using SFHS, 
in order to identify asymptomatic PAD defined by ABPI, I used a younger age cut-
off. While, in the study using SHeS, to include symptomatic PAD based on the 
Edinburgh Claudication Questionnaire, I used an age cut-off of >45 years. Survival 
bias is a type of selection bias and is possible in cross-sectional studies. Survival 
bias could be a possible explanation about why the association between SHS 
exposure and PAD appeared to be weaker in those over 60 years of age. If this is 
the case, the magnitude of association among younger participants is likely to be 
a better measure of the true association.  
 
In the cohort study, participants were restricted to confirmed non-smokers (self-
reported non-smokers who had salivary cotinine concentration <15.0 ng/mL) who 
were free of IC at baseline and had consented to passive follow-up via record 
linkage to routine administrative data. Potential bias could be a question. 
Selection bias may distort the results about the association between SHS and PAD. 
It is not possible to extract the participant’s records without their consent to 
passive follow-up, and therefore, selection bias is inevitable. In my analyses, HR 
was calculated from the Cox proportional hazards model. HR has a built-in 
selection bias (291). The subjects were follow-up over certain period of time until 
some events took place. It is possible that those participants who were observed 
to be event-free up to the defined time point were observed for a shorter time 
(e.g. participants from the 2008 SHeS and 2010 SHeS) than those who did have 
PAD. If so, the observed magnitude of association between SHS and incident PAD 
cases can be biased. 
 
Information bias occurs during data collection. It is often known as observation or 
measurement or classification bias (363) (Appendix 5). It often occurs when the 
individual measurements or classifications of the disease or exposure are not 
accurate. As a result, exposed and/or diseased subjects can be misclassified as 
non-exposed and/or non-diseased and vice versa (361, 364). In the cohort study, 
the NHS Scotland’s ISD links the administrative SHeS data to hospitalization record 
and death certificates. Over 90% of SHeS participants consented at each survey to 
the passive follow-up with data linkage (310). In this respect, information bias in 
the outcome measure was less of an issue. However, SHS exposure was only 
measured at baseline. Repeat measures of SHS exposure were not available in this 
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cohort study. Information bias may be a potential question. This may distort the 
association between SHS exposure and PAD. In addition, when smoking status was 
self-reported, because of the social undesirability of smoking, a proportion of 
participants who might be current smokers misclassified themselves as non-
smokers. This may introduce potential reporting bias. In the study using SFHS, SHS 
exposure was self-reported. If the participants know the harmful effect of SHS, 
especially if they already have SHS-related conditions, potential information bias 
may be a concern. It is possible that the estimate of the effect size is 
overestimated.  
 
Confounding occurs when a variable is a known risk factor for the outcome and is 
associated with the exposure but is not a result of the exposure (363) (Appendix 
5). Unlike a mediator, a confounder is not an intermediate step in the causal 
pathway between the exposure and the outcome. A confounder is unequally 
distributed among the groups being compared (359). Confounding can be reduced 
by restricting, matching and randomisation at the design stage, and stratifying, 
making multivariable statistical adjustment and doing standardised rate analysis 
at the analysis stage (363, 365). As mentioned in Section 1.3.2, Chapter 1, PAD 
shares many risk factors with CHD (121). I developed statistical models with 
increasing level of adjustment for the well-established confounders. However, 
other omitted confounders such as concentrations of homocysteine (366), CRP 
(367, 368), and cadmium (369) may affect the observed association between SHS 
and PAD. In the baseline data of SFHS, I did not have access to measurements of 
these risk factors. Baseline concentrations of CRP were measured and collected in 
the SHeS. In the studies using SHeS in this chapter, after further adjustment for 
other confounders, the association did not reach statistical significance. It is 
possible that confounding may play a role in the observed association. 
Furthermore, other unknown risk factors may introduce confounding bias. 
Residual confounding may also be an issue. Residual confounding refers to the 
distortion that remains after controlling for confounding in the design and/or 
analysis of a study. It occurs when: additional confounding factors were not 
considered or not measured; confounding was not controlled well enough; and 
there were errors in the measured confounders including misclassification of 
subjects with respect to confounding variables due to reporting or measurement 
errors (370, 371). Residual confounding is likely to affect the association between 
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SHS exposure and PAD. Since a confounder can be a risk factor or a preventive 
factor for the disease (297), residual confounding can either underestimate or 
overestimate the true association. The biggest concern about confounding is that 
a causal relationship could appear from confounding but in fact does not exist 
(222). My studies used secondary analyses of the SFHS and SHeS and data on a 
proportion of confounders were not collected. I restricted the eligible study 
populations to a certain age range in order to include the largest possible number 
of PAD cases. There might still be differences in age among the groups being 
compared.  
 
Confounders can be identified by empirical methods or theoretical methods. An 
example of theoretical strategies is the directed acyclic graphs (DAGs) (372). 
Empirical strategies generally include forward, backward, and stepwise regression 
analyses, and a 10% change-in-estimate (CIE) criterion (373). Furthermore, there 
are other criteria to aid the selection of variables into the multivariable analysis 
including the likelihood ratio χ2 test. The likelihood ratio χ2 test is performed by 
comparing the log likelihoods of two models (a model with the additional variable 
and a model without the additional variable) and can be used to compare the fit 
of one model to the fit of the other (324, 374). Comparing the model χ2 on addition 
of additional confounders can be another approach to assess the presence of 
confounding. In my studies, the confounders were chosen based on the available 
prior knowledge, in keeping with previous published evidence on the association 
between SHS and CHD (4). It is possible that potential confounders which were not 
detected with the stepwise selection approach could have been identified by 
comparing the model χ2. This may result in biased estimates of the exposure-
outcome association (370, 375). However, researchers suggested that theoretical 
confounders should always be adjusted for even if empirical and theoretical 
methods yield contradictory results (376, 377).  
 
Chance is a random error that occurs unpredictably (222). Random error may 
produce the appearance of an association between an exposure and an outcome 
which in fact does not exist. It may also produce the absence of an association 
which in fact is real. Furthermore, it can lead to either underestimation or 
overestimation of a measurement value from the true population value. There are 
three sources of random error including sampling error, measurement error and 
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individual biological variation (Appendix 5). Due to chance alone, different 
samples can produce different estimates. Caution must be taken whenever an 
inference is being made from a sample to a population (222).  
 
If a study is unbiased, the CI generally presents the precision of an estimate of 
the association between the exposure and the outcome (Appendix 5). The number 
of subjects with the outcome, which is often influenced by the sample size, affects 
the width of the CI (297). In my studies, the findings may be affected by the small 
number of PAD cases. This may explain the wide range of CIs in the high exposure 
groups. However, these studies are so far the largest studies that have assessed 
the association between SHS and PAD. Further research is needed to examine the 
association between SHS and PAD to reduce the possibility of false positive 
association due to bias, confounding and chance. 
 
As discussed above, before the observed association between SHS exposure and 
PAD is assessed for the possibility that it is a causal relationship, other 
explanations for the observed association should be excluded, including chance, 
bias and confounding. One of the criteria to judge causation is reverse causality 
(Appendix 5). A review of the meta-analyses of randomised controlled trials 
suggested that permanent smoking cessation is probably the most clinical and cost 
effective intervention for PAD patients (156). As mentioned in Chapter 1, previous 
studies suggested that comprehensive smoke-free legislation was associated with 
lower hospital admission rates (or deaths) for coronary events, other heart disease 
and  cerebrovascular accidents (112, 113). Pell et al. also found a 21% reduction 
of admissions for ACS among never smokers during the 10 months after the smoke-
free legislation in nine hospitals in Scotland, compared with the 10 months before 
the legislation (116). In contrast, the studies on hospital admission of PAD are 
rare. It is important to assess the impact of smoke-free legislation on hospital 
admissions of PAD to avoid reverse causality. 
 
The three studies described in this chapter used different measurements of SHS 
and different definitions of PAD. Whilst this prohibits direct comparison of the 
results between studies, it means that the limitations of one study are somewhat 
offset by the strengths of another. The consistency of the findings using these 
different approaches provides reassurance that the findings may reflect a true 
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association and provide evidence that the harmful effects of SHS exposure extend 
beyond CHD and CVD to PAD and underpin the need to protect the general 
population from exposure.     
 
Whilst possibly underpowered to assess the overall association between SHS 
exposure and PAD, the third study is the first to have attempted to do so using 
incident cases in a cohort design. In the future, new, larger cohort studies are 
required to study this hitherto neglected area; ideally using objective 
measurements of both SHS exposure and PAD.   
 
Some previous studies on cardiovascular disease suggested that SHS exposure may 
carry a disproportionate risk compared with active smoking (29-31, 52, 67, 334, 
378). In my cross-sectional study using the SHeSs, when I reran the models by 
including confirmed current smokers (self-reported current smokers with salivary 
cotinine ≥ 15.0 ng/mL) in the analysis. The margin plot suggested a positive dose 
relationship between cotinine and IC (Figure 3.6). The association between 
current smoking and IC was comparable to that of non-smokers with high SHS 
exposure dosage (≥ 2.7 ng/mL) (adjusted OR =1.81, CI 1.07-3.08, p=0.021 for non-
smokers with high SHS exposure; adjusted OR =2.12, CI 1.52-2.96, p<0.001 for 
current smokers). Studies on the underlying mechanisms have been relatively few 
in number. In my next chapter, I will examine the relationship between the 
cotinine concentration and a number of cardiovascular biomarkers among non-
smokers and current smokers for a given level of smoke exposure. 
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Figure3.7 Odds ratios for the association between salivary cotinine 
concentration among both non-smokers and current smokers and 
intermittent claudication, Scottish Health Survey 
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4  Chapter 4: Active smoking, secondhand smoke 
and cardiovascular biomarkers 
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4.1 Chapter summary 
 
CVD is the global leading cause of death. Both active smoking and SHS are 
important risk factors for many age-related diseases including CVD. In my previous 
chapter, I have demonstrated the association between exposures to SHS and PAD. 
There is good evidence that both active smoking and SHS exposure are associated 
with well-established cardiovascular biomarkers such as CRP, fibrinogen, and low-
density lipoprotein (LDL) cholesterol. Sidestream smoke contains higher levels of 
small particles and toxic gases than mainstream smoke. In spite of this, there is a 
lack of studies directly comparing non-smokers with high levels of secondhand 
exposure, and light and moderate active smokers. Therefore, in this chapter, I 
aim to examine the relationship between exposure to SHS and several 
cardiovascular biomarkers among non-smokers and specifically test the hypothesis 
that SHS carries a disproportionately higher cardiovascular risk than active 
smoking for a given level of tobacco exposure. 
 
Shortened telomeres have been described as a biomarker for biological ageing 
including atherosclerosis phenotypes. Many studies have demonstrated an 
association between active smoking and telomere length attrition. In contrast, the 
association between SHS exposure and leukocyte telomere length attrition per 
year of age among adult non-smokers remains unknown.  Therefore, in this 
chapter, I will also examine the relationship between exposure to secondhand 
smoke and telomere length.   
 
I identified two potential sources of data among the Scottish general population: 
the SHeS and a subgroup of participants from the SFHS who were included in a 
previous study on biomarkers of aging. Ideally, I would have included studies with 
objective measurement of SHS exposure (for example cotinine concentration).  
The SHeS measured SHS exposure using salivary cotinine concentration, but the 
SFHS used self-reported exposure to SHS.  
 
To examine the relationship between cotinine concentration and a number of 
cardiovascular biomarkers among non-smokers and active smokers, I undertook a 
cross-sectional study using the SHeSs conducted between 1998 and 2010. Inclusion 
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was restricted to participants aged ≥ 16 years who had provided saliva and blood 
samples and were not taking a nicotine replacement therapy. Univariate and 
multivariate regression models were used to examine the relationships between 
cotinine concentration and CRP, high-density lipoprotein (HDL) cholesterol and 
fibrinogen concentrations, as well as TC/HDL cholesterol ratios.  
 
Further in line with the hypothesis of the association between SHS exposure and 
leukocyte telomere length shortening per year of age, I undertook another cross-
sectional study using a subgroup of 1,779 participants from the SFHS. These 
participants were chosen because they had participated in a previous sub-study 
on aging and therefore had already had their telomere length measured. The 
inclusion criteria, dictated from the previous study, were non-smokers aged ≥ 18 
years who were not taking nicotine replacement therapy. Linear regression models 
were used to relate the telomere T/S ratio to age, where the T/S ratio is the 
telomere repeat copy number to the single copy gene ratio (379, 380).  
 
In my study using the SHeSs, of the 10,018 eligible participants, 7,345 (73.3%) 
were confirmed non-smokers (cotinine <15.0 ng/mL) and 2,673 (26.7%) were 
confirmed current smokers (cotinine ≥15.0 ng/mL). CRP and TC/HDL cholesterol 
increased, and HDL cholesterol decreased, with increasing cotinine concentration 
across non-smokers and smokers (all p<0.001). However, there were step changes 
at the interface, whereby non-smokers with high exposure to SHS had lower 
concentrations of cotinine than light active smokers but comparable 
concentrations of CRP (p=0.709), HDL cholesterol (p=0.931) and TC/HDL 
cholesterol (p=0.405). Fibrinogen concentrations were significantly raised in 
moderate and heavy active smokers only (both p<0.001).  
 
In my study using the subgroup from SFHS, 1,303 eligible participants were 
included because they were self-reported non-smokers, had provided self-
reported SHS exposure status and had had telomere assays performed as part of a 
previous study of aging. Of these, 779 (54.4%) reported no SHS exposure, 495 
(34.5%) low exposure (1-19 hours per week), 29 (2.0%) high exposure (≥20 hours 
per week). Compared with those with no SHS exposure, participants with high SHS 
exposure were older (p value for trend=0.025) and more likely to live in 
socioeconomically deprived areas (p value for trend <0.001). In the univariate 
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linear regression analyses, the relative telomere T/S ratio declined with increasing 
age in years in all exposure groups. Telomere length decreased more rapidly with 
increasing age among those with high exposure to SHS when compared with both 
those with no exposure to SHS (adjusted p=0.010) and those with low exposure to 
SHS (p=0.005).  
 
These findings suggest that:  
1) Exposure to SHS is associated with disproportionately higher concentrations of 
biomarkers of cardiovascular risk compared with active smoking; 
2) High SHS exposure may accelerate normal biological aging.   
 
Premature telomere attrition may be an intermediate step between exposure to 
SHS and CVD including PAD. Further studies on the relevant mechanisms should be 
conducted and efforts on protecting the public from SHS exposure should be 
increased. 
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4.2 Introduction 
 
Globally, CVD is the leading cause of death and is projected to cause 23 million 
deaths per annum by 2030 (381). The global prevalence of smoking is increasing, 
due to increasing prevalence in large, developing countries such as China. A 2013 
WHO report indicated that only 16% of the world’s population is covered by 
comprehensive smoke-free legislation (3). Active smoking is an established risk 
factor for CHD (15), stroke (14), and PAD (118). There is growing evidence that 
exposure to SHS is also a risk factor. Two meta-analyses reported relative risks of 
1.25 (95% CI 1.17-1.32) and 1.25 (95% CI 1.12-1.38) for CHD (4) and stroke (6) 
respectively. To date, four cross-sectional studies have examined the association 
with PAD (38, 45, 46, 328), with three reporting significant associations (45, 46, 
328). In my work described in the last chapter, I demonstrated that non-smokers 
with cotinine concentrations ≥2.7 ng/mL were significantly more likely to have 
intermittent claudication than those with cotinine concentrations <0.7 ng/mL 
(adjusted OR 1.76, 95% CI 1.04-3.00)(328).  
 
Active smoking is associated with higher concentrations of cardiovascular 
biomarkers including: CRP (382), fibrinogen (383), and low-density lipoprotein 
(LDL) cholesterol (384). SHS contains mainly sidestream smoke, from burning 
cigarette tips, as well as exhaled mainstream smoke. Sidestream smoke contains 
higher concentrations of small respirable particles (<2.5 µm) and toxic gases than 
mainstream smoke inhaled by active smokers (28-31). Brief exposure to SHS 
produces rapid changes in inflammatory markers (52, 53), resulting in 
concentrations comparable to active smokers (334, 378, 385). Therefore, the 
sidestream smoke inhaled by non-smokers exposed to SHS may convey a 
disproportionately higher risk of cardiovascular disease. In the British Regional 
Heart Study, the risk of CHD events over 20 years of follow-up was comparable in 
non-smokers exposed to high levels of SHS (adjusted HR 1.57, 95% CI 1.08-2.28) 
and light active smokers (adjusted HR 1.66, 95% CI 1.04-2.68) in spite of cotinine 
concentrations being nearly 30-fold higher in the latter group (mean 4.9 versus 
138 ng/mL) (67, 306).  
 
The telomere is a region of repetitive DNA sequences (TTAGGG) at the end of a 
chromosome, which protects the end of the chromosome from deterioration and 
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end-to-end fusion (386). The telomeres of somatic cells are eroded with each 
cycle of cell division.  Telomere attrition normally limits cells to a fixed number 
of divisions and cumulative oxidative stress accelerates the attrition and, 
therefore, biological ageing (386, 387). Previous studies have demonstrated that 
common age-related diseases including CVD and a shorter life span are associated 
with shorter telomeres through mechanisms involving oxidative stress associated 
with cigarette smoking (388, 389).  However, whether SHS accelerates telomere 
attrition with age is unknown. 
 
I used the SHeS to explore the association between the level of secondhand and 
active smoke exposure, measured by salivary cotinine concentration, and a 
number of preclinical cardiovascular biomarkers: CRP, high-density lipoprotein 
(HDL) cholesterol, TC/HDL cholesterol and fibrinogen. To examine the association 
between levels of SHS exposure and telomere length shortening per annum, I 
conducted another cross-sectional study using a subgroup of individuals from the 
SFHS who had had telomere assays performed as part of a previous study of 
biological aging. This data source provides information on telomere length in blood 
leukocytes among the consented individuals from this subgroup. As mentioned in 
my previous chapter, data from the SFHS used self-reported exposure to SHS.  
 
4.3 Materials and methods 
4.3.1 Data source 
Scottish Health Survey (SHeS) 
I conducted another cross-sectional study using baseline data collected on SHeS. 
As described in the previous chapter, the Surveys are ongoing, repeated, cross-
sectional studies used to monitor the health and health-related risk factors of the 
general population living in private households across Scotland (309). The surveys 
were undertaken in 1995, 1998 and 2003, and then annually from 2008 using a 
multi-stage, stratified sampling frame. Each survey recruited different 
households. Trained staff conducted face-to-face interviews and obtained 
measurements, including height and weight. All consenting individuals aged ≥16 
years were visited by a nurse and invited to provide a salivary sample, for cotinine 
assay, and blood samples, for assays including lipids, CRP and fibrinogen. 
Cholesterol concentrations were measured using cholesterol oxidase assays on an 
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Olympus 640 analyser (Olympus, Canter Valley, Pennsylvania) prior to 2010 and, 
subsequently a Roche Modular P analyser (Roche, Basel, Switzerland).  CRP 
concentrations were determined using the N Latex CRP mono-immunoassay on the 
Behring Nephelometer II analyser (Behring, Milan, Italy). Fibrinogen 
concentrations were measured using the Organon Teknika MDA 180 analyser 
(Organon, Oss, the Netherlands). Cotinine was assayed using a Hewlett Packard 
hp5890 gas chromatograph (Hewlett Packard, Palo Alto, CA, USA).  
 
Generation Scotland : Scottish Family Health Study (GS: SFHS) 
 
GS:GFHS is a family-based, cross-sectional study of the general population, with 
a specific focus on cardiovascular risk factors and disease (308). Probands aged 
between 35 and 55 years were randomly selected for invitation from the records 
of general practitioners based in Glasgow and Dundee. Between 2006 and 2011, 
7,953 probands were recruited along with 16,007 consenting first degree relatives 
aged ≥18 years; producing a total of 23,960 participants (341). All participants 
completed a questionnaire that provided information on demographics (including 
age, sex and postcode of residence) and lifestyle (including smoking status, and 
number of hours of exposure per week to SHS). Trained staff measured height and 
weight. Trained staff collected blood samples from each consenting participants.  
 
Ethical approval for the GS:SFHS was obtained from NHS Tayside Committee on 
Medical Research Ethics (REC Reference Number: 05/S1401/89). GS:SFHS has been 
granted Research Tissue Bank status by the Tayside Committee on Medical 
Research Ethics (REC Reference Number: 10/S1402/20) providing generic ethical 
approval for a wide range of uses within medical research. Permission to use the 
GS:SFHS data and access to the blood samples was provided following review by 
the GS:SFHS Access Committee.  
 
In this chapter, I used existing data on a subgroup of 1,779 individuals from the 
SFHS, randomly selected to participate in a study on ageing. DNA was extracted 
from peripheral blood leukocytes using Maxwell automated purified system 
(Promega, WI, USA). Telomere lengths in the DNA samples were determined by 
quantitative-polymerase chain reaction (Q-PCR) blindly using a Roche Light Cycler 
LC480 (Roche Diagnostics, Indianapolis, Indiana, USA). (379) 
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Analyses were performed in triplicate for each sample using a single-copy gene 
amplicon primer set (acidic ribosomal phosphoprotein, 36B4) and a telomere-
specific amplicon primer set (390). A cut-off 0.15 for the SD of the threshold cycle 
(Ct) for sample replicates was used as a quality control parameter for the 
amplification. The samples were reanalysed if an SD above 0.15 was encountered. 
The average SD across plates was 0.07. Relative telomere length was estimated 
from Ct scores using the comparative Ct method when telomere and control gene 
assays yielded similar amplification efficiencies. The ratio of telomere repeat 
copy number to single copy gene number (T/S) ratio in experimental samples 
relative to a control sample DNA was determined. This normalised T/S ratio was 
defined as the estimate of relative telomere length (Relative T/S). The inter-assay 
variation was tested by comparing the relative T/S estimates for positive controls 
on every assay plate. The average inter-assay coefficient of variance was 0.58% 
for telomere length and 0.23% for 36B4 (379, 380, 391, 392), which indicates a 
low variation.  
 
4.3.2 Inclusion criteria and definitions 
Scottish Health Survey (SHeS) 
In this chapter, I collated data from the 1998, 2003, 2008, 2009 and 2010 surveys 
as they collected consistent information on cotinine, CRP, fibrinogen and lipid 
concentrations. Inclusion was restricted to participants aged ≥16 years who 
provided saliva and serum samples, and were not taking nicotine replacement 
products. Consistent with guidelines, non-smokers were defined as self-reported 
never or ex-smokers who had a salivary cotinine concentration <15.0 ng/mL (40). 
Current smokers were defined as self-reported current smokers who had a cotinine 
concentration ≥15.0 ng/mL. Among non-smokers, SHS exposure was classified into 
low (cotinine <0.7 ng/mL), moderate (cotinine 0.7-2.6 ng/mL) and high (cotinine 
≥2.7 ng/mL). Current smokers were categorised into light (cotinine 15.0-100.0 
ng/mL), moderate (cotinine 100.1-300.0 ng/mL) and heavy (cotinine >300.0 
ng/mL). BMI was categorized into normal weight (<25 kg/m2), overweight (BMI 25-
30 kg/m2) and obese (≥30 kg/m2) (312). Alcohol consumption was based on self-
report and classified as never drinker, ex drinker, low-risk drinker (men <28 
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units/week, women <21 units/week), increasing-risk drinker (men <50 
units/week, women <35 units/week) and high-risk drinker (men ≥50 units/week, 
women ≥35 units/week) (316). Being physically active was defined as self-report 
of any kind of physical activity for at least three hours per week (315). 
 
Generation Scotland : Scottish Family Health Study (GS: SFHS) 
In this chapter, inclusion was restricted to non-smokers aged ≥ 18 years who had 
provided blood samples for telomere analysis.  As mentioned in the previous 
chapter, in Scotland, an index of socioeconomic status based on postcode of 
residence at recruitment-the SIMD (313) was used. There are 6,505 datazones 
based on postcode of residence, with a mean population of 800. The SIMD for each 
datazone incorporates information on income, employment, health, education, 
housing, crime and access to services and is divided into quintiles for the Scottish 
population. Levels of SHS exposure were self-reported and categorised into no 
exposure, low exposure (1-19 hours per week) and high exposure (≥ 20 hours per 
week). 
 
 
 
4.3.3 Statistical analyses 
Scottish Health Survey (SHeS) 
The characteristics of non-smokers and current smokers were summarised using 
frequencies and percentages for categorical data, medians and inter-quartile 
ranges for non-parametric continuous data (CRP) and mean and standard deviation 
for parametric continuous data (fibrinogen and lipids). The differences between 
the exposure groups were assessed using chi-square tests for categorical variables 
and analysis of variance (ANOVA) for continuous variables. Non-smokers and 
current smokers were included in the same model, in order to examine the effect 
of increasing cotinine concentration across the whole spectrum from non-smokers 
protected from SHS exposure to heavy active smokers. Univariate and multivariate 
median regression models were used to examine the association between cotinine 
concentration and serum CRP using non-smokers with low SHS exposure (cotinine 
<0.7 ng/mL) as the referent category. General linear regression models were used, 
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in the same way, to examine the associations between cotinine concentration and 
fibrinogen and lipid concentrations. Three models were developed for each assay: 
unadjusted; partially adjusted (age and sex) and fully adjusted (age, sex, social 
class, body mass index, alcohol consumption and physical activity). Interactions 
with age, sex and socioeconomic status were tested by fitting interaction terms 
in the regression models. Statistical significance was defined as a two-sided p 
value <0.001 for main effects and <0.05 for interactions. All statistical analyses 
were undertaken using Stata 12.0 (Stata Corporation, College Station, Texas, 
USA). 
 
Generation Scotland : Scottish Family Health Study (GS: SFHS) 
Linear regression models were used to relate the telomere T/S ratio to age. The 
dose effect of SHS on telomere T/S ratio was presented as change per increasing 
year of age across each exposure group. The differences between the exposure 
groups were assessed by comparing the coefficients (slopes) of the linear 
regression lines by age. Statistical significance was defined as two-sided p<0.05. 
Interactions with covariates (age, sex and socioeconomic status) in the fully 
adjusted models were tested. All statistical analyses were performed using Stata 
12.0 (Stata Corporation, College Station, Texas, USA). 
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4.4 Results 
Scottish Health Survey (SHeS) 
Of the 51,802 participants in the SHeS, 38,436 were aged ≥16 years. Of these, 180 
were excluded because they were taking nicotine replacement therapy (nicotine 
chewing gum, patch or nasal spray).  Of the remaining 38,256, 10,512 provided 
saliva and blood samples and had valid assay results. Three hundred and eighty 
four (3.7%) were excluded because they classified themselves as non-smokers but 
had a cotinine concentration ≥15.0 ng/mL, 94 (0.9%) because they classified 
themselves as current smokers but had a cotinine concentration <15.0 ng/mL, and 
16 (0.1%) because of missing smoking status. The remaining 10,018 participants 
constituted the study population (Figure 4.1). 
 
Of the 10,018, 7,345 (73.3%) were non-smokers and 2,673 (26.7%) were current 
smokers and, of the 2,725 ex-smokers, 2,604 (95.6%) had quit smoking at least one 
year prior to the survey and 2,251 (82.6%) had quit smoking for at least five years 
prior to the survey. Among the non-smokers, 2,208 (30.1%) had either moderate 
or high SHS exposure. Of the current smokers, 208 (7.8%), 980 (36.7%) and 1,485 
(55.5%) were light, moderate and heavy smokers, respectively. Across the 
different cotinine groups, there were differences in age, sex, social class, BMI 
category, physical activity and alcohol consumption (Table 4.1).  
 
CRP, fibrinogen, and cholesterol concentrations and TC/HDL cholesterol ratios 
differed for varying cotinine concentration (Table 4.2). CRP concentration and 
TC/HDL cholesterol ratio increased with increasing cotinine concentration but 
exhibited a step reduction between high exposure non-smokers and light active 
smokers (Table 4.2). Conversely, the HDL cholesterol concentration fell with 
increasing cotinine concentration but exhibited a step increase at the same point. 
There was no clear pattern relating to fibrinogen (Table 4.2).   
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Figure 4.1 Flow diagram of participant inclusion and exclusion. Scottish Health 
Survey 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted with friendly permission from Eur. J. Endovasc. Surg. (378)
38,436 participants aged≥ 16 years  
180 participants on nicotine replacement therapy 
(NRT) 
10,018 participants (7,345 self-
reported non-smokers with cotinine < 
15.0 ng/mL, 2,673 self-reported 
current smokers with cotinine ≥ 15.0 
ng/mL) 
 38,256 participants aged≥ 16 years 
and were not on NRT 
10,512 participants provided saliva 
and blood samples and had valid 
assay results 494 participants excluded: 
384 self-reported non-smokers with 
cotinine ≥ 15.0 ng/mL 
94 self-reported current smokers with 
cotinine < 15.0 ng/mL 
16 missing data 
 
13,366 participants aged < 16 years  
 
51,802 participants from collated 
Scottish Health Surveys 1998, 
2003, 2008, 2009 and 2010 
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Table 4.1 Characteristics of study population by cotinine concentrations. Scottish Health Survey 
 
   
 Cotinine (ng/mL)  
 Non-smokers Current smokers  
        
        
 0-0.6 0.7-2.6 2.7-14.9 15.0-100.0 100.1-300.0 ≥ 300.1  
 N=5,137 N=1,684 N=524 N=208 N=980 N=1,485 P 
values* 
        
        
 
Age (years) 
N (%) N (%) N (%) N (%) N (%) N (%)  
  16-45 2,002 (39.0) 793 (47.1) 231 (44.1) 139 (66.8) 542 (55.3) 752 (50.6) <0.001 
  46-59 1,422 (27.7) 444 (26.4) 114 (21.8) 43 (20.7) 233 (23.8) 466 (31.4)  
  ≥ 60 1,713 (33.3) 447 (26.5) 179 (34.1) 26 (12.5) 205 (20.9) 267 (18.0)  
  Missing  0 0 0 0 0 0  
Sex        
  Male 2,249 (43.8) 850 (50.5) 290 (55.3) 89 (42.8) 425 (43.4) 773 (52.1) <0.001 
  Female 2,888 (56.2) 834 (49.5) 234 (44.7) 119 (57.2) 555 (56.6) 712 (47.9)  
  Missing 0 0 0 0 0 0  
Social class        
  Professional 440 (8.6) 94 (5.6) 19 (3.6) 13 (6.3) 28 (2.9) 32 (2.2) <0.001 
  Managerial technical 1,758 (34.2) 361 (21.4) 119 (22.7) 57 (27.4) 231 (23.6) 269 (18.1)  
  Skilled non-manual 710 (13.8) 223 (13.2) 67 (12.8) 26 (12.5) 132 (13.5) 164 (11.0)  
  Skilled manual 1,308 (25.5) 592 (35.2) 175 (33.4) 61 (29.3) 290 (29.6) 501 (33.7)  
  Semi-skilled manual 588 (11.4) 265 (15.7) 93 (17.7) 32 (15.4) 195 (19.9) 343 (23.1)  
  Unskilled manual 203 (4.0) 104 (6.2) 31 (5.9) 13 (6.3) 79 (8.1) 137 (9.2)  
  Missing  130 45 20 6 25 39  
BMI (kg/m2)        
  <25.0 1,564 (30.4) 469 (27.9) 143 (27.3) 81 (38.9) 386 (39.4) 676 (45.5) <0.001 
  25.0-29.9 2,008 (39.1) 647 (38.4) 198 (37.8) 79 (38.0) 312 (31.8) 461 (31.0)  
   ≥ 30 1,174 (22.9) 430 (25.5) 145 (27.7) 36 (17.3) 198 (20.2) 231 (15.6)  
  Missing 391 138 38 12 84 117  
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Physically active        
  Yes 2,624 (51.1) 847 (50.3) 235 (44.8) 123 (59.1) 468 (47.8) 729 (49.1) 0.018 
  No 2,301 (44.8) 757 (45.0) 256 (50.6) 76 (36.5) 469 (47.9) 692 (46.6)  
  Missing 212 80 33 9 43 64  
Alcohol consumption        
  Never drinker 322 (6.3) 75 (4.5) 33 (6.3) 4 (1.9) 31 (3.2) 47 (3.2) <0.001 
  Ex drinker 204 (4.0) 64 (3.8) 24 (4.6) 4 (1.9) 54 (5.5) 96 (6.5)  
  Low-risk drinker 4,139 (80.6) 1,321 (78.4) 371 (70.8) 145 (69.7) 695 (70.9) 1,086 (71.9)  
  Increasing-risk drinker 351 (6.8) 148 (8.8) 63 (12.0) 26 (12.5) 112 (11.4) 155 (10.4)  
  High-risk drinker 101 (2.0) 55 (3.3) 27 (5.2) 27 (13.0) 84 (8.6) 96 (6.5)  
  Missing 20 21 6 2 4 5  
        
 
Values given as n (%) unless otherwise stated. 
CI confidence interval; BMI body mass index  
*χ2 test for age, sex, social class, body mass index, physical activity, alcohol consumption 
Reprinted with friendly permission from Eur. J. Endovasc. Surg. (378)  
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Table 4.2 Concentrations of C reactive protein, high-density lipoprotein cholesterol and fibrinogen, and total cholesterol/high-density 
lipoprotein cholesterol ratio by cotinine concentrations. Scottish Health Survey 
 
 
 
CRP C-reactive protein; TC total cholesterol; HDL high-density lipoprotein; IQR inter-quartile range; n number; SD standard deviation 
*Kruskal-Wallis test for C-reactive protein; one-way ANOVA test for HDL cholesterol, TC/HDL cholesterol and fibrinogen 
**Adjusted for age, sex and social class; Mean±standard error 
         
    Cotinine(ng/mL)    
   Non-
smokers 
  Current 
smokers 
  
         
         
  0-0.6 0.7-2.6 2.7-14.9 15.0-100.0 100.1-300.0 ≥ 300.1  
  N=5,137 N=1,684 N=524 N=208 N=980 N=1,485 P 
values* 
         
         
  Median (IQR) Median 
(IQR) 
Median 
(IQR) 
Median 
(IQR) 
Median 
(IQR) 
Median 
(IQR) 
 
CRP (mg/L)  1.30 (0.60-
3.00) 
1.50 (0.60-
3.50) 
1.80 (0.70-
4.40) 
1.30 (0.50-
3.65) 
1.85 (0.70-
4.30) 
2.10 (0.90-
4.60) 
<0.001 
  Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)  
HDL cholesterol 
(mmol/L) 
Unadjusted  1.52±0.42 1.47±0.39 1.43±0.39 1.50±0.43 1.42±0.40 1.37±0.38 <0.001 
 Adjusted**  1.37±0.04 1.36±0.04 1.33±0.04 1.39±0.04 1.30±0.04 1.26±0.04 <0.001 
TC/HDL cholesterol Unadjusted  3.94±1.33 4.00±1.30 4.32±6.24 3.73±1.23 4.14±1.69 4.48±2.33 <0.001 
 Adjusted**  3.05±0.11 3.10±0.12 3.42±0.25 3.06±0.11 3.35±0.12 3.53±0.14 <0.001 
Fibrinogen (g/L) Unadjusted  2.87±0.66 2.78±0.70 2.81±0.75 2.77±0.73 2.97±0.79 3.09±0.74 <0.001 
 Adjusted**  2.07±0.14 2.02±0.14 2.00±0.16 2.18±0.17 2.20±0.15 2.37±0.12 <0.001 
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The median regression analyses suggested a dose relationship whereby CRP 
concentration increased with increasing cotinine concentration among non-
smokers and among smokers but there was a step between high exposure non-
smokers and light active smokers. In the fully adjusted model, non-smokers with 
high levels of SHS exposure had CRP concentrations that were higher than non-
smokers protected from SHS exposure and were comparable to those of light 
(p=0.709) and moderate (p=0.136) active smokers (Table 4.3, Figure 4.2). There 
were statistically significant interactions with age (p=0.001) and sex (p=0.002). 
There was evidence of a dose response relationship between cotinine and CRP 
concentration in all subgroups but the difference in CRP concentration between 
non-smokers protected from SHS exposure and those with high exposure levels 
only reached statistical significance in men (p=0.005) and those over 60 years of 
age (p<0.001). In all subgroups there was no significant difference in CRP 
concentration between high-exposure non-smokers and light active smokers.  
 
In the fully adjusted linear regression analysis, HDL cholesterol concentration 
generally decreased with increasing cotinine concentration. Non-smokers with 
high levels of SHS exposure had HDL cholesterol concentrations that were lower 
than those of non-smokers protected from SHS exposure and were comparable to 
those of light active smokers (p=0.931) (Table 4.4, Figure 4.3). There was a 
significant interaction with sex (p<0.001). The difference in HDL cholesterol 
concentration between non-smokers protected from SHS and those with high 
exposure was statistical significant among women (p=0.006) but less significant 
among men (p=0.216). There were no significant differences in the HDL 
cholesterol concentrations between non-smokers with high SHS exposure and light 
active smokers among either men or women. TC/HDL cholesterol ratios generally 
increased with increasing cotinine concentration. In the fully adjusted model, only 
moderate and heavy active smokers had ratios that were higher than non-smokers 
protected from SHS exposure. The ratios of non-smokers with high exposure were 
similar to those of light (p=0.405) and moderate (p=0.827) active smokers (Table 
4.4, Figure 4.4). There were significant interactions with both age (p<0.001) and 
sex (p=0.039) but the TC/HDL cholesterol ratios generally increased with 
increasing cotinine concentration in all subgroups and the ratio was not 
significantly different between non-smokers with high SHS exposure and light 
active smokers in any subgroup. The relationship between cotinine and fibrinogen 
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was less clear-cut with only moderate and heavy active smokers having raised 
concentrations (Table 4.4, Figure 4.5).  
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Table 4.3 Median regression analyses of the association between cotinine concentration and C reactive protein concentration. 
Scottish Health Survey  
 
    
 Cotinine (ng/mL) C reactive protein 
 
Unadjusted  Partially adjusted†   Fully adjusted‡  
  Coefficient (95%CI) P value P value 
for 
trend 
Coefficient (95%CI) P value P value 
for 
trend 
Coefficient (95%CI) P value P value 
for 
trend 
           
           
Non-smokers 0-0.6* - - <0.001 - - <0.001 - - <0.001 
 0.7-2.6 0.200 (0.037-0.363) 0.016  0.200 (0.075-0.325) 0.002  0.125 (0.034-0.216) 0.007  
 2.7-14.9 0.500 (0.230-0.770) <0.001  0.500 (0.255-0.745) <0.001  0.300 (0.121-0.479) 0.001  
           
Current smokers 15.0-100.0 -0.000 (-0.299-0.299) 1.000  0.200 (-0.152-0.552) 0.265  0.250 (0.039-0.461) 0.020  
 100.1-300.0 0.600 (0.370-0.830) <0.001  0.700 (0.511-0.889) <0.001  0.475 (0.311-0.639) <0.001  
 ≥ 300.1 0.800 (0.628-0.972) <0.001  1.000 (0.829-1.171) <0.001  0.925 (0.788-1.062) <0.001  
    
 
CI confidence interval 
*reference category 
† adjusted for age and sex; ‡ adjusted for age, sex, social class, body mass index, physical activity and alcohol consumption 
Reprinted with friendly permission from Eur. J. Endovasc. Surg. (378) 
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Table 4.4 Linear regression analyses of cotinine concentration associated with high-density lipoprotein cholesterol concentration, 
total cholesterol/ high-density lipoprotein cholesterol ratio and fibrinogen concentration. Scottish Health Survey 
 
 Cotinine 
(ng/mL) 
Unadjusted  Partially adjusted†  Fully adjusted‡  
  Coefficient (95%CI) P 
value 
P value 
for 
trend 
Coefficient (95%CI) P 
value 
P value 
for 
trend 
Coefficient (95%CI) P 
value 
P value 
for 
trend 
           
 
HDL cholesterol 
          
 
Non-smokers 
 
0-0.6* 
 
- 
 
- 
 
<0.001 
 
- 
 
- 
 
<0.001 
 
- 
 
- 
 
<0.001 
 0.7-2.6 -0.049 (0.072- -0.027) <0.001  -0.027 (-0.048- -0.006) 0.013  -0.016 (-0.037-0.005) 0.134  
 2.7-14.9 -0.092 (-0.130- -0.055) <0.001  -0.063 (-0.099- -0.028) <0.001  -0.053 (-0.088- -0.018) 0.003  
           
Current smokers 15.0-100.0 -0.018 (-0.079-0.044) 0.568  -0.005 (-0.061-0.051) 0.863  -0.050 (-0.105-0.005) 0.076  
 100.1-300.0 -0.102 (-0.131- -0.073) <0.001  -0.094 (-0.121- -0.066) <0.001  -0.117 (-0.145- -0.090) <0.001  
 ≥ 300.1 -0.153 (-0.176- -0.129) <0.001  -0.127 (-0.151- -0.104) <0.001  -0.156 (-0.178- -0.134) <0.001  
 
Total/HDL cholesterol 
         
 
Non-smokers 
 
0-0.6* 
 
- 
 
- 
 
<0.001 
 
- 
 
- 
 
<0.001 
 
- 
 
- 
 
<0.001 
 0.7-2.6 0.057 (-0.016-0.130) 0.124  0.046 (-0.025-0.117) 0.207  0.008 (-0.061-0.077) 0.810  
 2.7-14.9 0.378 (-0.186-0.941) 0.189  0.334 (-0.236-0.905) 0.251  0.297 (-0.249-0.843) 0.287  
           
Current smokers 15.0-100.0 -0.207 (-0.384- -0.031) 0.022  -0.076 (-0.252-0.099) 0.395  0.055 (-0.111-0.221) 0.515  
 100.1-300.0 0.197 (0.081-0.314) 0.001  0.279 (0.163-0.396) <0.001  0.360 (0.247-0.472) <0.001  
 ≥ 300.1 0.536 (0.407-0.664) <0.001  0.532 (0.409-0.654) <0.001  0.657 (0.525-0.789) <0.001  
 
Fibrinogen  
          
 
Non-smokers 
 
0-0.6* 
 
- 
 
- 
 
<0.001 
 
- 
 
- 
 
<0.001 
 
- 
 
- 
 
<0.001 
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CI confidence interval; HDL high-density lipoprotein   
*reference; † adjusted for age and sex; ‡ partially adjusted plus social class, body mass index, physical activity and alcohol consumption 
Reprinted with friendly permission from Eur. J. Endovasc. Surg. (378) 
 0.7-2.6 -0.095 (-0.136- -0.054) <0.001  -0.044 (-0.083- -0.005) 0.029  -0.060 (-0.097- -0.024) 0.001  
 2.7-14.9 -0.065 (-0.139-0.009) 0.087  -0.032 (-0.102-0.038) 0.369  -0.056 (-0.125-0.014) 0.116  
           
Current smokers 15.0-100.0 -0.096 (-0.205-0.012) 0.081  0.018 (-0.086-0.123) 0.734  0.027 (-0.072-0.124) 0.596  
 100.1-300.0 0.102 (0.047-0.157) <0.001  0.172 (0.118- -0.225) <0.001  0.171 (0.118-0.224) <0.001  
 ≥ 300.1 0.216 (0.171-0.261) <0.001  0.291 (0.247-0.334) <0.001  0.313 (0.270-0.356) <0.001  
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Figure 4.2 Change in C reactive protein concentration per unit change in 
cotinine concentration (fully adjusted). Scottish Health Survey 
 
 
 
Figure 4.3 Change in high-density lipoprotein cholesterol concentration per 
unit change in cotinine concentration (fully adjusted). Scottish Health Survey 
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Figure 4.4 Change in total cholesterol/high-density lipoprotein cholesterol 
ratio per unit change in cotinine concentration (fully adjusted). Scottish Health 
Survey 
 
 
 
Figure 4.5 Change in fibrinogen concentration per unit change in cotinine 
concentration (fully adjusted). Scottish Health Survey 
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Generation Scotland : Scottish Family Health Study (GS: SFHS) 
Of the 1,779 participants, 1,721 had provided adequate blood samples for 
telomere assays. Among these, 1,433 were self-reported non-smokers. Among 
these non-smokers, 1,303 provided self-reported SHS exposure status and were 
therefore included in my study. Among these, 861 (66.1%) were men and 442 
(33.9%) women, 846 (64.9%) self-reported as never smokers and 457 (35.1%) self-
reported as ex-smokers. Among the 1,303 eligible participants, 779 (59.8%) 
reported no SHS exposure, 495 (38.0%) low exposure (1-19 hours per week), 29 
(2.2%) high exposure (≥20 hours per week) (Table 4.5). Participants with high SHS 
exposure were older at age (p value for trend=0.025), lived in more 
socioeconomically deprived areas (p value for trend<0.001), and were more likely 
to be obese (p value for trend=0.012) when compared with participants with no 
SHS exposure. 
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Table 4.5 General Characteristics of the 1,303 Non-smokers. A subgroup from 
Scottish Family Health Study chosen as part of a study on biomarkers of 
ageing 
 
   
 Total hours per week  
 0 
(n=779) 
1-19 
(n=495) 
≥ 20 
(n=29) 
P 
value* 
     
     
Age group, n (%)     <0.001 
<45 years 368 (47.2) 327 (66.1) 20 (69.0)  
45-59 years 193 (24.8) 98 (19.8) 5 (17.2)  
≥60 years 218 (28.0) 70 (14.1) 4 (13.8)  
Missing  0 0 0  
Gender, n (%)    0.190 
Male 529 (67.9) 312 (63.0) 20 (69.0)  
Female 250 (32.1) 183 (27.0) 9 (31.0)  
Missing  0 0 0  
Deprivation, n (%)    <0.001 
1 (least deprived) 297 (38.1) 164 (33.1) 4 (13.8)  
2 211 (27.1) 123 (24.9) 6 (20.7)  
3 99 (12.7) 73 (14.8) 5 (17.2)  
4 52 (6.7) 64 (12.9) 8 (27.6)  
5 (most deprived) 50 (6.4) 44 (8.9) 4 (13.8)  
Missing  70 27 2  
     
* χ2 test 
 
 
 
In the univariate linear regression analyses, relative telomere T/S ratio declined 
with increasing year of age in all exposure groups. Telomere length decreased 
more rapidly with increasing age among those with high exposure to SHS when 
compared with both those with no exposure to SHS (p=0.047) and those with low 
exposure to SHS (p=0.047).  After adjustment for sex and deprivation, the 
significant association accentuated. With increasing age per annum, telomere 
length decreased more rapidly among those with high exposure to SHS when 
compared with both those with no exposure to SHS (p=0.010) and those with low 
exposure to SHS (p=0.005) (Figure 4.6). 
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Figure 4.6 Change in telomere length T/S ratio per year of age and levels of 
secondhand smoke exposure among non-smokers (adjusted for sex and 
deprivation). A subgroup from Scottish Family Health Study chosen as part of 
a study on biomarkers of ageing 
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4.5 Discussion 
 
Pre-clinical biomarkers of cardiovascular disease 
My study using the Scottish Health Survey data, corroborated previous studies by 
demonstrating that within both non-smokers and active smokers, there was a dose 
response relationship whereby increasing exposure to tobacco smoke was 
associated with higher risk concentrations of most cardiovascular risk biomarkers. 
It also added to existing evidence on SHS exposure by demonstrating a step change 
in the relationship between tobacco exposure and biomarkers at the interface 
between non-smokers and active smokers. Compared with light, and sometimes 
moderately, active smokers, non-smokers exposed to high levels of SHS had lower 
cotinine concentrations but comparable concentrations of most cardiovascular risk 
biomarkers. My findings suggest that SHS exposure carries a disproportionately 
higher cardiovascular risk than would be anticipated from extrapolation of the 
effects seen in active smokers.  
 
There is strong evidence that both active smoking and exposure to SHS are 
associated with CVD (4, 6, 14, 15, 118). Inflammation plays a crucial role in the 
initiation and the progression of atherosclerosis in various vascular beds, from 
endothelial dysfunction to all stages of plague progression and to clinical events 
of ischemic injury including PAD (393-398). LDL and fibrinogen included in my 
study relate to the pathophysiology of atherosclerosis (397). CRP and fibrinogen 
are acute phase proteins and markers of inflammation and haemostasis (399-403). 
However, there is an ongoing debate on whether or not CRP may be a predictor of 
future adverse cardiovascular events or may be directly involved in the 
atherosclerotic process. One argument presents that the association between CRP 
and clinical outcomes is likely to be a consequence of confounding in the notion 
that CRP has been found to be associated with increasing age, sex, BMI and 
socioeconomic status (404-406). Recent published evidence does not support the 
causal role of CRP in the pathogenesis of atherosclerosis. Although there are 
several limitations on inferring causality using mendelian randomisation (407), a 
study of four Danish cohorts suggested that CRP polymorphisms are not associated 
with increased risk of ischemic vascular disease (408). A mendelian randomisation 
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meta-analysis indicated CRP is unlikely to be a causal factor in CHD (409). Yet, in 
2012, a meta-analysis of 52 prospective studies comprising 246,669 participants 
without known CVD investigated the value of adding information on CRP or 
fibrinogen levels to conventional risk factors for the prediction of cardiovascular 
events. This meta-analysis suggested that after initial screening with conventional 
risk factors alone, the additional assessment of the CRP or fibrinogen level in 
people at intermediate risk (a predicted risk of 10% to < 20% over a period of 10 
years) for a cardiovascular event could help prevent one extra event over a period 
of 10 years for approximately every 400 to 500 people screened (410). Taken 
together, although the association between CRP and CVD are unlikely to be causal, 
CRP can be an integrative indicator of chronically elevated inflammation and 
relates to many cardiovascular risk factors (411). Researchers suggested that CRP 
and fibrinogen have a significant though limited incremental prognostic value in 
addition to conventional risk factors (412, 413). Cholesterol is a major risk factor 
for the development of atherosclerotic disease with adverse effects on endothelial 
function and vasomotion as well as directly promoting atherogenesis. In contrast 
to total, and especially LDL, cholesterol, the reverse cholesterol transport 
mediated by HDL particles protects against atherogenesis and endothelial 
dysfunction (414, 415).  Similarly, there is mixed evidence on the association 
between LDL and cardiovascular events (416). However, several global risk 
assessment scores including the Framingham Risk Score (417) take total 
cholesterol and HDL cholesterol into the CVD risk calculation.  
 
Studies have shown that active smoking is associated with increased CRP, 
fibrinogen and total and LDL cholesterol concentrations, and reduced TC/ HDL 
cholesterol ratios (418, 419). Fewer studies have been conducted on chronic 
exposure to SHS in humans and the results are controversial. In a cross-sectional 
study of 995 never smokers, CRP concentrations were 0.08 mg/dL (95% CI 0.02-
0.10, p=0.03) higher in those exposed to SHS for more than 3 days per week 
compared with those who were not exposed (334). Using data from the Third 
National Health and Nutrition Examination Survey on 7,599 never smokers, Venn 
et al. reported that raised cotinine concentrations were associated with higher 
fibrinogen concentrations (adjusted mean difference 9.96 mg/dL, 95% CI 0.92-
19.01, p=0.03 for cotinine >0.215 ng/mL) but not CRP concentrations (420).  Two 
studies have examined the association between cotinine and CRP across both non-
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smokers and active smokers (325, 421).  Both applied a cotinine concentration of 
15.0 ng/mL to differentiate between active and non-smokers. Hamer et al. 
studied the 13,443 people aged ≥35 years who participated in the English and 
Scottish Health Surveys conducted between 1998 and 2004 (325).  Non-smokers 
were categorised into three groups, according to cotinine concentration (<0.01, 
0.06-0.7 and 0.71-14.99 ng/mL), but current smokers were included as a single 
group. Also in my study using the Scottish Health Survey, moderate and high SHS 
exposure groups comprised a single group in the Hamer study. Among non-
smokers, higher concentrations of cotinine were associated with higher 
concentrations of CRP. Overall, active smokers had higher CRP and fibrinogen 
concentrations, and lower HDL cholesterol concentrations, than non-smokers, but 
the investigators were not able to compare non-smokers exposed to high levels of 
SHS with light active smokers. The adjusted HR for CHD mortality over eight years 
follow-up was 2.00 (95% CI 1.06-3.78) for never smokers with high SHS exposure 
and 1.74 (95% CI 1.24-2.46) for current smokers (325) .   
 
The British Regional Heart Study recruited individuals aged ≥59 years from general 
practices in 24 towns. Jefferis et al. conducted a cross-sectional study using 
baseline data on 5,029 non and light (<10 cigarettes/day) active smokers. Among 
the non-smokers, higher cotinine concentrations were associated with higher CRP 
(p for trend <0.001) and fibrinogen (p for trend = 0.026) concentrations (421).   
Compared with non-smokers with cotinine >0.7 ng/mL, light active smokers had 
higher unadjusted mean CRP (2.29 vs 1.78 mg/L) and fibrinogen (3.49 vs 3.28 g/L), 
lower unadjusted mean HDL cholesterol (1.49 vs 1.53 mmol/L) and identical total 
cholesterol (both 6.37 mmol/L) but the investigators only calculated p values for 
a comparison between light active smokers and non-smokers with cotinine ≤0.05 
mg/mL (421). The risk of CHD events over 20 years of follow-up was comparable 
in non-smokers exposed to high levels of SHS (adjusted HR 1.57, 95% CI 1.08-2.28) 
and light active smokers (adjusted HR 1.66, 95% CI 1.04-2.68) in spite of cotinine 
concentrations being nearly 30-fold higher in the latter group (mean 4.9 versus 
138 ng/mL) (67).  
 
In my study using the SHeS, the main novelty was the direct comparison between 
non-smokers with high levels of SHS exposure, and light and moderate active 
smokers using several biomarkers. I used data from a representative Scotland-
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wide survey and based SHS exposure on salivary cotinine concentrations rather 
than self-report. Salivary cotinine measurements have been shown to be more 
sensitive than serum or urine cotinine concentrations in classifying smoking status 
(34). Applying a cut-off of 15 ng/mL enabled us to differentiate between genuine 
non-smokers exposed to high levels of SHS exposure and smoking deceivers. Any 
cut-off could result in some misclassifications in both directions. However, the 
cut-off value I used complies with published guidelines and is consistent with 
previous studies on this topic (40, 325). I was able to exclude participants using 
nicotine replacement therapy from the study. I did not have data on use of other 
forms of tobacco, such as chewing tobacco, but this is used very uncommonly in 
Scotland.  I combined ex- and never smokers to maximise statistical power but the 
vast majority of ex-smokers had not smoked for more than five years. I combined 
a number of survey years to increase statistical power. I did not have sufficient 
power to test for interactions for study year or perform subgroup analysis by year.  
 
In the regression models, I was able to adjust for potential confounders including 
demographic, socioeconomic and lifestyle risk factors. In relation to the 
association between cotinine and CRP, HDL cholesterol concentrations, there 
were interactions with sex. After stratifying the analyses, the difference in CRP 
concentration or HDL cholesterol concentration between non-smokers protected 
from SHS exposure and those with high exposure levels was less pronounced in the 
subgroups. However, results of low statistical significance can still be clinically 
relevant. This requires cautious interpretation and further investigation to reduce 
the play of chance. There were no interactions with socioeconomic and lifestyle 
risk factors. To increase statistical precision, I used median regression models to 
estimate the change of median CRP value produced by one unit change in cotinine 
across different levels of SHS exposure and active smoking. In contrast to the two 
previous studies, I included all current smokers and classified them into three 
groups according to the amount smoked in order to examine the association 
between cotinine and CRP across the whole range of non-smokers and active 
smokers. I also split non-smokers with cotinine concentrations >0.7 ng/mL into 
two groups. I examined the overall trend in biomarkers by cotinine concentration 
and also specifically tested the difference between non-smokers with high SHS 
exposure and light active smokers. As with the previous investigations, my study 
was cross-sectional. Therefore, a temporal relationship cannot be demonstrated 
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but reverse causality is unlikely (Appendix 5). It is acknowledged that there are 
numerous biomarkers relevant to the pathophysiology of atherosclerosis including 
markers of coagulation cascade (e.g. apolipoprotein B) (422) and markers of 
hemodynamic stress (e.g. B-type natriuretic peptides) (423). In my study, I had 
access to four biomarkers relevant to different pathways, but did not have access 
to other endothelial, inflammatory and haemostatic markers.  
 
Biomarker of biological aging  
In my study using a subgroup of participants from the SFHS, my findings suggested 
that high SHS exposure may accelerate normal biological ageing, as measured by 
leukocyte telomere length. 
 
Telomeres consist of TTAGGG tandem repeats, which cap the chromosomes and 
protect them from DNA-damage repair pathways (424). In regard to the telomere 
as a biomarker of ageing in humans, Mather et al. suggested the evidence is 
inconclusive due to many of the previous studies being cross-sectional and possibly 
underpowered and more longitudinal studies are needed to unravel the association 
between telomere length and human ageing (425). However, it is widely accepted 
that telomere is a biomarker for cumulative oxidative stress, inflammation and 
consequently biological ageing (389). As atherosclerosis is an age-related disease, 
telomere attrition has been demonstrated to be associated with CVD phenotypes 
(426-428). In a genome-wide meta-analysis of almost 50,000 individuals, 
researchers calculated a genetic risk score with the lead variants of mean 
leukocyte telomere length in seven genetic loci. They found an association 
between this score and an increased risk for CVD (429).  In a case-control study, 
relative telomere length with T/S ratios were measured among 241 male patients 
diagnosed with symptomatic PAD and 249 age- and diabetes- matched controls. 
They found that the mean relative telomere length was significantly shorter in 
patients with PAD than in the control groups. Per telomere length attrition by one 
standard deviation increased the odds for PAD by 44% (adjusted OR=1.44, 95%CI 
1.19-1.75, p<0.001). Correlations between relative telomere length and HDL 
cholesterol, CRP and ABPI were observed (correlation coefficients: r=0.121, 
p<0.01 for HDL; r=-0.111, p<0.05 for CRP; r=0.178, p<0.01 for ABPI) (430).  
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Both active smoking and SHS exposure increase inflammation, thrombosis and 
oxidative stress (59, 306). Several studies have demonstrated an association 
between active smoking and telomere attrition. One study related blood leukocyte 
telomere attrition to active smoking and demonstrated this association among 
1,122 healthy women aged 18-72 years. Telomeres were measured as the mean of 
the terminal telomere restriction fragment lengths. They showed that never 
smokers had longer age-adjusted telomeres than former smokers and both had 
longer telomeres than current smokers. Among current smokers, there was a dose 
relationship whereby each pack-year smoked equated to an additional 5 base 
pairs (bp), or 18% of the average annual loss in age-adjusted telomere length 
(389). In contrast, evidence on examining SHS is sparse. In a cross-sectional study 
conducted in the US among 77 traffic officers exposed to high levels of traffic 
pollutants and 57 office workers as controls, ever smoking was associated with 
shorter telomeres among controls (unadjusted OR=1.17, 95% CI 1.10-1.25, 
p=0.04). Telomeres were measured as relative T/S ratios. However, they did not 
find a significant association between telomere and pack-years smoked, or 
number of cigarettes per day.  They also reported no significant association with 
exposure to SHS (431). However, this previous study reflected a lack of statistical 
power. Of the 26 never smokers among the 57 office workers included in their 
study, 12 reported exposure to SHS. Of the 40 never smokers among the 77 traffic 
officers, 16 reported exposure to SHS. In my study using the subgroup of SFHS, of 
the 1,303 non-smokers included, 524 reported SHS exposure. This enabled me to 
categorise non-smokers into groups with different level of SHS exposure. 
 
My study is among the few published studies, and the largest to date, to examine 
the association between telomere and SHS. I was able to compare the attrition in 
telomere length T/S per year of age across different levels of SHS. In this subgroup 
from SFHS for ageing study, real-time (RT) PCR assays were used to determine 
telomere length. RT-PCR involves detecting the telomere-to-single copy gene 
(T/S) ratio, which is demonstrated to be proportional to the average telomere 
length in a cell (379, 380, 392). It is feasible to be used in large epidemiological 
studies. In order to maximise statistical power, non-smokers in this study included 
ex-smokers but the majority of the ex-smokers had not smoked for more than a 
year.  
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In the regression models, I was able to adjust sex and deprivation quintile. The 
association increased in magnitude. This may suggest that individuals exposed to 
both scocioeconomic deprivation and SHS exposure may be at particularly high 
risk of premature biological ageing. I did not have access to salivary cotinine data 
and therefore had to reply on self-report of SHS exposure. This study was cross-
sectional and therefore the temporal relationship cannot be established. 
However, reverse causation is unlikely to be plausible. Future research is needed 
to explore the possible mechanisms by which the observed association between 
SHS exposure and accelerated shortening of telomeres can be explained. However, 
plausible mechanisms may include cumulative oxidative stress-mediated damage 
and the stimulation of inflammation after exposure to SHS that leads to telomere 
attrition and therefore to age-related diseases including CVD. One limitation of 
the study using SFHS is the small sample size. Ideally, sample size should not be 
too small or too large (432). Small sample size makes the interpretation of the 
results including the p values and CIs difficult. Generally large studies produce 
small p value and narrow CIs. A very small p value and very narrow CIs generally 
suggest that the result is precise and is less likely to be due to chance (433). In 
my study, the 95% CIs are wide. It is possible that the results are false-positive or 
the magnitude of association between SHS exposure and telomere length attrition 
is overestimated. However, this study using SFHS is a hypothesis-testing study. 
There is suggestion of an association. Because of the small size of this study using 
a subgroup from the SFHS, the results should be interpreted accordingly and 
should be corroborated in future by larger studies or meta-analyses. Future, larger 
studies should also compare the effects of SHS exposure and active smoking on 
telomere length in order to establish whether the disproportionately large effect 
on the biomarkers of cardiovascular risk studied in the first part of this chapter 
also applies to biomarkers of aging. There will be a possible plan to corroborate 
the findings from this cross-sectional study using record linkage to follow-up data 
of telomere and other CVD-related inflammatory markers measurements.  
 
Since there can be a lag between past smoking behaviour among ex-smokers and 
the disease onset (357), ex-smokers still carry the risk of developing 
cardiovascular events including PAD (118, 358). Including only never smokers 
would have been ideal for the research. In reality, the analyses were possibly 
underpowered to show the association between SHS and these biomarkers. In my 
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studies, in order to maximise available power, I included ex-smokers with never 
smokers, as non-smokers. However, most of the ex-smokers had stopped smoking 
at least for five years prior to the survey. Including ex-smokers in the studies is an 
important limitation of this thesis.  
 
There may be other alternative analytical approaches.  According to the SHeS 
report (www.gov.scot/resource/0040/00402630.pdf), the proportion of non-
smokers who reported being exposed to SHS in public places has declined since 
2008. As mentioned in Chapter 1, exposure to SHS has fallen markedly since the 
implementation of the smoke-free legislation in 2006 in Scotland. This may be a 
possible explanation that in my studies the majority of participants were either 
no or low exposure to SHS. In the study using SHeS, I would have conducted 
subgroup analyses split by pre-legislation period and post-legislation period 
provided that there are sufficient numbers of participants in each exposure group. 
Furthermore, I would have included more potential confounders. In particular, it 
is important to include only never smokers and compare the absolute differences 
of the strength of the association by cotinine concentrations between never 
smokers, ex-smokers and current smokers, provided that there are sufficient 
numbers of participants in each survey.  
 
Both studies in this chapter are observational studies, which are susceptible to 
potential for built-in bias including confounding (Appendix 5). A confounder is an 
extraneous factor that is associated with the exposure and affects the outcome, 
but it is not an intermediate step in the causal pathway between the exposure 
and the outcome (363).  Confounding can be minimised by restricting, matching 
and randomisation at the design stage, and by stratifying, making multivariable 
statistical adjustment and doing standardised rate analysis at the analysis stage 
(363, 365). In the study using SHeS, the effects of confounding were reduced both 
by stratifying the analysis as well as by developing multivariable statistical models 
with adjustments. After multivariable adjustment, the change of CRP or HDL 
concentration per unit change of cotinine concentration among non-smokers with 
high SHS exposure was still comparable to light active smokers. The change of 
TC/HDL cholesterol ratios per unit change of cotinine concentration among non-
smokers with high SHS exposure was similar to those of light and moderate active 
smokers. Similarly, confounding was controlled by multivariable adjustments in 
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the study using SFHS, telomere length still decreased more rapidly among non-
smokers with high exposure to SHS when compared with no or low exposure 
groups. Admittedly, these findings may still have some confounding effect of the 
unknown or omitted confounders, which may affect the observed association 
between cotinine and these biomarkers, and the association between SHS 
exposure and telomere length attrition. Residual confounding occurs when 
additional confounding factors were not considered or not measured; confounding 
was not controlled well enough; and there were errors in the measured 
confounders including misclassification of subjects with respect to confounding 
variables due to reporting or measurement errors (370, 371). Therefore, residual 
confounding may also be an issue. Both studies in this chapter use existing 
secondary data and therefore data on a proportion of confounders were not 
collected.  
 
Furthermore, stratifying the analyses by the confounding variables would be 
beneficial in reducing the confounding effects. However, the results of these 
subgroup analyses could, at least to some extent, be due to the play of chance 
(Appendix 5). Therefore, caution should be taken when interpreting the results. 
However, the presented studies are exploratory and warrant further research. The 
association between SHS and CVD-related biomarkers would be more plausible if 
in future longitudinal studies include only never smokers with repeat measures of 
SHS exposure and repeat follow-up measures of relevant biomarkers. 
 
Both studies were cross-sectional and therefore the temporal relationship 
(Appendix 5) cannot be implied. One of the criteria to gauge causality is reverse 
causation (Appendix 5). However, in my studies, reverse causation is unlikely to 
be plausible. Reverse causation occurs when the probability of the outcome is 
causally related to the exposure under study (appendix 5). As mentioned in 
Chapter 1 (Section1.2.5), there is now substantial evidence that comprehensive 
smoke-free legislations is associated with reduced SHS exposure (25, 26, 91) and 
reduced hospital admissions of coronary events, other heart disease and 
cerebrovascular accidents (113). In contrast, there is a paucity of studies on the 
association smoke-free legislation and cardiovascular biomarkers and telomere. 
Both active smoking and SHS exposure increase inflammation, thrombosis and 
oxidative stress (59, 306). Previous studies demonstrated an association between 
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active smoking and telomere attrition (389, 434, 435). However, there is very 
limited evidence on SHS and telomere. The limited research into the effect of 
passive exposure to tobacco focused on prenatal exposure among children and 
pregnant women (436, 437). As mentioned in Chapter 1, sidestream smoke 
contains higher concentrations of toxic gases and small (<2.5µm), respirable 
particles than mainstream smoke (28-31). LDL, fibrinogen and other inflammatory 
factors are involved in the atherosclerosis process (179, 397). Given these 
considerations, there is clearly a higher possibility that increased cardiovascular 
risk follows SHS rather than the other way around. As discussed above, including 
ex-smokers in the analyses is an important limitation. It should be pointed out 
that in future studies, it is important to divide participants into never-smokers 
with no exposure to SHS, never smokers with exposure to SHS, and active current 
smokers, and compare the changes of a number of cardiovascular biomarkers per 
unit change in cotinine concentration across these groups separately to avoid 
reverse causality.  
 
From the findings in the two studies in this chapter, exposure to SHS carries a 
disproportionately higher cardiovascular risk than would be anticipated from 
active smoking. Telomere attrition relating to per year of age may be an 
intermediate step between exposure to SHS and CVD including PAD. These findings 
add to the limited published evidence supporting an association between SHS 
exposure and CVD-related biomarkers.  
 
Chapter 5 Discussion 
 167 
 
 
 
 
 
 
 
5 Chapter 5: Discussion 
 
Chapter 5 Discussion 
 168 
This chapter summarises the key findings, discusses the strengths and limitations 
of the methodology used in the studies in this thesis, and suggests 
recommendations on future research and public health and clinical implications, 
based on the findings of the studies in this thesis. 
5.1 Review of key findings 
5.1.1 A systematic review on the association between active 
smoking, exposure to SHS and PAD 
In Chapter 2, I did a systematic review on the existing published evidence up to 
30 April 2012 on the association between active smoking, SHS and PAD. The results 
corroborated the previous and only systematic review which was undertaken in 
2004 (16). Based on a substantial number of eligible studies on active smoking, I 
was able to conduct a meta-analysis. There is now substantial evidence of an 
increased risk of PAD among current smokers. The risk is lower among ex-smokers 
but, nonetheless, significantly increased compared with never smokers.  
In contrast, only two studies on the association between SHS and PAD were 
identified prior to my studies in this thesis. Both of these two studies were cross-
sectional but only one showed an overall positive association. The first study was 
among 1,209 Chinese women aged ≥ 60 years who had never smoked. SHS exposure 
was defined as self-reported exposure either in the home or in the workplace. 
Participants who were exposed to SHS had an overall 1.47-fold increased risk of 
PAD defined by an ABPI <0.9. Dose-response relationships were also found in 
relation to both the number of cigarettes these participants were exposed to each 
day and the daily cumulative time of exposure (45). But this study did not provide 
detailed information on SHS exposure in public settings and the duration of SHS 
exposure such as overall exposure per week or overall years of exposure. The other 
study was conducted in the USA using data of 5653 non-smokers from the NHANES. 
They defined self-reported non-smoking status with a serum cotinine <10.0 ng/mL 
as SHS-exposed non-smokers. But neither an overall association between cotinine 
concentration and PAD nor a dose-relationship was found. By dividing the serum 
cotinine concentration in this study population into 20 equal quantiles, they 
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suggested a threshold effect of cotinine > 155ng/mL, above which the risk for PAD 
was significantly increased (38). 
Furthermore, this systematic review has suggested that very few studies have 
collected information on both SHS exposure and PAD. Therefore, in Chapter 3, I 
used data from the GS:SFHS and SHeS to examine the association between SHS 
and PAD among adult non-smokers.  
5.1.2 SHS and the risk of PAD 
In Chapter 3, I undertook two cross-sectional studies and one retrospective cohort 
study to examine the association between SHS exposure and PAD among adult non-
smokers. For the cross-sectional studies, I used the baseline data from the SFHS 
and SHeS. The SFHS measured PAD objectively using ABPI <0.9 but used self-
reported exposure to SHS. Information on venues of SHS exposure was provided: 
at home, at work and in other public places. Overall duration of SHS exposure was 
interpreted as hours per week. The SHeS collected information on symptomatic 
PAD based on the Edinburgh Claudication Questionnaire and measured SHS 
exposure objectively using salivary cotinine concentration. I also used record 
linkage of the SHeS in my third, retrospective cohort study to determine whether 
SHS exposure was an independent predictor for PAD incidence. 
Overall, the two cross-sectional studies suggested a significant association 
between level of SHS exposure and PAD, after adjustment for potential 
confounding factors. In my study using the SFHS, self-report high level of SHS 
exposure at work, at other locations and overall exposure of ≥ 40 hours per week 
were significantly associated with PAD defined by ABPI < 0.9 among never smokers.  
In my studies using the SHeS, non-smokers with high concentration of salivary 
cotinine (≥ 2.7 ng/mL) were significantly more likely to have IC defined by 
Edinburgh Claudication Questionnaire. The association varied by age category, 
such that individuals aged <60 were more strongly and significantly associated 
with PAD. Survival bias may explain why the association turned out weaker among 
participants aged ≥ 60 years. Overall, among all participants included in this study, 
9.2% of cases of IC were attributed to raised cotinine concentrations. Both studies 
suggested a dose response relationship whereby the risk of PAD/IC increased with 
increasing level of SHS exposure.  
Chapter 5 Discussion 
 170 
Cross-sectional studies are not adequate to establish a temporal relationship. To 
address this limitation, I conducted the third, retrospective cohort study. 
Compared with low SHS exposure, increased cotinine concentration at baseline 
was associated with increased risk of all-cause mortality, with a dose-response 
relationship. The risk of incident PAD increased statistically significantly only in 
male non-smokers with high cotinine concentration (≥ 2.7 ng/mL).    
These findings added to the limited existing published evidence. My study using 
the SFHS included 5,686 never smokers and is so far the largest published study 
on this research topic. Using ABPI as the objective PAD evidence, I was able to 
include a close to complete number of ascertained PAD cases which otherwise is 
difficult because early stage PAD is asymptomatic. In contrast, symptomatic PAD, 
typically IC, increases with advancing age. Thus, I used a lower age cut-off in the 
study using the SFHS. In my studies using the SHeS, I included non-smokers (ex or 
never smokers) to maximise statistical power and identify more IC cases. However, 
in the record linkage data of the SHeS, the ascertainment of incident PAD was 
confined to cases serious enough to warrant hospitalisation or surgery or lead to 
death. Therefore, the association between SHS exposure and PAD could be due to 
an association with all incident PAD, an association with disease progression or a 
combination of both. However, the third study in Chapter 3 was the first attempt 
to examine the association between SHS exposure and PAD in a cohort design. 
5.1.3 SHS and cardiovascular biomarkers 
In Chapter 4, I conducted two cross-sectional studies. Firstly, using the SHeS, I 
examined the relationship between SHS exposure and active smoke exposure, 
measured by salivary cotinine, and several preclinical cardiovascular biomarkers: 
CRP, HDL cholesterol, TC/HDL cholesterol ratio and fibrinogen. Subsequently, I 
compared the changes of the concentrations of these cardiovascular biomarkers 
per unit change of cotinine concentration in non-smokers with high SHS exposure 
and in active smokers. 
The findings corroborated previous studies. I demonstrated dose-response 
relationships between tobacco exposure and the concentrations of most 
cardiovascular risk biomarkers in both non-smokers and active smokers. Compared 
with non-smokers protected from SHS exposure (no or low SHS exposure), CRP 
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concentration increased with increasing cotinine concentration among both non-
smokers and active smokers. The TC/HDL cholesterol ratio showed a similar trend. 
HDL cholesterol concentration decreased with increasing cotinine concentration.  
But the association between cotinine and fibrinogen was less clear-cut. Fibrinogen 
concentration only increased in moderate and heavy active smokers (cotinine > 
100.0 ng/mL). An important novelty of my study was the direct comparison 
between non-smokers with high level of SHS exposure (cotinine ≥ 2.7 ng/mL), and 
light/moderate active smokers. The changes of CRP concentration and the 
changes of TC/HDL cholesterol ratio with increasing cotinine concentration in non-
smokers with high level of SHS exposure was comparable to those changes in 
light/moderate active smokers. The changes of HDL concentrations in non-
smokers with high SHS exposure were similar to light active smokers. There was a 
step change in the relationship between tobacco exposure and cardiovascular 
biomarkers at the interface of non-smokers exposed to SHS and active smokers. 
This added to the limited existing evidence that SHS may carry a 
disproportionately higher cardiovascular risk than active smoking for a given level 
of SHS exposure. 
Active smoking increases telomere attrition. However, there is a paucity of studies 
on SHS. Therefore, I conducted another cross-sectional study using a subgroup of 
participants from the SFHS to explore the association between SHS exposure and 
telomere attrition. I compared the attrition in telomere length T/S per year of 
age across different level of SHS exposure among adult non-smokers. Telomere 
length decreased more rapidly with increasing age among participants with high 
level of SHS exposure, compared with both those with no exposure and those with 
low exposure. In this study, participants with high level of SHS exposure were 
more likely to live in socioeconomically deprived areas. After further adjusting for 
other risk factors including socio-economic deprivation quintiles in the regression 
models, the association with telomere attrition inflated. This suggests that, if a 
high level of SHS exposure is combined with other factors including deprivation, 
then telomere attrition per year of age may accelerate.  
In summary, previous published evidence supports that active smoking is strongly 
associated with PAD. In contrast, there was a paucity of studies on the association 
between SHS and PAD. My thesis added to the limited existing evidence on 
establishing the importance of SHS as a risk factor for PAD and then further 
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demonstrated that exposure to SHS carries a disproportionately high 
cardiovascular risk compared to active smoking for a given level of smoke 
exposure. Telomere attrition per year of age may be an intermediate step 
between SHS and CVD including PAD. This also supports the association between 
SHS exposure and the atherosclerosis-related biomarkers, which play an important 
role in the pathophysiology of PAD. 
5.2 Strengths and limitations of this thesis 
This thesis comprises six complementary studies using different study designs: a 
systematic review and meta-analysis, cross-sectional studies and a retrospective 
cohort study. The strengths and weaknesses of each study have been discussed in 
each relevant chapter in this thesis. Therefore, this section mainly focuses on the 
overall strengths and limitations of the thesis.  
5.2.1 Strengths 
This thesis has made many contributions to the limited literature on the 
association between SHS exposure and PAD, particularly in Scotland. My 
systematic review on active smoking, SHS and PAD was reported in accordance 
with PRISMA guidelines. I used four databases, namely the Medline, Embase, 
Pubmed and ISI Web of Science databases, to ensure that all eligible studies were 
identified. The only published systematic review, prior to the studies in this thesis, 
was on the association between active smoking and symptomatic PAD, published 
in 2004 (16). I included many more studies published based on both objective PAD 
measured by ABPI and symptomatic PAD defined by a claudication questionnaire 
or peripheral angiography. Therefore, I was able to conduct a meta-analysis to 
quantify the association and to attempt to explain the between-study 
heterogeneity. However, my systematic review only identified two studies on the 
association between SHS and PAD. This showed that most studies have not 
collected data on both PAD and SHS exposure, while in Scotland, population-based 
data are available for analysing the association between SHS exposure and PAD. 
In this thesis, all of the four cross-sectional studies and the cohort study were 
conducted based on existing secondary data in Scotland: the Scottish Family 
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Health Study and the Scottish Health Survey (SFHS and SHeS). These data sources 
provided very large numbers of participants from the general population living in 
Scotland. The samples covered a large geographic area across Scotland and 
therefore enable researchers to assess national trends. One advantage of 
analysing existing data is their rapid and low cost access. The quality of these data 
is good with a high percentage of completeness and accuracy (310, 329, 341). Both 
data sources include a wide range of information on socio-demographics, 
lifestyles, anthropometric measurements and samples of blood or saliva, despite 
the difference in data collection and certain measurements. The SFHS recruited 
probands aged between 35 and 55 years randomly selected from the general 
practitioner records in Glasgow and Dundee in Scotland, and their first degree 
adult relatives aged ≥ 18 years. Over 90% of the participants consented to link 
data with medical and related records (341) . The SHeSs are based on a stratified, 
clustered random probability sample of individuals living in private households 
across mainland Scotland and the large inhabited islands. Data were collected in 
two stages: a face-to-face interview followed by a nurse visit for anthropometric 
measurements and biomedical measurements. Over 90% of the participants 
consented to passive follow-up via record linkage to routine administrative data 
(310). 
In Chapter 3, despite the measures of PAD and SHS exposure being not the same 
in SFHS as in SHeS, I was able to demonstrate the consistency of findings across 
the studies based on these data sources. For example, the SFHS defined PAD using 
ABPI while the SHeS used the Edinburgh Claudication Questionnaire. In the study 
using the SFHS, I used a lower age cut-off as (participants aged ≥ 18 years) in order 
to include cases of early-stage, asymptomatic PAD. In the study using SHeS, I 
applied a higher age cut-off (participants aged >45 years) because symptomatic 
PAD increases with advancing age.  In my study using the SFHS, I included only 
never smokers due to the sufficient number of participants who classified 
themselves as never smokers via self-reported smoking status. This study included 
five times the number of never smokers as in the previous Chinese study, and 
showed consistent results. One of the other strengths of this thesis was the access 
to salivary cotinine concentration, an objective measurement of tobacco 
exposure, in SHeS. I was able to exclude the smoking deceivers based on the 
maximum cut-off concentrations suggested by the SRNT. Despite the different 
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measurements of SHS exposure in the studies, ordinal data were summarised to 
show the increasing levels of exposure. Therefore, whether there was evidence of 
a dose relationship was determined by analysing these ordinal data. I was also 
able to adjust for potential confounding factors such as age, sex and 
socioeconomic status (SES). I tested the interactions with these confounding 
factors and conducted subgroup analyses where appropriate. In contrast to the 
previous Chinese study, I did not adjust for diabetes, blood pressure and lipid 
concentrations in my regression models because these are potential mediators 
rather than confounders.   
Furthermore, with the linkage to data on hospitalisations and mortality from each 
SHeS, I was able to undertake a third, retrospective cohort study to examine 
whether SHS exposure increased the risk of incident PAD among a representative 
sample of the Scottish population. My study is also the first to have attempted to 
demonstrate the association between SHS and PAD in a cohort design. Worldwide, 
few large population-based linked data are available to study the association 
between SHS and PAD. Scotland is pioneering the use of linked health service data 
for population-based research. Data linkage allows for studies in retrospective or 
prospective cohort design to analysis past trends and forecast future scenarios. 
Compared to primary longitudinal survey in which participants are asked for the 
same information continuously, data linkage reduces the cost and the length of 
time of the survey, and respondent burden (438). The linkages of data maximise 
the value of existing data by reusing them to undertake new research and provide 
new statistics (310). The linkages also help to build up more reliable and more 
complete data by deleting duplicate records and correcting data artifacts (439). 
They offer the potential to monitor the quality of life in a community or region 
over time. Therefore, the outcomes of the research projects help to inform health 
policy decisions and service delivery (440). 
In Chapter 4, to understand whether SHS exposure carries a disproportionately 
higher cardiovascular risk compared with active smoking, I used SHeS because the 
data collection was principally focused on CVD and the related risk factors 
including cotinine concentrations in Scotland. Pre-clinical biomarkers of 
cardiovascular disease including CRP, HDL, LDL, total cholesterols and fibrinogen 
concentrations were determined by standard assays in SHeS (309).  I collated 
several surveys to increase statistical power. This enabled me to have sufficient 
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number to classify participants into groups with different levels of tobacco 
exposure. My findings were consistent with previous studies by showing a dose 
response relationship between increasing level of tobacco exposure and higher 
risk of concentrations of most of these cardiovascular biomarkers. I was also able 
to directly compare between non-smokers with high levels of SHS exposure, and 
light and moderate active smokers in relation to the changes of these 
cardiovascular risk biomarkers. Very few published studies have done such a direct 
comparison. However, my study indicated that non-smokers exposed to a high 
level of SHS had comparable concentrations of most of these cardiovascular risk 
biomarkers, despite lower cotinine concentrations, compared with light, and 
sometimes moderate active smokers.  In Chapter 4, I also used a subgroup of SFHS 
for ageing study, in which telomere T/S ratios in the DNA samples were detected, 
to examine the association between SHS and telomere attrition. This study was 
among the very few published studies, and so far the largest study, to determine 
the relationship between SHS and telomere. This data from SFHS enabled me to 
compare the attrition in telomere length per years of age across different levels 
of SHS. My findings demonstrated that exposure to high level of SHS may 
accelerate normal biological ageing assessed by telomere attrition. There has 
been growing evidence on telomere attrition associated with age-related diseases 
such as CVD phenotypes including PAD (426-428). Therefore, my two studies in 
Chapter 4 further demonstrated SHS as a risk factor for PAD by affecting pre-
clinical biomarkers of cardiovascular disease and increasing telomere attrition per 
year of age.  
5.2.2 Limitations 
Study-specific limitations have been discussed in relevant chapters. This chapter 
will mainly describe the methodological limitations relating to the research in this 
thesis, and suggest how to improve the research on the association between SHS 
and PAD.  
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5.2.2.1 Systematic review and meta-analysis 
In Chapter 2, the meta-analyses were based on the aggregated results of individual 
studies. I did not have access to the individual data of each study. The effect size 
from each study was of different adjustment levels. Therefore, I could not adjust 
for the same potential confounders across different studies. The choice of 
confounders in the regression models in the individual studies was generally based 
on prior knowledge and/or stepwise regression analyses or other commonly 
suggested statistical methods. If overadjustment occurs, the adjusted would be 
smaller than the unadjusted estimate. Then, the estimate of the risk of PAD is 
likely to be attenuated due to overadjustment. Since the population prevalence 
of PAD is relatively low (38, 121), RR approximates OR (222, 289). In my meta-
analyses, I treated RRs equivalent to ORs. Publication bias is one type of reporting 
bias that occurs when the outcome of a research study influences the decision of 
whether or not to publish it. Systematic reviews regarding support for a hypothesis 
can be biased if the original individual studies are subject to publication bias (441). 
In my systematic review and meta-analysis, the funnel plot was used to visually 
assess the likelihood of publication bias. However, Egger’s test, as described in 
Section 2.6.3 in Chapter 2, has some limitations when it is used to test for the 
funnel plot asymmetry. The SE of the log OR is correlated with the size of the OR 
because of sampling variability alone even in the absence of small-study effects. 
Funnel plots which were plotted using log ORs may appear asymmetric, leading to 
false-positive test results of the Egger’s test  (290). These meta-analyses included 
studies of different design: cross-sectional studies, case-control studies and 
cohort studies. However, when I used meta-regressions to explain the between-
study heterogeneity, study design and level of statistical adjustment were not 
significantly associated with the magnitude of effect size after adjustment for 
multiple testing. My systematic review of the published studies on active smoking, 
SHS and PAD identified only two studies on the association between SHS and PAD 
prior to the studies in my thesis. I only included observational studies published 
in English. This could bring in potential selection bias in the meta-analysis. I did 
not include studies on other sources of tobacco other than cigarettes. 
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5.2.2.2 Cross-sectional Studies 
As with the previous two published studies on SHS and PAD prior to this thesis, 
most of my studies in this thesis were cross-sectional. Cross-sectional studies are 
one type of observational studies used to describe the frequency of an illness or 
health-related characteristics, variables of interest and the relations among them 
as they exist in a defined population at a particular point of time.  
A weakness of cross-sectional studies is that risk factor/exposure and 
disease/outcome are ascertained simultaneously. Therefore, a temporal 
relationship between exposure and outcome cannot be established. Although 
there is an association between exposure and outcome, cross-sectional studies 
cannot prove that the exposure causes the outcome. Association may in principle 
be due to possible reverse causation (see Appendix 5). Secondly, cross-sectional 
studies are often used to evaluate prevalent outcomes other than incident 
outcomes. There is survival bias (see Appendix 5) towards including those 
individuals who are less likely to die after developing the outcome and excluding 
individuals who develop the outcomes but die before the study. Thirdly, since 
there may be other confounding factors associated with both the exposure and 
outcome, alternative explanations need to be ruled out when trying to infer 
causation from a simple association (359) (Appendix 5). In my thesis, from the 
cross-sectional studies, SHS exposure and prevalent PAD were measured at one 
point in time. The observed association between high level of SHS exposure and 
prevalent PAD cannot demonstrate whether SHS exposure predisposes to PAD. It 
may be a result of those individuals exposed to high level of SHS exposure being 
more likely to develop PAD, or less likely to die after developing PAD, or a 
combination of both. However, reverse causation is very unlikely (Appendix 5). 
Barnoya and Glantz have suggested that the cardiovascular effects of even brief 
exposure to SHS could be 80% to 90% as large as that of chronic active smoking 
(306). Therefore, SHS exposure is very unlikely to be negatively associated with, 
or even a preventive factor of, PAD. If SHS exposure is associated with survival as 
well as incidence, survival bias may explain why the association with PAD 
appeared to be weaker in those over 60 years of age. If this is the case, then the 
magnitude of association in younger participants is likely to be a better measure 
of the true association.  
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The two studies in Chapter 4 were also cross-sectional. Ideally, measurements of 
tobacco exposure should be collected prior to the assay results of cardiovascular 
biomarkers. In the baseline data of SHeS and SFHS, these were recorded at the 
same time. However, the cross-sectional studies in both Chapter 3 and 4 underpin 
several hypotheses that might be answered in the future.  
5.2.2.3 Cohort Studies 
A cohort study was used in Chapter 3 to address the methodological limitations of 
the cross-sectional studies. I used the record linkage of SHeS 1998, 2003, 2008 and 
2010 to undertake a third, retrospective cohort study to investigate SHS exposure 
as a risk factor for incident PAD, which was defined as the date of PAD 
hospitalisation or death because of PAD.  
Like other record linkage, the linked datasets of SHeS have both strengths and 
weakness. The data are collected for other purposes and thus may not be ideally 
suited to test the current hypothesis. Primarily, the linked data in Scotland are 
overall of good quality but certain variables used to test the hypothesis may be 
incomplete or even unavailable (442). The baseline data of SHeS were linked to 
death record and hospital admission and death due to PAD. The PAD case 
ascertainment in my cohort study was, therefore, restricted to those participants 
with PAD that was sufficiently severe to warrant hospitalisation or surgery or lead 
to death. The observed association between SHS exposure and the incident severe 
PAD defined in this way could be from the result of an overall association with all 
incident PAD, an association with disease progression or a combination of both. 
Secondly, the SHeS only includes the general population living in private 
households and exclude others living in Scotland. This may result in sampling bias 
(see Appendix 5) in the baseline data and subsequently to the linked data. The 
linked data assumed all participants to be alive and living in Scotland all the time, 
but in reality, some participants might have moved out from Scotland and develop 
the outcome or died because of the outcome somewhere. Moreover, since some 
of the follow-up has been conducted on a relatively short timescale (such as SHeS 
2008, 2010), the number of PAD cases is not very high and may underestimate the 
actual number. I did not have the periodic information on SHS exposure over time. 
Therefore, it was unclear whether the level of exposure measured at baseline was 
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valid over the follow-up time period. This may be a potential bias in the cohort 
study in this thesis. 
In the cohort study using survival analysis, SHS exposure was measured years prior 
to PAD or death outcome.  Since the first positive association in a cohort design 
has been identified in my thesis, it supports the need for further investigation and 
replication to determine whether SHS exposure is a real cause of the disease or 
not. 
5.2.2.4 Bias, confounding and chance 
Caution should be taken whenever an inference is being made from a sample to a 
population. The findings of an epidemiological study may be due to alternative 
explanations including bias, confounding, and chance. These alternative 
explanations may lead to the appearance of an association between an exposure 
and an outcome which actually does not exist, or alternatively the absence of an 
association which is truly present (222). Bias is a systematic error. Some 
researchers consider confounding as a type of bias (361). Chance is a random error 
(222) (Appendix 5). 
In epidemiological studies, two important considerations are internal validity and 
external validity. Internal validity means the rigour with which a study is designed 
and implemented. In relation to internal validity, all observational studies to some 
extent are vulnerable to built-in bias (see Appendix 5) which is generally 
categorised into selection bias, information bias and confounding (363).  
Selection bias (Appendix 5) occurs when the method of selecting subjects into a 
study or their likelihood of being retained in a study distorts the exposure-
outcome relationship from that present in the target population (363). If sampling 
is not representative of the exposure-outcome distributions in the entire target 
population, then the measures of association will be biased (443). There are 
several mechanisms that can result in selection bias, including inappropriate 
selection of controls in case-control studies (control selection bias), differential 
loss to follow-up in a cohort study (loss to follow-up bias), differences between 
subjects who agree to participate in studies and those who do not with regard to 
study outcome (volunteer bias or consent bias), nonresponse bias (missing data 
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bias), bias attributed to selective survival among the prevalent cases (incidence-
prevalence bias or selective survival bias), and healthy worker bias (361, 443). In 
SFHS, probands were randomly drawn from the general population from general 
practitioner records in Glasgow and Dundee. Over 90% of participants consented 
to link data with medical and related records (341). The SHeS uses multi-stage, 
stratified probability sampling frame and is designed to be representative of the 
general population living in private household nationwide in Scotland. When 
comparing those who had provided a saliva sample for cotinine assays with those 
who did not, there was no significant difference in the prevalence of IC. Therefore, 
my cross-sectional studies in this thesis were reliable in this respect. The 
participants in SFHS were adults aged ≥ 18 years. In the cross-sectional studies, in 
order to identify asymptomatic PAD defined by ABPI, I used a younger age cut-off 
of ≥ 18 years in the study using SFHS. While, the age cut-off of > 45 years was 
applied in the study using SHeS to include symptomatic PAD based on the IC 
questionnaire. This might introduce potential bias.  
Cross-sectional studies and case-control studies are susceptible to survival bias. 
Survival bias can occur when a series of survivors are selected, if the exposure is 
a prognostic determinant or is related to prognostic factors, the sample of cases 
distorts the frequency of the exposure (444). The observed association between 
SHS and prevalent PAD may result from those exposed to SHS being more likely to 
develop PAD or less likely to die after developing PAD, or a combination of both. 
Over 90% of the participants in SHeS consented to passive follow-up via record 
linkage to routine administrative data (310). However, selection bias could also 
have an influence on the cohort study in this thesis. Inclusion criteria were 
restricted to confirmed non-smokers (self-reported non-smokers with salivary 
cotinine concentrations <15.0 ng/mL) free of IC at baseline and linked to 
hospitalisation and death record to ascertain the outcome. The extent to which 
those who had consented to passive follow-up differ from those who did not in 
terms of SHS exposure, incident PAD and some other important aspects may affect 
the results presented in the cohort study in thesis. Since baseline IC was defined 
by a claudication questionnaire, it was unknown whether or not those who were 
free of IC might in reality have had asymptomatic PAD at baseline. Incident PAD 
case ascertainment was restricted to those participants with PAD that was 
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sufficiently severe to warrant hospitalisation or surgery or contribute to death. 
This can also introduce potential bias and impact the study outcome.  
Information bias (Appendix 5) refers to the incorrect determination of exposure 
or outcome, or both (363). It is also known as observation or measurement or 
classification bias. In cohort studies, a concern is whether the information on the 
outcome is obtained in the same way for both the exposed and non-exposed group. 
In my cohort study, the ISD of the NHS collates and links the SHeS data to 
hospitalisation (SMR 01) and death certificates (collected by General Registrar 
Office). The outcome/disease was defined by the disease and procedure codes 
(ICD-9, ICD-10, OPCS). Over 90% of SHeS participants consented at each survey 
and had been followed up with data linkage from 1981(310). Therefore, the 
outcome measurement in my retrospective cohort study was reliable in this aspect. 
However, the case ascertainment for PAD was restricted to those participants with 
PAD that was sufficiently severe to warrant hospitalization or surgery or contribute 
to death. The observed association between SHS and incident PAD could be biased. 
As described in the previous section, SHS exposure was only measured at baseline. 
Whether these exposure measurements were valid over the latency or follow-up 
time at risk was unknown. This may be a potential information bias in the cohort 
study. In Chapter 4, information bias may occur because cholesterol 
concentrations were measured using a different analyser after 2010.  
Reporting bias refers to selective revealing or suppression of information by 
subjects, that is, people’s tendency to under-report the information (445).  In the 
cross-sectional studies using SFHS, smoking status was self-reported. Due to the 
social undesirability of smoking, a proportion of current smokers can misclassify 
themselves as ex-smokers, termed “smoking deceivers” (355). Recall bias is 
important in retrospective case-control studies. Case may be more likely to recall 
past exposure, especially if the exposure is widely known to be associated with 
the disease being studied. Recall bias can either exaggerate or underestimate the 
true strength of association between the exposure and the outcome (446). In the 
SFHS, SHS exposure was based on self-report exposure. Recall bias is possible 
especially if the subjects already had some health conditions which are widely 
known to be associated with SHS. Then, the observed association can be 
exaggerated. In contrast, in the SHeS, the access of salivary cotinine measurement 
is a strength. In both the SFHS and the SHeS, since alcohol consumption and level 
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of physical activity were self-reported, recall bias in these confounders is likely. 
Information bias from self-report of information on confounding variables can lead 
to either overestimate or underestimate of the association. In SFHS, SHS exposure 
at home was predefined and categorized into: none, a little, some and a lot 
exposure. It is possible that non-smokers who live with current smokers share 
many or most of the lifestyle factors associated with smoking. Due to this, there 
may be some biases which cannot be quantified. This can lead to an 
underestimation of the confounding effects from these lifestyle factors.  
Confounding (Appendix 5) occurs when the effect of an exposure on an outcome 
is blurred by an extraneous factor (363). A confounding variable is a known risk 
factor for the outcome and is associated with the exposure but is not a result of 
the exposure. Confounding can be minimised by restricting, matching and 
randomisation at the recruitment stage, and stratifying, making multivariate 
statistical adjustment and doing standardised rate analysis at the analysis stage 
(363). In my cross-sectional studies in this thesis, I developed analytical models 
with multivariate statistical adjustments. I tested whether there were statistically 
significant interactions with covariates (age, sex and socioeconomic status). When 
there was a statistically significant interaction with the covariates, I stratified the 
analysis accordingly. For example, age is a strong confounding factor for PAD. In 
the cross-sectional study using SHeS in Chapter 3, the effect of age was minimised 
by stratifying the analysis and making multivariate adjustment. Adjustment for 
the demographic confounders plus BMI did not change the significant association 
between SHS and PAD until further adjustment for other lifestyle confounders. In 
my study using the SFHS on the association between SHS and PAD, I was able to 
adjust the well-established risk factors for PAD including demographics 
confounders (age, sex, deprivation quintile) and lifestyles confounders (alcohol 
consumption, physical activity and BMI). The association remained significant and 
did not change largely after adjusting for these potential confounders.  In the 
cohort study, a high level of SHS exposure was only associated with incident PAD 
in male participants after adjusting for age. Further adjustment for other 
potential confounders, the association did not reach statistical significance. In 
Chapter 4, stratified analyses were also undertaken when necessary, but the 
overall associations between tobacco exposure and cardiovascular biomarkers 
persisted. As confounding bias is inherent in epidemiological studies (365), this 
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limitation does not invalidate any of the results but underpin some hypotheses 
which promote further research. 
External validity means the usefulness of the findings of a study with respect to 
other populations (447). In Chapter 3 and 4, eligible participants in each specific 
study were identified based on the availability of the variables of interest. These 
studies were conducted among the Scottish population. To complete the picture, 
in future, studies are needed among other populations and should be performed 
on more than one occasion among one population. 
All observational studies are vulnerable to the effect of chance (random error) 
(Appendix 5). Due to random error alone, the value of the sample measurement 
can distort the true population value, which produces inaccurate measurement of 
an association between an exposure and an outcome. There are three sources of 
random error including sampling error, measurement error and individual 
biological variation (222). Different samples can produce different estimates. 
Random error cannot be completely eliminated but the likelihood of it occurring 
can be reduced. Sampling error of this type can be reduced by increasing the 
sample size of the study. Measurement error of this type can be minimised by 
using state-of-the-art methods of data collection. Individual biological variation is 
inevitable. Cautions must be taken whenever an inference is being made from a 
sample to a population (222).  
 
Therefore, the results from my studies should ideally be replicated in a cohort 
study design with repeat measures of SHS exposure and objective measures of 
incident PAD among never smokers in different populations to reduce the play of 
chance in the observed association. 
 
5.2.2.5 Estimation 
A point estimate for a population parameter, which is calculated from the sample, 
is single-valued. CIs (defined as the point estimate±margin of error) provide the 
likely range of plausible values for the population mean or other population 
parameters including a correlation (Appendix 5). CIs also help to estimate the 
precision of results from a sample, compared with the true population. Therefore, 
it is good practice to report CIs along with the point estimate in the attempt to 
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make an inference from a sample to a population (448). If a study is unbiased, the 
CI generally interprets the precision of an estimate of the association between the 
exposure and outcome. The wider the CI, the less convincing the estimate of the 
association is (297). A CI at 95% level is commonly used, which technically means 
if 100 different samples were taken and a 95% CI was computed for each sample, 
95% of the CIs would contain the true value of parameter in the population (448). 
In reality, often one random sample is selected and one CI is computed. The 
observed interval may overestimate or underestimate the true mean value or true 
association (449). CI is built based on the point estimate and a margin error that 
incorporates the confidence level and the standard error or sampling variability 
(449).  
In my studies, the findings may be affected by the small sample size. Because of 
the small number of PAD cases, some CIs were wide and therefore, the precision 
of the estimates of effect size was relatively low.  Furthermore, since the margin 
error only covers the random sampling errors (448), systematic errors including 
nonresponse bias or loss to follow-up bias could affect the precision of an estimate 
(449). The results should be interpreted accordingly and should be corroborated 
in future large studies and meta-analyses. However, these studies add to the 
limited published evidence in support of the association between SHS and PAD. It 
is anticipated that research-based evidence will be helpful to inform policy making 
and clinical and public health practice. Compared to a p value, which tests 
whether or not there is a statistically significant difference between groups, a CI 
provides a method to show the strength of the effect or the association. However, 
there is a need to judge the clinical significance of statistically significant results. 
On the other hand, if the sample size is too small or the dispersion in the sample 
is too great, results of high clinical relevance but low statistical significance can 
still be meaningful (450).  A decision cannot be made simply based on the p value. 
A very small p value and very narrow CIs generally suggest that the result is precise 
and is less likely to be due to chance (433). In my studies, some of the 95% CIs are 
wide. It is possible that the results are false-positive or the magnitude of 
association between SHS exposure and PAD and telomere length attrition is 
overestimated. However, there is suggestion of an association. Further research 
is needed to examine the association between SHS and PAD and cardiovascular 
biomarkers to reduce the possibility of false positive association or overestimation 
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of the magnitude of association due to alternative explanations including bias, 
confounding and chance, and therefore better inform policy and practice. 
5.2.2.6 Possible additional analyses 
Very few studies conducted on the general population have collected information 
on both SHS and PAD. The studies in Chapter 3 and Chapter 4 were conducted 
using existing secondary data available in Scotland (the SHeS and SFHS). The small 
number of PAD cases confined the methods used. As mentioned in Chapter 3, in 
SheS, the definition of baseline PAD was based on the Edinburgh Claudication 
Questionnaire. As mentioned in Chapter 1, many PAD cases were asymptomatic. 
It is often challenging to include asymptomatic PAD in a retrospective cohort study 
based on linked data on hospitalisations and deaths. I do not have access to GP 
data. In the linked data of SHeS, the ascertainment of the incident PAD cases was 
restricted to those severe cases that lead to hospitalisation or surgery or death. 
The SHeS also did not collect repeat measurements of SHS exposure. In SFHS, SHS 
exposure was self-reported. In both datasets, some of the potential confounders 
were predefined. The analyses could be improved if the measurements for the 
SHS exposure, incident PAD, and confounders are improved.  
 
As mentioned in Chapter 1, exposure to SHS has fallen markedly since the 
implementation of the smoke-free legislation in 2006 in Scotland. This may be a 
possible explanation that in my studies the majority of participants were either 
no or low exposure to SHS. In the study using SHeS, I combined the SHeS between 
1998 and 2010. Since now the SHeS 2011-2014 are available, it is possible to 
conduct subgroup analyses split by pre-legislation period and post-legislation 
period if there are sufficient numbers of participants (in particular never smokers) 
in each exposure group. Categorising participants into: never smokers with no, 
low, moderate, and high SHS exposure groups, ex-smokers with no, low, 
moderate, and high SHS exposure groups and light, moderate and heavy current 
smokers will show more information on the association between cotinine 
concentrations and PAD, and relevant biomarkers. Furthermore, I would have 
included more potential confounders. The inclusion criteria of confounders would 
better be based on both most recent published evidence and statistical 
approaches including stepwise selection approach, a 10% change-in-estimate (CIE) 
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criterion (373) and comparison of the model χ2 on addition of additional 
confounders. In particular, it is important to include only never smokers and 
compare the absolute differences of the strength of the association by cotinine 
concentrations between never smokers, ex-smokers and current smokers, 
provided that there are sufficient numbers of participants in each survey. There 
will be a possible plan to corroborate the findings of this thesis using record 
linkage to follow-up data of telomere and other CVD-related inflammatory 
biomarkers measurements. 
 
Another concern is the treatment of missing data in the analyses. There are 
generally three types of missing data: completely at random (MCAR), missing at 
random (MAR), and missing not at random (MNAR). MCAR means there are no 
systematic differences between the observed values and the missing values. If 
missing data are all MCAR, including only participants with complete data in the 
analyses generally produced unbiased results but can lead to a substantial 
reduction of the sample size and larger standard errors (451, 452). When data are 
MAR or MNAR, analysing only complete data can result in biased parameter 
estimates and undermine the validity of the results (453). Sterne et al. suggested 
that multiple imputation is a useful strategy for dealing with the biases caused by 
missing data that are MAR. Multiple imputation replaces each missing value with 
a set of plausible imputed values that reflects the uncertainty around the true 
value. The procedure of multiple imputation involves building up multiple imputed 
datasets including the missing values replaced by imputed values and using 
standard statistical methods to fit the analytic model of interest to the imputed 
datasets (454). However, multiple imputation cannot deal with missing data that 
are MNAR (454) and it can bring in biases (455). In the secondary datasets used in 
my studies, it is impossible to distinguish between MAR and MNAR. In my studies, 
it was decided that missing data were to be coded as dummy values and included 
in the analyses. In future, it may be a merit to compare different techniques for 
dealing with missing data including multiple imputation and interpret the results 
accordingly. 
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5.3 Recommendations 
5.3.1 Future research 
This thesis added to the limited evidence on SHS as a risk factor for PAD. As the 
studies in this thesis are observational studies, they underpin several hypotheses 
but merit further research.  
There is substantial evidence on active cigarette smoking associated with PAD. In 
contrast, published studies on the association between SHS and PAD are limited. 
Future research is needed to determine whether there is a causal link or simply 
an association. There are several criteria to gauge the strength of association 
before causality is inferred: a great magnitude of the association, consistency, a 
graded response to a graded dose, a temporal relationship, reversibility, a 
plausible mechanism (222) (Appendix 5).  
 
The cross-sectional studies in this thesis on the association between SHS and PAD 
have suggested an overall association and a dose response relationship whereby 
the risk of PAD increased with increasing level of SHS exposure. Prior to the 
published studies in this thesis, only two studies had published on the association 
between SHS and PAD. In the cohort study, SHS exposure was measured prior to 
PAD or death outcome. There was a suggestion of an association between high 
exposure to SHS and increased risk of incident PAD events in men.  
 
On reviewing the published evidence relating to smoking cessation on the MEDLINE 
and the Cochrane Library including meta-analyses of randomised controlled trials, 
Hobbs et al. suggested that permanent smoking cessation is probably the most 
clinically and cost effective intervention for PAD patients (156). Previous studies 
also showed a 21% reduction of admissions for ACS among never smokers during 
the 10 months after the smoke-free legislation in Scotland, compared with the 10 
months before the legislation (116). A meta-analysis based on a systematic search 
for published evidence on the Science Citation Index, Google Scholar, PubMed, 
and Embase also demonstrated that comprehensive smoke-free legislation is 
associated with significantly lower rates of coronary events (RR 0.85, 95% CI 0.82-
0.88), other heart disease (RR 0.61, 95% CI 0.44-0.85), and cerebrovascular 
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accidents (RR 0.84, 95% CI 0.75-0.94) (113). In contrast, the studies on the impact 
of smoke-free legislation on admission of PAD are limited. However, reverse 
causality is unlikely. 
 
Previous studies suggested that the mechanisms by which cigarette smoking is 
associated with CVD include inflammation, thrombosis, oxidation of LDL 
cholesterol and oxidative stress (385, 456). As mentioned in Chapter 1, sidestream 
smoke is often the major source of SHS (20). Sidestream smoke contains a range 
of chemicals similar to mainstream smoke. However, sidestream smoke contains 
higher concentrations of toxic gases and small (<2.5µm), respirable particles than 
mainstream smoke (28-31). A review based on epidemiological studies, 
experimental studies and clinical studies pointed out the cardiovascular effects of 
SHS is nearly as large as those of active smoking (306). Studies on acute effect of 
exposure to SHS on peripheral vascular function showed controversial results (457, 
458). Studies on comparing the effect of SHS with active smoking on the 
conventional atherosclerosis-related biomarkers are limited.  
 
My studies in Chapter 3 and Chapter 4 underpin several hypotheses but causality 
cannot be inferred. Future research is needed to address the evidentiary weakness. 
The findings in Chapter 3 and Chapter 4 will need to be corroborated with large 
cohort studies to establish temporality and intervention studies to demonstrate 
reversibility. Intervention studies to assess the impact of smoke-free legislation 
on admission of PAD will be useful. There is also a need to undertake experimental 
studies to explore the mechanisms by which SHS is associated with PAD. It is also 
useful to explore whether or not SHS carries a disproportionately higher 
cardiovascular risk, compared to active smoking.  Future studies should divide 
participants into never-smokers with no exposure to SHS, never smokers with 
exposure to SHS, and active current smokers, and compare the changes of a 
number of cardiovascular biomarkers per unit change in cotinine concentration 
across these groups separately to avoid reverse causality.  
 
The cohort study presented in this thesis highlighted that high exposure to SHS at 
baseline was associated with incident PAD in male non-smokers. However, in the 
record linkage of SHeS, incident PAD ascertainment was restricted to those cases 
which were sufficiently severe to warrant hospitalisation or surgery or lead to 
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death, which underestimated the number of incident PAD cases in reality. A lot of 
the PAD cases are asymptomatic and therefore they are difficult to be included in 
the secondary dataset. However, in Scotland, we do not have the access to GP 
data. One potential option is the Clinical Practice Research Datalink (CPRD), but 
the CPRD does not collect data on SHS exposure. The other big dataset in the UK 
is the UKBiobank, but it does not collect data on PAD. In future, there may be 
merit in exploring data collected from primary care such as GP consultation or 
similar to identify early stage PAD.  
The findings in this thesis suggest using ABPI to confirm PAD in future research. 
This is consistent with previous studies which have demonstrated the assessment 
of IC based on physical examination or clinical history underestimated the present 
of PAD (459, 460). Consequently, PAD defined by claudication questionnaires can 
increase the risk of weakening the actual association between SHS and all-stage 
PAD. Allen and colleagues have shown in their research that resting ABPI 
measurements correlated with 83% of PAD, defined by color Duplex ultrasound as 
the gold standard for PAD confirmation. When resting ABPI was combined with 
postexercise ABPI, the correlation increased to 85% (461). Therefore, ABPI is a 
reliable assessment of PAD in future research settings. 
Self-report smoking status has the tendency to underestimate smoking prevalence. 
Cotinine is an objective measure of tobacco smoke exposure and proportionate to 
the amount of exposure. It is suitable for cumulative doses over short exposure 
periods. Salivary cotinine is non-invasive and has high sensitivity value of detecting 
tobacco exposure (34). In this thesis, salivary cotinine was measured only at 
baseline in the SHeS. No information was available on whether baseline exposure 
would be valid over the time period of follow-up. Therefore, in future research, 
in terms of revealing long-term SHS exposure conditions, repeat measures of 
cotinine will show more information objectively.  
Also in this thesis, in the cohort study, the at-risk period of time for follow-up (till 
December 31, 2011) was short for linkage of SHeS 2008 and 2010 when comparing 
to the timescales typical for the disease development. Therefore, in future 
research, a longitudinal study with longer follow-up time and repeat measures of 
SHS exposure will provide more useful insights into whether the cumulative effect 
of SHS is related to incident PAD.  
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In order to maximise available power, in the studies using SHeS and the study using 
a subgroup of SFHS, I analysed never and ex-smokers together as non-smokers. 
The majority of the eligible participants in each study had quitted smoking for 
more than a year. However, since ex-smokers still carry the risk of developing PAD 
or other cardiovascular events, in terms of assessing the association between SHS 
and PAD or the effect of SHS on cardiovascular biomarkers, it would be more 
plausible to include only never smokers in future studies. 
The prevalence and incidence of PAD are age-dependent. In this thesis, in Chapter 
3, I included participants aged >45 in the cross-sectional study and cohort study 
using SHeS because PAD was defined as IC, whereas in the study using SFHS, I used 
a lower age cut-off as ≥ 18 to identify asymptomatic, early stage PAD. In future 
study, if ABPI or color Duplex ultrasound is the tool to identify PAD cases, a lower 
age cut-off is more credible not only for more complete case ascertainment but 
also for subgroup analysis to better understand whether the effect of SHS varies 
in different age group.  
In this thesis, in the cohort study, high SHS exposure defined as high cotinine 
concentration at baseline was statistically significant with the risk of incident PAD 
among male participants only. It did not show significant association among non-
smokers overall. The sex variation on the prevalence of PAD is controversial. 
However, this thesis supports the need to consider sex variation in future research 
on SHS as a risk for incident PAD as there are sex differences both in biology and 
SHS exposure conditions. 
In addition, socio-economic circumstances, BMI, alcohol intake and physical 
activity or other unknown factors may have some confounding effects on the 
observed association between SHS and PAD or cardiovascular biomarkers. In this 
thesis, after further adjustment for some of these confounders, some of the 
associations became statistically non-significant. It is clear that replications of 
multivariate models are required in future research among different populations. 
In future studies, interactions with covariates should always be tested as overall 
results may lead to missing information and misleading conclusions. 
SHS exposure is associated with PAD but the underlying mechanism is not fully 
understood. To understand whether SHS carries a disproportionately higher 
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cardiovascular risk, I compared between non-smokers with high levels of SHS 
exposure and light/moderate active smokers using several biomarkers: CRP, HDL, 
TC/HDL cholesterol ratio, and fibrinogen. These results need to be replicated in 
a cohort study design with measures of more biomarkers relevant to different 
pathways of systematic atherosclerosis and with frequent measures of tobacco 
exposure. This thesis also included a study on the association between SHS and 
telomere length attrition. However, given the small sample size and its cross-
sectional design, it should be corroborated in future larger studies or meta-
analyses. Comparing the effect of SHS and active smoking on telomere length 
attrition would be helpful to establish whether the disproportionately large effect 
on cardiovascular biomarkers also applies to biomarkers of ageing. Also further 
basic science research is needed to fully understand the underlying mechanism on 
the cardiovascular effect of SHS exposure. 
In summary, this thesis supports the evidence on SHS as an independent risk factor 
for PAD. There was suggestion of a dose response relationship whereby the risk of 
PAD increased with the increasing level of exposure. In future, observational 
studies especially in cohort design with long follow-up, repeat measures of SHS 
exposure and objective measure of PAD among never smokers in different well-
defined populations will provide useful insights into answering whether there is a 
causality or purely an association. Randomised controlled trials might be 
impractical and unethical in this case. But intervention studies such as smoking 
cessation will be useful to demonstrate reversibility. Assessing the effectiveness 
of smoke-free legislation on reducing the risk of PAD related to SHS exposure will 
be a merit. Further investigation and replication are needed to explore the 
underlying mechanisms.  
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5.3.2 Public health and clinical implications 
The global prevalence of smoking is increasing, especially in large, developing 
countries such as China (22). If the smoking pattern persists, cumulative tobacco-
related deaths including those attributable to SHS will be over 175 million by 2030 
(381). However, a 2013 WHO report indicated less than 16% of the global 
population are protected by comprehensive nationwide smoke-free legislation (3). 
In Scotland, six years after the legislation, 17% adult non-smokers reported 
exposure to SHS in their own home or other people’s home and 11% reported 
exposure in public places outside buildings (27). SHS is a potential public health 
threat. 
Globally about 202 million people were living with PAD in 2010 (119). In Scotland, 
from a Government report in 2011, based on the data collected in SHeS 2008 and 
2010, the prevalence of Grade 1 or Grade 2 IC was 2.3% among adults overall and 
increased with age, from 0.7%-1.7% in those aged 16-54, to 2.7% of those aged 55-
64, 4.1% of those aged 65-74, and 7.4% of those aged 75 and over (462). This 
estimate of prevalence is conservative, as it only includes Grade 1 and Grade 2 IC 
but most PAD cases are asymptomatic (122). Furthermore, the prevalence and 
incidence of PAD are higher in people with CVD or diabetes than those without. In 
this report, 20.1% of men and 16.7% of women had either CVD or diabetes. That 
being the case, the public health burden of PAD is remarkable. It is of public health 
importance that clinicians and other health care professionals assess patients and 
advise on the prevention, diagnosis and treatment of CVD, diabetes or 
hyperlipidemia. It is recommended to include objective measures of PAD such as 
ABPI.  
My systematic review on active smoking, SHS and PAD revealed the limited 
research on the association between SHS and PAD. Most existing cohorts and 
surveys have not collected information on both SHS exposure and PAD. It is 
anticipated that the findings of the studies in this thesis will inform new or existing 
policy makers, public health physicians, clinicians and others who are dealing with 
PAD in the general population or in high-risk populations and in particular those 
who are active smokers or exposed to SHS.  
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In my thesis, in the cross-sectional study using SFHS, participants with PAD were 
more likely to be female never smokers. On the other hand, in the cohort study, 
a high level of SHS exposure was associated with incident PAD in male non-smokers 
only but not in overall non-smokers. These findings suggest that there might be a 
sex variation in the smoking habits and SHS exposure conditions. Future 
investigations may be designed accordingly. 
Children who live with smokers are much more likely to start smoking themselves 
in adolescence or later life (463). It is critical to evaluate the cumulative health 
hazard related to active smoking cigarette or exposure to SHS or a combination of 
both since an early life. So far, a few countries or regions such as Australia, 
England and Wales have banned smoking in a private vehicle carrying children. 
Stopping smoking at home depends completely on volunteer restriction. In 2013, 
the theme of Faculty of Public Health in Scotland was ‘Making Scotland a healthier 
place’. Therefore, it is essential in Scotland to take actions to protect general 
public and in particular children from SHS exposure. 
In this thesis, variables describing SES are viewed as a potential confounder for 
PAD or cardiovascular biomarkers. In Chapter 4, participants with high SHS 
exposure were more likely to live in more socioeconomically deprived areas. This 
implies when high SHS exposure coexists with deprivation, the adverse effect can 
be worse. Studies investigating smoking cessation and SES have found that lower 
SES groups have higher rates of tobacco use and are less likely to successfully quit 
smoking (464, 465). Individuals from lower SES groups or living in deprived regions 
are essentially more likely to be exposed to SHS (320, 466). Moreover, PAD may 
not be detected in these individuals because they are less likely to engage in 
activities that would facilitate early diagnosis. In future, individuals from lower 
SES groups or living in deprived regions may be in particular need of intervention 
and PAD detection. 
5.4 Conclusion 
In summary, there is substantial evidence on the association between active 
cigarette smoking and PAD. This thesis adds to the limited evidence on SHS as an 
independent risk factor for PAD. Because of the methodological limitations of the 
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studies, causality cannot be inferred. However, it is expected that these studies 
will provide a foundation for future research. This thesis also provides evidence 
that exposure to SHS carries a disproportionately higher cardiovascular risk than 
active smoking for a given level of smoke exposure. Telomere attrition per year 
of age may be an intermediate step between early effects of SHS and the 
occurrence of CVD including PAD. The association between SHS exposure and the 
atherosclerosis-related biomarkers and telomere attrition may contribute to the 
development of PAD. Nevertheless, further research is needed to better 
understand the underlying mechanisms. It may be possible that other confounding 
factors affect the observed associations in the observational studies in this thesis. 
Therefore, future research using a cohort design with long follow-up, repeat 
measures of SHS exposure and objective measure of PAD among never smokers in 
different well-defined large populations, will yield better insight. This thesis lends 
support for measures to protect the public from SHS exposure and screening PAD 
at an early stage.
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Appendix 1: Literature search strategy 
 
Database searched 
 
 
Search terms  
 
Date of search 
 
Ovid Medline 
 
peripheral arter* OR peripheral athero* OR peripheral vascular OR claudication OR ABPI OR ABI OR ankle 
brachial) AND (smoking OR cigarette* OR tobacco OR nicotine OR smoke* 
Limit to: Publication date from 1 January 1980 to 30 April 2012, humans, Journal Article, English 
 
 
30 April 2012 
 
 
Embase 
 
peripheral arter* OR peripheral athero* OR peripheral vascular OR claudication OR ABPI OR ABI OR ankle 
brachial) AND (smoking OR cigarette* OR tobacco OR nicotine OR smoke* 
Limit to: Publication date from 1 January 1980 to 30 April 2012, humans, Journal Article, English 
 
 
30 April 2012 
 
 
PubMed 
 
peripheral arter* OR peripheral athero* OR peripheral vascular OR claudication OR ABPI OR ABI OR ankle 
brachial) AND (smoking OR cigarette* OR tobacco OR nicotine OR smoke* 
Additional filters: Publication date from 1 January 1980 to 30 April 2012, humans, Journal Article, English 
 
 
30 April 2012 
 
 
ISI Web of Science 
 
peripheral arter* OR peripheral athero* OR peripheral vascular OR claudication OR ABPI OR ABI OR ankle 
brachial) AND (smoking OR cigarette* OR tobacco OR nicotine OR smoke* 
Refined by: Publication date from 1 January 1980 to 30 April 2012, humans, Journal Article, English 
 
 
30 April 2012 
 
 
* a truncation symbol to retrieve plurals or varying endings 
 
 
Appendices 
196 
 
Appendix 2: Checklist for assessing the quality of quantitative studies 
 
 
Criteria 
 
 
Yes (2) 
 
Partial (1) 
 
No (0) 
 
N/A 
 
1.Question / objective sufficiently 
described? 
    
 
2. Study design evident and 
appropriate? 
    
 
3. Method of subject/comparison 
group selection or source of 
information/input variables 
described and appropriate? 
    
 
4. Subject (and comparison group, 
if applicable) characteristics 
sufficiently described? 
    
 
5. If interventional and random 
allocation was possible, was it 
described? 
    
 
6. If interventional and blinding of 
investigators was possible, was it 
reported? 
    
 
7. If interventional and blinding of 
investigators was possible, was it 
reported? 
    
 
8. Outcome and (if applicable) 
exposure measure(s) well defined 
and robust to measurement / 
misclassification bias? means of 
assessment reported? 
    
 
9. Sample size appropriate? 
    
 
10. Analytic methods 
described/justified and 
appropriate? 
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11. Some estimate of variance is 
reported for the main results? 
    
 
12. Controlled for confounding? 
    
 
13. Results reported in sufficient 
detail? 
    
 
14. Conclusions supported by the 
results? 
    
 
The calculation of the summary score was done according to Kmet et al. 
(216) 
Source: Adapted from Kmet et al. (216) 
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Appendix 3: Data extraction form template* 
 
Reviewer: __________   Date: _____________ 
Author: ____________   Year: _____________ 
Journal: ___________    Record number: ___ 
 
Study method:  Observational         Other 
 
Participants: 
Setting __________________ 
Population _______________ 
Sample size ______________ 
 
Intervention/exposure: _________________ 
Measure (s) of intervention/exposure: _______ 
Clinical outcome measure (s): ____________ 
 
Study characteristics 
 
Year year of publication; Country country where the study was conducted; Sex sex of the participants; Age years of age of the participants; N number 
¶ level of statistical adjustment in the regression models in the eligible studies 
study Year Country 
 
Study 
design 
Sample 
size 
Sex Age PAD 
definition 
Referent 
group 
Smoking 
status 
Current 
smokers 
(N) 
Non-smokers 
(N) 
ex-smokers 
(N) 
never 
smokers 
(N) 
Effect 
size 
CI statistical 
adjustment
¶ 
Other 
disease 
                  
Appendices 
199 
 
*This template was modified from the Joanna Briggs Institute (JBI) data extraction form for observational studies (221) 
Authors’ conclusion: _______________________________ 
Comments: _______________________________________ 
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Appendix 4: PRISMA checklist* 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  56 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
57 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  58,59 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
58,59 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
N/A 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
59-61 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
59-61 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
59-61 
Appendices 
201 
 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
59-61 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
61 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
61 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
61-62 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  61-62 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
61-62 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
61-62 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
61-62 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions 
at each stage, ideally with a flow diagram.  
63-65, 72 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
64-67 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  75 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
70, 71, 73, 
74 
Synthesis of results  21 Present the main results of the review. If meta-analyses are done, include for each, confidence intervals and 
measures of consistency.  
64, 65, 73, 
74, 76 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  64, 65, 76 
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Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  64, 65, 76 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance 
to key groups (e.g., healthcare providers, users, and policy makers).  
76-83 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval 
of identified research, reporting bias).  
77-83 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
84 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 
the systematic review.  
N/A 
*this template was available from (213) 
Appendices 
203 
 
Appendix 5: Epidemiological principles 
 
In brief, the basic elements of an epidemiological study include (222, 359): 
1) Formulation of the study question or hypothesis; 
2) Selection of study populations and study samples; 
3) Selection of indicators of exposure; 
4) Measurement of exposure and disease; 
5) Analysis of the relationship between exposure and disease; 
6) Evaluation of the role of bias; 
7) Evaluation of the role of chance. 
 
The following table discusses chance, hypothesis vs. estimation, bias (including selection bias), confounding (including residual 
confounding), measurement error, causation and reverse causation.  
 
 
Chance  
 
Bias, confounding and chance can influence the quality of an epidemiological study. In reality, 
epidemiological studies cannot include the entire target populations and remain unchanged in time. 
Chance is a random error. There are three major sources of random error including sampling error, 
measurement error and individual biological variation. Measurement error can be minimised by using 
state-of-the-art methods of data collection. Sampling error can be reduced by increasing the sample 
size of the study. Individual variation is inevitable. Due to chance alone, a value of the sample 
measurement can diverge from the true population value, even if bias and confounding are absent. 
The evaluation of role of chance involves two components, which include hypothesis testing and the 
estimation of confidence interval. To determine the probability that the observed association can be 
explained by chance, despite being arbitrary in nature, a p value of either 0.05 or 0.01 is often used 
as the statistical significance value for testing the null hypothesis. If the p value is low, it is unlikely 
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that the observed association would have been explained by chance alone. P value reflects both the 
magnitude of effect and the size of sample. If the sample size is too small, the p value can be above 
the level of significance. Confidence intervals (CIs) reflect the precision of the point estimate from a 
sample, compared with the true population and are normally presented using the 95% confidence 
level (467).Variations from the trues value can be minimised if the study is large in sample size and 
long in time (468).  
 
 
Hypothesis vs. estimation 
 
The classic hypothesis testing process includes defining the null hypothesis and the alternative 
hypothesis, calculating a p value, and accepting or rejecting the null hypothesis based on the p 
value. It is important to make a careful consideration of the statistical hypothesis to be tested, the p 
value associated with this test and the statistical power (1-β) for detecting the difference of a 
specified magnitude between the groups being compared. If the null hypothesis is accepted, it 
indicates that there is no difference between the two groups to be compared. The null hypothesis is 
rejected because the observed study outcome was deemed to be rare under the assumption that the 
null hypothesis was true. Although arbitrary in nature, it has been pointed out that the cut-point for 
rejecting the null hypothesis is usually set when α=0.05. The p value represents the probability of 
obtaining the results observed, if the null hypothesis were true. The p value and α level are related 
in a sense that if α=0.05, then the null hypothesis would be rejected when p< 0.05. If the null 
hypothesis is rejected, then the alternative hypothesis is accepted as true, which indicates that 
there is a difference between the two groups being compared. If a p value is less than 0.01, it is very 
unlikely the observed results are due to chance. A p value< 0.05 indicates the observed difference is 
“statistically significantly” different between the two groups. However, it does not show the 
uncertainty around the point estimate and the likelihood of clinical significance.  
 
A point estimate for a population parameter, which is calculated from the sample, is single-valued. 
CIs (defined as the point estimate±margin of error) provide the likely range of plausible values for 
the population mean or other population parameters including a correlation. CIs reflect the precision 
of results from a sample, compared with the true population. If a study is unbiased, the CI generally 
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interprets the precision of an estimate of the association between the exposure and outcome. The 
wider the CI, the less convincing the estimate of the association is. The number of subjects with the 
outcome, which is often influenced by the sample size, affects the width of the CI (297). Similar to 
the selection of 0.05 as level of significance for p value, a CI at 95% level, despite being arbitrary in 
nature, is usually used. It is good practice to report the point estimate alongside with the CIs 
wherever an inference is to be made from a sample to a population. 
 
 
Bias  
 
Bias (or systematic error) is the lack of internal validity or incorrect assessment of the association 
between an exposure and an outcome in the target population (361). All observational studies to 
some extent are vulnerable to built-in-bias generally categorised into selection bias, information bias 
and confounding (363). There are many specific types of bias. The principal biases are selection bias 
and information bias.  
 
Selection bias occurs when the method of selecting subjects into a study or their likelihood of being 
retained in a study distorts the exposure-outcome relationship from the true value in the target 
population. There are several mechanisms that can result in selection bias, including inappropriate 
selection of controls in case-control studies (control selection bias), differential loss to follow-up in a 
cohort study (loss to follow-up bias), differences between subjects who agree to participate in 
studies and those who do not with regard to study outcome (volunteer bias or consent bias), 
nonresponse bias (missing data bias), bias attributed to selective survival among the prevalent cases 
(incidence-prevalence bias or selective survival bias), and healthy worker bias (361, 443). Survival 
bias is a type of selection bias and can occur in both cross-sectional studies and case-control studies. 
It occurs when individuals with favourable survivorship are included in the analysis because the 
exposure relates to the mortality from the disease being studied. Sampling bias occurs when the 
selection procedure yields a non-representative sample in which the estimate of the population 
parameter differs from the true value in the target population (361). Information bias (or 
measurement bias or classification bias) occurs when the individual measurements or classifications 
of disease or exposure are inaccurate. Recall bias is particularly important in retrospective case-
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control studies. Reporting bias refers to selective revealing or suppression of information by 
subjects, that is, people’s tendency to under-report the information. Publication bias is one type of 
reporting bias that occurs when the outcome of a research study influences the decision to whether 
or not to publish it. Confounding is one type of bias but it is usually considered as its own entity 
(361).  
 
Overadjustment bias occurs as a consequence of the control (including statistical adjustment, 
stratification and restriction) for an intermediate variable or a descending proxy for an intermediate 
variable on the causal pathway between the exposure and the outcome (298). A descending proxy for 
an intermediate variable is a variable that leads to imperfect measurement of intermediate variable.  
A descending proxy for an intermediate variable is a variable that leads to imperfect measurement 
of intermediate variable (469). Overadjustment would either increase net bias or decrease precision, 
and usually bias results towards the null (298).  
 
Bias cannot be completely eliminated in epidemiological studies. The aim, therefore, is to minimise 
it.  
 
 
Confounding  
 
Confounding is another major issue in epidemiological studies. It occurs when the effect of an 
exposure on an outcome is blurred by an extraneous factor. A confounder is an extraneous factor, 
which is often a determinant or known risk factor for the health outcome and is associated with the 
exposure but is not a result of the exposure. Confounding arises if this extraneous factor is unequally 
distributed among the groups being compared. Unlike a mediator, a confounder is not an 
intermediate step in the causal pathway between the exposure and the outcome. Confounding can 
be minimised by restricting, matching and randomisation at the design stage, and stratifying, making 
multivariate statistical adjustment and doing standardised rate analysis at the analysis stage. 
Residual confounding refers to the distortion that remains after controlling for confounding in the 
design and/or analysis of a study. It occurs when: additional confounding factors were not 
considered or not measured; control of confounding was not narrow enough; and there are errors in 
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the measured confounders including misclassification of subjects with respect to confounding 
variables due to reporting or measurement errors (370, 371). 
  
 
Measurement error 
 
Measurement error can be either a source of random error or a type of systematic error (bias). If 
measurement error is a source of random error, it can be minimised by using state-of-the-art 
methods of data collection. Measurement bias refers to a type of systematic error that occurs when 
the measurements or classifications of exposure or outcome are inaccurate. There are different 
sources of measurement bias. Recall bias is particularly important in retrospective case-control 
studies. Recall bias occurs when there is a differential recall of information by cases and controls. It 
is noted that cases may be more likely to recall past exposure, especially if the exposure is widely 
known to be associated with the disease under study (i.e. smoking and lung cancer). Recall bias can 
either exaggerate or undermine the true strength of the association between an exposure and an 
outcome. Different laboratories and different analysers often produce different results despite 
measuring the same specimen or sample. Measurement error can be reduced by improving the 
precision of individual measurements by systematic quality control procedures. Observer bias occurs 
when the investigators, laboratory technicians or participants know the knowledge of the exposure 
status. A blind or a double-blind fashion can reduce the observer bias. 
 
 
Causation  
 
An important focus of epidemiology is to inform efforts to prevent and control disease, and to 
promote health and wellbeing. Therefore, there is a need to study the causation of disease or health 
outcome. A cause of a disease or health outcome is a condition, characteristic, event or a 
combination of these factors that produces the health outcome. A cause is considered as sufficient 
when it inevitably initiates the outcome. A cause is considered as necessary when the outcome 
cannot develop without it. The cause of a specific health outcome usually comprises several factors. 
There are almost always some environmental component causes and genetic component causes in a 
causation of a disease. Before an association between the exposure and the outcome is assessed for 
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the possibility that it is a causal relationship, other possible explanations for the observed 
association have to be excluded, including the play of chance, bias and confounding.  
 
It has been pointed out that there are several criteria for judging the strength of association before 
making a causal inference:  
1) A temporal relationship between the exposure and outcome (Does the cause precede the 
effect?);  
2) A sufficient strength of association (Is the association between the possible cause and the 
effect strong, as measured by the size of relative risk?) 
3) Plausibility (Is the association consistent with other knowledge i.e. laboratory experiments to 
explore the mechanisms?); 
4) Consistency (Have other studies demonstrated similar results?);  
5) A dose-response relationship (Are increased levels of exposure to a possible cause associated 
with the increased prevalence or incidence of the effect?) 
6) Reversibility (Does the removal of a possible cause result in the reduction of disease risk?)   
7) Study design (Is the study design strong in establishing causality?). 
 
Each study design has its strengths and weakness. Well-designed randomised controlled trials and 
cohort studies are good to assess causation. Well-designed case-control studies are viewed to provide 
moderate evidence. Cross-sectional and ecological studies are generally viewed as weaker evidence. 
As there is always unknown evidence, causal inference is often tentative and judgements have to be 
made on the basis of the available evidence. 
 
 
Reverse causation 
 
Reverse causation (or reverse causality) refers to a direction of cause-and-effect contrary to a 
common presumption or to a two-way causal relationship, as it were, a loop. It occurs when the 
outcome precedes and causes the exposure being studied instead of the other way around. 
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Source: Adapted from Bonita R, Beaglehole R, Kjellström T. Basic epidemiology 2nd edition. WHO. 2006 
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Appendix 6: Logistic regression analyses of the association between secondhand smoke exposure and peripheral arterial disease, 
Scottish Family Health Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      OR odds ratio; CI confidence interval  
*adjusted for age, sex, deprivation quintile, body mass index, physical activity and alcohol consumption 
   
Unadjusted 
  
 Fully adjusted* 
 
   
OR 
 
95% CI 
 
P value 
 
 
P value for trend 
 
OR 
 
95% CI 
 
P value 
 
P value for trend 
 
Work  
 
None 
 
1.00 
 
- 
 
- 
 
0.395 
 
1.00 
 
- 
 
- 
 
0.542 
 A little 0.38 0.14-1.05 0.061  0.45 0.16-1.23 0.121  
 Some 1.69 0.68-4.21 0.262  2.00 0.79-5.05 0.145  
 A lot 
 
3.54 1.07-11.70 0.038  3.80 1.12-12.89 0.032  
Home  None 1.00 - - 0.316 1.00 - - 0.151 
 A little 0.96 0.39-2.38 0.935  0.95 0.38-2.38 0.910  
 Some 1.77 0.71-4.42 0.220  1.68 0.66-4.28 0.276  
 A lot 
 
1.34 0.42-4.30 0.622  1.13 0.34-3.71 0.841  
Other locations None 1.00 - - 0.635 1.00 - - 0.346 
 A little 0.74 0.48-1.14 0.176  0.76 0.48-1.20 0.240  
 some 1.20 0.55-2.62 0.652  1.38 0.62-3.09 0.435  
 A lot 
 
3.32 1.17-9.42 0.024  3.56 1.20-10.56 0.022  
Total hours per week 0 1.00 - - 0.214 1.00 - - 0.208 
 1-19  0.86 0.57-1.29 0.468  0.90 0.58-1.39 0.632  
 20-39  2.09 0.64-6.81 0.219  2.02 0.60-6.76 0.254  
 ≥40  
 
5.01 1.74-14.44 0.003  4.53 1.51-13.56 0.007  
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Appendix 7: Certificate of completion of Scottish Health Informatics 
Programme to use the Scottish Morbidity Record linked data 
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